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  Antibiotic resistance is a growing problem, and is now being recognized as a world-
wide crisis in modern medicine. Coordinated awareness and action are needed to combat the 
fact that antimicrobial resistance is creating a health crisis rapidly outpacing available treatment 
options. b-lactam antibiotics are the most commonly used antibiotic, and the most widespread 
b-lactam resistance is the expression of enzymes with the ability to hydrolyse b-lactam 
antibiotics. Herein class D b-lactamases are commonly referred to as OXA-enzymes. OXA-
enzymes are considered an increasing problem as they are spreading rapidly, and can be found 
among clinically relevant Gram-negative species.   
 OXA-48 was first identified from a carbapenem- and multidrug- resistant Klebsiella 
pneumoniae isolate in Turkey in 2001, and is now one of the most geographically widespread 
members of the class D b-lactamases. Multiple aspects concerning OXA-48 and OXA-48 like 
enzymes were examined during this thesis, using methods such as site-directed mutagenesis, 
X-ray crystallography, enzyme kinetics, microscale thermophoresis (MST) and differential 
scanning calorimetry (DSC), to contribute to a better understanding of the enzyme mechanism 
and structure-function relationship.    
 OXA-48 like b-lactamases differ only by a few amino acid substitutions and/or 
deletions, and the resulting effects were not always evident. To gain a greater insight into the 
different OXA-48 like b-lactamases, protein crystals were obtained for OXA-181, OXA-163 
and the novel b-lactamase OXA-436, to determine the crystal structure. DSC analysis was used 
to determine the thermal stability for OXA-48, OXA-181, OXA-245, OXA-163 and OXA-436 
in two different buffer systems. The differences in thermal stability were discussed based on 
the obtained crystal structures.  
Many class D b-lactamases, including OXA-48 forms dimers in solution, however the 
structural nor the functional basis for this dimerization were obvious. Specific residues at the 
dimer interface could be potential targets for allosteric inhibitors. Three OXA-48 mutants 
affecting the dimer interface (R189A, R206A and R189A/R206A) were investigated by thermal 
stability analysis, dimer affinity determination, and enzyme activity assays. Based on these 
results it was concluded that the OXA-48 dimer is strong and held together by many salt-bridges 
at the dimer interface. Destabilization of the dimer does not seem to affect the enzyme activity 
significantly, but appears to be important for the thermal stability of the enzyme.  
Previously conducted mutational studies concerning the active site triad S70-T71-L73 
had shown S70 to be crucial for enzyme activity, but also that the active site serine contributes 
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to steric strain in the active site. S70 and L73 are assumed to be essential for the enzyme 
mechanism, however the role of the conserved active site residue T71 is not known. To further 
investigate the nature of the active site and the function of T71, the crystal structure of the 
OXA-48 mutants S70T and S70T/T71S were determined, and the enzyme activity measured. 
The obtained results suggested that both residues are crucial for the enzyme since the mutations 
greatly reduced the enzyme activity. This was explained by an increased steric strain, and 
unfavorable orientation of the active site residues.  
Ceftazidime and ceftazidime/avibactam is used against a broad range of b-lactamases, 
and it is possible that pathogens carrying the blaOXA-48 gene could be exposed to this treatment. 
Many pathogens carrying the blaOXA-48 gene, are multi-drug resistant, and a selective pressure 
of ceftazidime/avibactam on OXA-48 carrying bacteria might cause mutations to occur within 
OXA-48 conferring resistance towards this drug combination. The OXA-48 mutants P68A and 
P68A/Y211S were discovered in previous evolution studies selecting for OXA-48 ceftazidime 
and ceftazidime-avibactam resistance. Enzyme kinetics were therefore used to investigate the 
effect of these mutations on the enzyme activity with different substrates. The results suggested 
increased flexibility in the active site due to lack of P68, allowing for hydrolysis of larger 
substrates such as ceftazidime, to which OXA-48 is inactive. However, this seems to come at 
the cost of reduced ability to hydrolyse other substrates, compared to OXA-48.    
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1 Introduction  
For more than 70 years, antibiotics have been used to cure infections, and has over the 
years been used, and produced, at an increasing rate. The use of antibiotics is a cornerstone in 
modern medicine, agriculture and farming. Its use in medicine has reduced childhood mortality 
and increased life expectancy, being crucial for treatments such as chemotherapy, surgery, and 
even to recover from common community-acquired infections such as pneumonia [1, 2].  
Antibiotic-resistance is a growing problem, and new multidrug-resistant pathogens are 
spreading rapidly causing increased mortality rates and treatment costs. Antibiotic resistance is 
now being recognized as a world-wide crisis in modern medicine, and is expected to get much 
worse. It has been estimated that antimicrobial resistance (AMR), or drug resistance claims 700 
000 lives a year, being a low estimate, with an expected increase to 10 million deaths per year 
by 2050 [3], as illustrated in Figure 1-1. 
The Global Risks Report from 2013 warned about the growing risk of antimicrobial 
resistance, and lists antimicrobial resistance as one of the greatest treats to human health [4]. 
WHO published in 2014 their first global surveillance report on antimicrobial resistance, to 
make it clear that widespread antimicrobial resistance is no longer simply a possibility, but is 
happening all over the world. Coordinated awareness and action is needed to deal with the fact 
that antimicrobial resistance is creating a health crisis rapidly outpacing available treatment 
options [5]. 
 
Figure 1-1: Estimated global number of deaths caused by common causes in 2016, showed in blue. The expected 
rise of antimicrobial resistance (AMR) caused deaths per year by 2050 is 10 million, compared to 700 000 in 2016. 
Figure from reference [3].  
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1.1 Antibiotic resistance; mechanisms of resistance and b-lactam antibiotics  
Alexander Fleming received the Nobel Prize in Medicine in 1945 for his part in 
discovering the first mass produced antibiotic; penicillin. Already in his speech he warned that 
bacteria could develop resistance towards this “miracle drug” [5]. The development of 
resistance towards antibiotics is a part of the microbe evolution. Their high population numbers 
and capacity to exchange genetic information makes them remarkably ready to adapt. It is clear 
however, that the extensive use of antibiotics has forced this evolutionary process to move much 
faster than expected, causing the rapid spread of multi-resistant pathogenic bacteria worldwide, 
by selecting for bacteria with an elevated mutation rate [6].  
Bacteria can develop antibiotic resistance through several mechanisms; by altering the 
antibiotic binding site (or target) through mutations, changing the cell permeability and efflux 
pump(s), and producing enzymes that can inactivate the antibiotic by hydrolysis or 
modifications (e.g. b-lactamases)  [1, 6], these mechanisms are illustrated in Figure 1-2.   
The method of changing the antibiotic binding site is a successful method that can be 
found for almost all classes of antibiotics, since the antibiotic often binds to its target with high 
specificity. Gram-negative bacteria are less permeable than Gram-positive bacteria to many 
antibiotics, due to their outer lipid membrane. Efflux pumps and porins are therefore major 
contributors to the resistance of some Gram-negative bacteria. Efflux pumps are often capable 
of recognizing multiple substrates, recognizing chemical properties rather than chemical 
structure, making many efflux pumps multi-drug resistant by increasing the expulsion. Porins 
are the most abundant protein on the outer membrane, and acts as a selective barrier. Both the 
porin size and number of porins may affect the ability of the drug to enter the cell [1, 7].  
There are different types of antibiotics, used more or less frequently depending on the 
class. The different classes of antibiotics functions by different mechanisms; (i) b-lactams 
interfere with the cell wall synthesis, and are the most commonly used antibiotics, (ii) 
macrolides binds to the 50S subunit of bacterial ribosomes, preventing protein synthesis, (iii) 
aminoglycosides also prevents protein synthesis, by binding to the 30S subunit of bacterial 
















Figure 1-2: Illustration of different mechanisms of resistance in Gram-negative bacteria. The example shows b-
lactam antibiotics targeting the penicillin-binding protein (PBP). Antibiotic A and B are able to enter the cell via 
a porin membrane protein. Antibiotic A reaches its target and can inhibit peptidoglycan synthesis. Antibiotic B 
cannot bind to its target, and is also removed from the cell by an efflux pump. Antibiotic C cannot cross the outer 
cell membrane, and hence cannot access its target. Figure from reference [1].     
 
1.1.1 b-lactam antibiotics  
Resistance to antibiotics typically appears within 2-3 years after clinical introduction 
and use [8], the rapid development of antibiotic resistance is especially clear for the b-lactam 
class [9]. The widespread resistance is due to b-lactams being the most commonly used 
antibiotic class [2]. 
b-lactams are bactericidal antibiotics, and act by inhibiting the bacterial cell wall 
synthesis. The peptidoglycan cell wall envelops the bacterial cell, with a thick outer layer for 
Gram-positive bacteria, and a thinner cell wall enclosed by a lipid bilayer in Gram-negative 
bacteria. The peptidoglycan cell wall is important for bacterial cells to define the cell shape and 
keep the cell from osmotic rapture. The peptidoglycan is made up of linear polysaccharide 
chains of alternating N-acetylglucosamine and N-acetylmuramic acid, cross linked by peptides, 
by the enzyme transpeptidase, also known as penicillin-binding proteins (PBP). PBPs bind to 
b-lactam antibiotics, because the b-lactams are structurally similar to the substrate (D-ala-D-
ala) of PBPs. Inhibition of PBPs by b-lactams reduces cross-linking between the linear 
peptidoglycan chains, eventually causing cell wall degradation, and making the cell unable to 
withstand the osmotic pressure, causing cell rupture [7, 10].  
b-lactams all have a four membered b-lactam ring in their structure core, and can be 
divided into four classes based on the structure; penicillins, cephalosporins, monobactams, and 






Figure 1-3: Chemical structure of the four different classes of b-lactam antibiotics in clinical use. The four 
membered b-lactam ring is the core of the structure. Figure from reference [7].  
 
1.1.1.1 Penicillins 
 Penicillin is the oldest known b-lactam antibiotic, initially derived from Penicillum 
fungi. It was discovered by a coincidence in 1928 by Alexander Fleming, who was the first to 
describe its inhibition of bacterial growth. Ernst Chain and Howard Florey were the ones 
responsible for turning the discovery of penicillin into medical use, and received the Nobel 
Prize in Medicine in 1945 together with Fleming for their work.  
The penicillin core consists of five-membered thiazolidine ring fused to the b-lactam 
ring, as illustrated in Figure 1-3. The penicillin family is divided into five basic classes; natural 
penicillins (e.g. penicillin G/ benzylpenicillin – early generation penicillins), penicillinase-
resistant penicillins (e.g oxacillin), aminopenicillins (e.g ampicillin), extended-spectrum 
penicillins (e.g piperacillin), and aminopenicillins/ b-lactamase inhibitor combinations. The 
aminopenicillins were the first penicillin group to function against Gram-negative bacteria. 
Even though penicillins are important in modern medicine its extensive use has led to decreased 
efficiency and resistance [7, 11].  
 
1.1.1.2 Cephalosporins  
Cephalosporin C was the first in the cephalosporin subfamily to be discovered from the 
fungi Chepalosporium acremonium in 1948. It consists of a six-membered dihydrothiazine ring 
attached to the b-lactam core, and has two sites for attachment of different sidechains, giving a 
wider structural diversity compared to penicillins which only has one site for sidechain 
attachment, as shown in Figure 1-3 [7].  
The closely related compound cephamycin is chemically similar to the structure of 
cephalosporins, and are sometimes classified as one, but was originally derived from the fungi 
Streptomyces and determined to be a separate class of b-lactams from the cephalosporins [12]. 
Cephalosporins are classified into 5 generations based on their antimicrobial properties; the 
first generation being the oldest classified cephalosporins, and the later generation having a 
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more extended-spectrum. Cephalothin is the oldest cephalosporin antibiotic in the first 
generation and was active towards most Gram-positive bacteria. The second generation had a 
slightly lower activity towards Gram-positive bacteria, but had an extended-spectra towards 
certain Gram-negative bacteria. An example of a second-generation cephalosporin is 
cefuroxime. Ceftazidime and cefepime are examples of third and fourth generation 
cephalosporins [13].  
 
1.1.1.3 Monobactams 
The only clinically approved and available monobactam is aztreonam, which is 
synthetically made. It differs from the other b-lactams by not having any ring structure fused 
with the b-lactam ring, as illustrated in Figure 1-3. Aztreonam is not widely used clinically 
since cephalosporins have a more extended-spectrum, but it is especially active against aerobic 
Gram-negative bacteria [7, 14].       
 
1.1.1.4 Carbapenems 
Carbapenems were developed from the discovery of thienamycin from Streptomyces 
cattleya, which turned out to be chemically unstable. This was overcome by the N-formimidoyl 
derivative, imipenem. The general structure of carbapenems is illustrated in Figure 1-3. Later, 
several different compounds have been derived from the original thienamycin. Some of the 
most clinically important are meropenem, ertapenem and doripenem, their specific structure of 
which, are shown in Figure 1-4 [15, 16].  
All clinically used carbapenems have a 6-hydroxyethyl R1-sidechain, which is proposed 
to disrupt the hydrolysis step of the b-lactam ring. This sidechain is more compact than some 
of the penicillins and cephalosporins [17]. Other factors that are considered to make 
carbapenems especially difficult to hydrolyze are; firstly, the fused pyrroline ring (as opposed 
to thiazolidine in penicillins, and thiazine in cephalosporins), the presence of the double bond 
in the pyrroline ring gives a flatter ring structure and allows for tautomerization upon acylation 
(sp2 or sp3 hybridization of C-2). Secondly the C-6 atom stereochemistry is S instead of R as 
found for penicillins and cephalosporins [17]. See Figure 1-3 and Figure 1-4 for labelling of 





Carbapenems have a remarkably broad antimicrobial activity compared to other b-
lactams, and are relatively resistant towards hydrolysis by b-lactamases. Carbapenems are still 
considered a “last defense” towards multi-resistant gram-negative pathogens. However, 
carbapenem resistance has spread rapidly, making carbapenems less and less useful. It is 




Figure 1-4: Structure of the carbapenem antibiotics; ertapenem, meropenem, imienem and doripenem. Certain 




1.2 b-lactamases and the class D b-lactamases – Oxacillinases   
The expression of b-lactamases is the most prevalent mechanism of resistance against 
the b-lactam class of antibiotics. By now over 4000 individual b-lactamases have been 
identified and reported, and the number is steadily growing (Beta-Lactamase DataBase, 
accessed 01.04.18) [19].  
There are two possible classification systems for b-lactamases; the Ambler system, and 
the Bush-Jacoby-Medeiros system. The latter is a functional-based system grouping the 
enzymes in three main-classes (1; cephalosporinases, 2; broad-spectrum, inhibitor-resistant, 
extended-spectrum b-lactamases, and serine-carbapenemases, 3; metallo-b-lactamases) and 
subclasses, based on their substrate and inhibitor profiles. This is a more subjective system than 
the Ambler classification, but relates the varied enzymes to their clinical role [20, 21]. The most 
widely used classification system is the molecular classification, or the Ambler system, dividing 
b-lactamases into four groups (A-D) based on the amino acid sequence and structure [22]. Class 
A, C and D are serine-b-lactamases, with an active site serine, while class B are metallo-b-
lactamases with a Zn2+ ion in the active site. The class A b-lactamases are the most common b-
lactamases, and were the first b-lactamases to be identified, in penicillin resistant isolates [8]. 
Class D b-lactamases are often termed “oxacilliases” or OXA-enzymes, due to the original 
observation that members of this class had a strong hydrolytic activity towards the b-lactam 
oxacillin.  
Class D b-lactamases are named using the OXA nomenclature and a number based on 
when they were discovered in time. Based on sequence identity class D b-lactamases are also 
divided into a number of subfamilies with >80% sequence identity. With more than 650 
members in the class D subfamily, it is not the largest, but the fastest growing subfamily. It is 
also the most diverse class, of the four Ambler classes, both in terms of genetics and 
biochemical properties [23]. Class D b-lactamases can hydrolyze both narrow and extended 
spectrum antibiotics. OXA-enzymes are considered increasingly problematic as they can be 
found among human pathogens - clinically relevant Gram-negative species, such as 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae (e.g Klebsiella 
pneumoniae and Escherichia coli) [23, 24]. In 2017 WHO published the first ever list of 
“antibiotic resistant priority pathogens” for which new antibiotics are urgently needed, meant 
as a tool to ensure that research is focused on public health needs. Listed as the most critical 
pathogens are the carbapenem resistant Acinetobacter baumannii, Pseudomonas aeruginosa 
 
 8 
and Enterobacteriaceae [25]. This highlights the need for a greater understanding of how b-
lactamases – especially those showing carbapenem resistance, functions and can be inhibited.    
Class D b-lactamases genes can be located both on chromosomes and plasmids, and are 
also coexisting with other OXA-enzymes on the same plasmid. The horizontal gene transfer 
using plasmids and transposons, promotes a rapid evolutionary process within, and even 
between bacterial species [8].  
Kinetically the class is quite diverse. Narrow-spectrum variant enzymes hydrolyze early 
generation penicillins and cephalosporins most effectively. Extended-spectrum variants are 
more problematic as the enzyme possess point mutations in the active site region that allow 
them to bind later generation cephalosporins with more bulkier side chains. But the most 
troublesome fact is that some OXA-enzymes are able to hydrolyze last resort antibiotics; 
carbapenem. The hydrolysis of carbapenems is slow, but with a high substrate affinity [24, 26].    
 
1.2.1 Overall structure and reaction mechanism of class D b-lactamases  
Despite class D b-lactamases being diverse, all OXA-enzymes display several 
conserved amino acid residues and motifs. The topological protein fold is highly conserved. 
The active site motifs Ser-Thr-Phe-Lys (amino acid number 70-73 using DBL numbering), Ser-
Val-Val (118-120) and Lys-Thr-Gly (208-210) are found for all OXA-enzymes [23, 24].  
In contrast to class A and C serine b-lactamases which are dominantly monomers, class 
D b-lactamases are both monomeric and dimeric. Each monomer has an independent active 
site. The OXA-enzyme fold is composed of two domains; one central b-sheet domain 
surrounded by a-helices, and one a-helical domain. The active site is found in the interface 
between the two domains, and is formed by a short 310 helix. One side of the active site is made 
up by the omega loop (W), a loop with W shape and varying length. [26]. 
 The general enzyme mechanism of serine-b-lactamases is widely accepted, where the 
active site serine hydrolyzes b-lactam antibiotics in a three-step model, as shown in equation 
1-1.  
 
 (1-1)                                                                              
                                                                                          




In the first step the enzyme interacts with the substrate forming into a Henri-Michaelis complex, 
which can either dissociate or form the acyl-enzyme complex. The acyl-enzyme complex is 
formed by a nucleophile attach by the active site serine, activated by a general base, forming 
an ester linkage to the b-lactam antibiotic. In the last step, the ester-linkage is hydrolyzed by an 
active site water molecule, activated by a general base. The product is released and the active 
site serine restored to its original state. The rate-constants k1, k2 and k3 describe the binding, 
acylation and deacylation rates of the reaction. The reaction is made possible by the use of a 
general base (in hydrogen bonding distance to the active site serine), making the weakly 
nucleophilic hydroxyl group into a strong nucleophile [27-29]. 
 Identifying the general base that activates the active site serine has been very 
challenging for all serine b-lactamases. After discovering the unusual N-carboxylation 
(covalent bond between amino acid side chain nitrogen and a carboxy group) chain and post-
translational modification for Lys73 in OXA-enzymes, and enzyme inactivation upon 
decarboxylation, it was concluded that this residue acts as the general base for both the acylation 
and deacylation step [27, 30].  
The formation of the carboxylated lysine in OXA-enzymes is favored by hydrophobic 
buried protein regions that lowers the pKa value, and local residues are able to stabilize the 
negatively charged deprotonated carbamate [31]. A study by Isom et al. on buried lysine 
residues, showed that the pKa value may be reduced by as much as 5 pH units, in favorable 
hydrophobic environments [32]. The very hydrophobic active site of class D b-lactamases, 
compared to class A and C b-lactamases allows Lys73 to exist in a deprotonated state at neutral 
pH for OXA-enzymes, able to react spontaneously with carbon dioxide forming the 
carboxylated lysine, characteristic for all class D b-lactamases [27].  
 The proposed general reaction mechanism for class D b-lactamases is illustrated in 
Figure 1-5, based on the reaction mechanisms presented in Leonard et al. [26] and Sun et al. 
[33]. First, the carboxylated Lys73 (KCX) acts as a general base, taking a proton from Ser70, 
making it a better nucleophile. Ser70 attacks the b-lactam ring carbonyl, yielding a covalent 
acyl-enzyme intermediate. The tetrahedral intermediate is stabilized by the main-chain amides 
of residue Ser70 and Tyr/Trp/Pro/Ala 211, and sidechain of Lys208. The easiest way of 
restoring the negatively charged lysine carbamate (enabling it to work as a general base and 
activating the active site water molecule) has been suggested to be a proton transfer to the b-
lactam nitrogen leaving group using Ser118 as an intermediate. Ser118 is mostly found at 
hydrogen bonding distance to Ser70, while KCX is not. Often Ser118 is not close enough to the 
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carboxylate group, but found at hydrogen bonding distance to the carbamate nitrogen, and it is 
suggested that the proton may be transferred in this manner. The now restored general base 
KCX takes a hydrogen from an active site water molecule, the hydroxyl nucleophile will then 
attack the cleaved b-lactam carbonyl, releasing Ser70, which is restored with the hydrogen from 
KCX [26, 33, 34]. Another residue conserved among class D b-lactamases is Arg250, found in 
the active site. Arg250 is suspected of contributing to the catalysis by trapping the substrate, 
forming an ionic bond with the carboxylate group of the substrate, or stabilizing the transition 
state [34].   
 
Figure 1-5: Proposed reaction mechanism for class D b-lactamases adopted from Leonard et al. [26], and Sun et 
al. [33], the movement of electrons are shown by curved arrows. The substrate is stabilized by an ionic interaction 
to Arg250 (showed only in the first step), Ser70 is activated by the carboxylated Lys73, and performes a 
nucleophilic attack on the b-lactam ring. The ring-structure opens and carboxylated Lys73 is restored to its 
deprotonated state through a proton transfer using Ser118 as an intermediate. Carboxylated Lys73 then acts as a 
general base again activating a catalytic water molecule, which attacks the carbonyl-group of the acyl-complex, 













































































 The importance of the carboxylated lysine has been proven in multiple studies, showing 
that mutation of Lys73 lead to an inactive enzyme [26, 35]. The hydrophobic core surrounding 
Lys73 has also shown to be highly important for enzyme activity. Mutational studies on the 
residues Val120 and Trp157, has also shown to promote decarboxylation and enzyme inactivity 
[27, 36].  
 Other mutational studies focusing on the carboxylated lysine show that the mechanism 
(perhaps not surprisingly) is likely not so simple as described. For class D b-lactamases 
deacylation has proven to be the rate-limiting step. Despite the lack of a carboxylated lysine 
Vercheval et al. [37] and Schneider et al. [27] managed to show the formation of the acyl-
enzyme intermediate, while the deacylation rate was almost completely stopped. Similar results 
have been shown for class A b-lactamases, being used as an argument for an asymmetric 
reaction mechanism – using two different residues as general bases [38]. However, as pointed 
out by Schneider et al. [27] the effect of mutation of residues essential to the enzyme mechanism 
should be considered with caution, the acylation (and lack of deacylation) may be effects of 
changes and adaptations in the active site upon mutating Lys73 [27]. The acylation and lack of 
deacylation (previously noted as enzyme inactivity) was also observed by Lund et al. [39] using 
surface plasmon resonance (SPR) to study interaction between substrate and OXA-48. Using a 
buffer without bicarbonate it was observed that acylation still was present, but deacylation only 
at a slow rate [39]. A possible explanation for why some enzyme activity is found with 
decarboxylated lysine in the active site could be found from the suggested reaction mechanism 
for class C b-lactamases. Here it is suggested that deprotonated lysine (not carboxylated) acts 
as the general base in the acylation step, or that the substrate carboxylgroup itself may act as a 
general base activating the active site serine [40].  
 Another study also show the complexity of enzyme mechanisms, by Sgrignani et al. 
[41] – using quantum mechanics/ molecular mechanics (QM/MM) calculations, suggests a 
different reaction mechanism for class D b-lactamase OXA-23 [41]. The study found that the 
simplest hypothesis of the direct proton transfer from Ser118 to the nitrogen of the b-lactam 
ring, was energetically highly unlikely. The most likely scenario was quite different; the 
acylation-step mechanism remained the same, but in the deacylation step the proton transfer to 
the nitrogen of the b-lactam ring would happen through another residue, Lys208, by stabilizing 
a water molecule, enabling the nitrogen to take a proton from the catalytic water. The hydroxyl 
would then act as a nucleophile (as previously explained). The carboxylated lysine will then 
 
 12 
only contribute in transferring a proton to Ser70, restoring it [41]. This does seemingly not help 
explain why the deacylation step is particularly affected by Lys73 decarboxylation or mutation.   
 These slightly conflicting results hints at the reaction mechanism of class D b-
lactamases being more advanced and intricate than currently understood, there are many 
residues involved, and highlights the need for further studies of both structural and functional 
aspects concerning the enzyme mechanistic details.  
  
1.2.2 Carbapenem-hydrolyzing class D b-lactamases 
Carbapenem-hydrolyzing b-lactamases can be found among class A, C and D serine-b-
lactamases, common to them is the ability to hydrolyze a broad range of b-lactams, including 
extended spectrum cephalosporins and carbapenems. Class B metallo-b-lactamases are also 
carbapenemases. Carbapenemase producing pathogens are often multidrug-resistant, and 
difficult to treat, with high mortality rates. Class D b-lactamases were first identified on the 
chromosomes in a single bacteria species, with narrow substrate specificity, and not considered 
a great clinical treat. The discovery of class D b-lactamases able to hydrolyze carbapenems and 
cephalosporins changed this view. Many carbapenemases are now found on mobile genetic 
elements, and are reported in clinically important pathogens such as A. baumannii, P. 
aeruginosa and Enterobacteriaceae (especially K. pneumoniae) [1, 42].  
Enterobacteriaceae is a bacterial family that inhabits the intestinal flora, and is among 
the most common human pathogens, causing both community and hospital-acquired infections. 
The first carbapenem resistant Enterobacteriaceae was reported in 1993, and has since spread 
worldwide. This is the cause of great concern due to the easy spread of this pathogen among 
humans, and the fact that carbapenem drugs are considered as “last defense” antibiotics in the 
clinic [43, 44].   
Carbapenem-hydrolyzing class D b-lactamases (CHDLs) are defined as class D b-
lactamases that produce clinical levels of resistance to carbapenem antibiotics. Enzymes 
belonging to the subfamilies OXA-23, OXA-24/40, OXA-48, OXA-51, OXA-58, OXA-143 
and OXA-235 comprise over 200 enzymes which are classified as CHDLs [17]. All these 
enzymes were isolated form A. baumannii (with the exception of the OXA-48 like enzymes) 
[17]. Although only a selection of OXA-enzymes are considered to be CHDLs, a study by 
Antunes et al. [45] show that perhaps all class D b-lactamases are CHDLs. In the study,      
OXA-10 and OXA-2 which are considered narrow-spectrum enzymes (based on MIC values 
from these enzymes produced in E. coli or P. aeruginosa) was expressed in A. baumannii. The 
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strain is unique due to its low permeability and low antibiotic concentration in its periplasma, 
contributing to increased levels of resistance. OXA-10 and OXA-2 enzymes expressed in A. 
baumannii, turned out to in fact be CHDLs. This is clinically concerning, as there is a possibility 
that class D b-lactamases not previously considered to be CHDLs could display carbapenem 
resistance if expressed by these bacteria [45]. CHDLs have been reported increasingly in recent 
years [28]. One of the major concerns for attempting to control the CHDL spread are difficulties 
identifying the enzymes [23].  
Determining the detailed reaction mechanism for carbapenem hydrolysis by CHDLs is 
an ongoing process, and several different mechanisms have been suggested, with arguments 
both for and against individual mechanisms among the different OXA subfamilies. Class D b-
lactamases are as mentioned, a highly divergent class, both structurally and functionally. The 
apparent lack of conserved residues involved in carbapenem hydrolysis across different OXA 
subfamilies, has led to the conclusion that CHDLs utilize different evolutionary strategies, 
where specific residues give a local active site conformation capable of positioning the catalytic 
water molecule favorable for carbapenem hydrolysis. Crystal structures of OXA-24/40 and 
OXA-48 has been used to show this [28, 46].    
The first carbapenem hydrolysis mechanism was suggested for OXA-24/40 from A. 
baumannii by Santillana et al. [47] who through crystallization and mutational studies identified 
that substrate specificity is affected by a hydrophobic barrier formed by Tyr112 and Met223, 
creating a tunnel-like entrance into the active site [47]. Later Schneider et al. [48] suggested 
that the hydrophobic bridge structure prevented tautomerization and the formation of sp3 
hybridized C-2 atom in the pyrroline ring (Figure 1-4), keeping the carbapenem substrate in the 
correct orientation and conformation in the active site, allowing for deacylation [17, 48]. A 
different mechanism was suggested by Docquier et al. [46] for OXA-48 from 
Enterobacteriaeae. OXA-48 have no hydrophobic bridge shaping its active site as OXA-24/40 
do, and is as a result more “open”. It was suggested that the specific conformation of the 
residues near the b5-b6 loop caused the hydroxyethyl-group of the carbapenem substrate to 
adopt a different rotamer and reposition, allowing for a distant active-site water molecule to get 
close enough to start the deacylation reaction [17, 26, 46].  
Toth et al. [17] found that the conserved hydrophobic surface residue Val119 play an 
important role for the deacylation step of carbapenem in OXA-143 (a close relative of OXA-
24/40), arguing that this might be an important part of a more universal reaction mechanism for 
CHDLs. Val119 was found to have two different conformations in the active site. In the first 
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both methyl groups are directed away from Ser70 (“open conformation”), while in the second 
conformation one of the methyl groups points towards Ser70 (“closed conformation”). The 
“open conformation” creates a small pocket around the active site residues, allowing for a water 
molecule to be present, and promoting deacylation. In the “closed conformation”, the water will 
be positioned too far away from the active site residues. Binding of the substrate is quite 
specific, and upon binding, the hydroxyethyl sidechain of the carbapenem substrate will clash 
sterically with the “closed” conformation of Val119, locking it into the “open conformation”. 
The formation of the acyl-enzyme complex in OXA-14, OXA-24/40 and OXA-23 leaves no 
space in the active site for the catalytic water molecule. However, the formed water-channel by 
the “open conformation” of Val119 solves this problem, and allows for deacylation [17]. 
The latest suggested reaction mechanism for carbapenem hydrolysis by class D b-
lactamases, presented by Lohans et al. [49] show a new hydrolysis product, using NMR and 
MS. Rather than cleavage of the b-lactam ring, a b-lactone product is proposed to be formed 
instead, where the hydroxyl group of the hydroxyethyl carbapenem side-chain acts as a 
nucleophile in place of the water molecule required for hydrolysis [49]. The two possible 
reaction mechanisms and the structure of the two possible hydrolysis products are shown in 
Figure 1-6. In the study b-lacton formation by OXA-48 with different substrates were 
examined, suggesting that the b-lacton formation is dependent on a 1b-methyl substituent. It 
was suggested that the lactone formation only represented a competitive pathway if hydrolysis 
is disfavored. No b-lactone formation was observed for class A and B b-lactamases [49]. 
The results from different studies show that we have come closer to understanding the 
specific mechanism of class D b-lactamases, but still much is not known, the different findings 
hint at a larger more complex reaction mechanism than shown earlier. Further mutational 
studies affecting the enzyme active site, and enzyme activity, will be important to gain a greater 




Figure 1-6: Proposed mechanism for suggested competitive carbapenem hydrolysis reaction through lactone 
formation. Hydroxy group acts as nucleophile instead of the catalytic water molecule. Ser is the active site serine, 
KCX is the carboxylated active site lysine functioning as a general base. 1b-methyl group important for lactone 




1.3 OXA-48 and OXA-48 like class D b-lactamases 
OXA-48 was first identified from a carbapenem- and multidrug- resistant K. 
pneumoniae isolate in Turkey in 2001. The identified blaOXA-48 gene was plasmid located, and 
showed low amino acid sequence similarity with other class D b-lactamases, therefore being 
recognized as its own OXA-subfamily (46% identity with OXA-10, as the highest sequence 
similarity). Enzyme kinetics showed that OXA-48 hydrolyze penicillins at a high level and 
carpabenems at a low level, but had only a weak activity towards extended-spectrum 
cephaloporins [50, 51].  
Since the discovery, OXA-48 producers have been identified worldwide in 
Enterobacteriaceae, even (rarely) in A. baumannii, and OXA-48 is one of the most 
geographically widespread members of the class D b-lactamases [43]. One of the reasons for 
the fast spread of OXA-48 producers, may be the difficulties in identifying these. Both the lack 
of a good phenotypic identification method, and the fact the blaOXA-48 gene has a generally weak 
activity towards carbapenems, made the identification challenging [43, 51].  
Some CHDLs have been shown to originate from Shewanella, a waterborne species. 
The main hypothesis is that insertion sequences (genetic tools) mobilized the chromosomal 
genes into plasmids which then transferred the gene into the more clinically relevant species. If 
the transfer was direct or was executed through an intermediate species is not clear, but Serratia 
mercescens has been suggest as an intermediate after blaOXA-48 was identified in this 
enterobacterial pathogen from an aquatic environment [23, 51].   
 
1.3.1 OXA-48 variants 
Several OXA-48 variants have been identified since the discovery of OXA-48, differing 
only by a few amino acids. Figure 1-7 shows a sequence alignment of the different OXA-48 
variants used during this thesis, namely OXA-48, OXA-163, OXA-245, OXA-436 and OXA-
181. OXA-48 like variants have shown to be rather heterogeneous in terms of their hydrolytic 
profile, although being homologous in terms of protein sequence [52].  
OXA-181 differs from OXA-48 by a four amino-acid substitution (T104A, N110D, 
E168Q and S171A), and generally show the same hydrolytic activity. Interestingly it is often 
found co-expressed with other carbapenemases, like metallo-b-lactamases. Despite the close 
sequence similarity, OXA-48 and OXA-181 has always been identified in distinct genetic 
contexts, suggesting that OXA-181 did not evolve from OXA-48 through mutations, but that 
the two occurred from mobilization of two different genes from two Shewanella strains [51].  
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OXA-163 is especially interesting in that it only differs from OXA-48 by a four amino-
acid deletion (residue 214-217) and one amino-acid substitution (S212D) but has a different 
substrate specificity and hydrolytic profile. OXA-163 hydrolyses extended-spectrum 
cephalosporins, but carbapenems very weakly, making it more an extended-spectrum b-
lactamase (ESBL) rather than a CHDL, as OXA-48 and other OXA-48 like variants [51, 53].  
OXA-245 displays a quite similar hydrolytic activity to OXA-181 and OXA-48, and 
differs only from OXA-48 by one amino acid substitution (E125Y), the reason for this mutation 
is not completely evident [54].   
OXA-436 is a newly identified OXA-48 like CHDL, isolated from patients in different 
hospitals in Denmark. Previously described OXA-48 variants differs only by > 97% in sequence 
identity, while OXA-436 has 90-93% sequence similarity to the other OXA-48 variants [55].    
 
 
Figure 1-7: Sequence alignment of OXA-48, OXA-181, OXA-245, OXA-163 and OXA-436, with secondary 
structure elements from the crystal structures of OXA-48 (top, PDB: 5QB4) and OXA-181 (bottom, PDB: 5OE0). 
The residues are labelled according to the DBL numbering system. The conserved active site motifs are marked 
with blue frames, and the red triangle marks the end of the signal peptide. The green stars denote the substituted 
residues in the OXA-48 mutants investigated in this thesis. Figure was prepared using ESPript 3.0 [56] in 
collaboration with researcher Hanna-Kirsti S. Leiros.    








1.3.2 OXA-48 structure and mutagenesis studies 
 
1.3.2.1 Mutants affecting the dimer interface of OXA-48 
It has been shown that some of the class D b-lactamases, including OXA-48, form 
homodimers, a protein-protein interaction where two identical polypeptide chains dimerize 
[35]. The binding affinity in a protein-protein interaction may vary a lot, with dissociation 
constants (Kd) spanning from µM to pM. The smaller the Kd value the stronger the binding 
affinity, and attraction between the polypeptide chains [57]. Studies on OXA dimerization for 
OXA-10, OXA-14 and OXA-29 determined Kd values from nM to µM range using gel filtration 
methods [58, 59]. For OXA-10 and OXA-14 divalent cations have been shown to facilitate 
dimerization, giving a more active dimer than monomer [58]. For OXA-48 a chloride ion was 
reported in the dimer interface bound between two amino acid Arg206, one from each protein 
chain upon dimer formation [39]. Chloride ions are known to form “packing bridges” 
connecting two adjacent protein chains, but are previously not known to be located in the dimer 
interface [60].    
Compounds targeting the dimer interface may be useful inhibitors as some dimeric OXA 
enzymes have shown to be more active than the monomeric [58]. Targeting the dimer interface 
has been challenging due to the generally large surface of the dimer interface, and the lack of 
binding pockets. However, it has been shown that not all residues in the dimer interface are 
critical, but that most of the binding energy arise from small “hot-spots”, often found near the 
center of the interface. This suggests that small molecule inhibitors may be used by targeting 
these “hot-spots” binding sites. Investigating the dimer interface is therefore important to be 
able to explore the possibility for such dimer inhibitors, and for elucidating the oligomeric state 
of the enzyme [61].  
In a study by Dr. Bjarte A. Lund (unpublished data) an OXA-48 mutant affecting the 
dimer interface was designed; residue Arg206 binding a chloride ion was mutated to alanine. 
The effect of disrupting the chloride binding in the dimer interface was studied using size 
exclusion chromatography, differential scanning calorimetry (DSC), enzyme kinetics, and 
microscale thermophoresis (MST) (unpublished data). Size exclusion chromatography showed 
that both OXA-48 and OXA-48 R206A eluted as dimers, only at pH 4.0 did the enzymes elute 
as monomers, indicating the importance of the salt-bridges in the dimer interface. MST results 
were not obtained for OXA-48, but showed a remarkable low Kd value of 700 pM for OXA-48 
R206A, indicating that the dimer interface of OXA-48 is more stable than of other class D b-
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lactamases. DSC showed that OXA-48 had >4°C higher melting temperature than OXA-48 
R206A, suggesting that the dimer formation is important for enzyme stability. No significant 
difference in enzyme activity was observed (unpublished data). A lower activity should in 
principle be observed, if the monomeric form was significantly less active than the dimeric 
form. It would therefore be interesting to design an even less thermostable OXA-48 mutant 
affecting the dimer interface, to better study the monomeric form and elucidate requirements 
for dimer formation (Figure 1-8 C).  
Based on an in situ alanine scan, residues contributing to stabilizing the OXA-48 dimer 
were identified and ranked by suspected influence, as shown in Table 1-1. Based on these 
results it was decided to design two OXA-48 mutants in this study; one single mutant Arg189 
to alanine (R189A), and one double mutant Arg189 to alanine and Arg206 to alanine 
(R189A/R206A). Figure 1-8 A shows the ribbon dimer structure of OXA-48, with residue 
interactions for R206 and R189 in the dimer interface (Figure 1-8 B), and the loss of interactions 
for the OXA-48 R189A mutant (Figure 1-8 C).     
 
Table 1-1: Calculated energy differences from changing the residue to alanine using BioLuminate [62], and the 
chain A and D of OXA-48 (PDB: 5DTK). Top ten most influential residues are shown, mutating one or more of 
these will most likely influence and reduce the dimer stability. Calculations performed by Dr. Bjarte A. Lund.   









































Figure 1-8: A) Proposed assembly of OXA-48 from a crystal structure (PDB: 5QB4), residues interacting with 
the dimer interface residues R189A and R206A are showed as stick figures. The active site residue S70 is also 
showed as a stick figure, and circled to highlight the active site. The chloride ion bound by residues R206 is shown 
as an orange sphere. B) Labelled residues with interactions to residue R189 showed as dashed lines. C) The lack 
of interactions for OXA-48 mutant R189A in the dimer interface, likely to contribute to reduced dimer affinity, 
from crystal structure of OXA-48 R189A. Ribbon structures made in PyMOL by researcher Hanna-Kirsti S. 
Leiros.   
 
A 
B OXA-48                                      OXA-48 R189A C 
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1.3.2.2 Mutants affecting the active site residues of OXA-48 
The active site of OXA-48 is a narrow crevice of 5x10x20 Å (width, depth, length). The 
catalytically relevant residues Ser70, Lys73 and Arg250 are spatially conserved [46]. The 
function of Ser70 as an active site nucleophile, and suggested reaction mechanism creating an 
acyl-enzyme complex was first suggested in the 1980s [63]. This led to multiple studies looking 
into the conserved active site motif involving Ser70. Mutational studies on the class A b-
lactamase TEM, was conducted both with cysteine and threonine substitutions [64, 65]. The 
“thiol-b-lactamase”, S70C, showed reduced, but detectable catalytic activity [65]. Another 
study using several different serine and threonine substitutions, showed no detectable activity 
for S70T, or S70T/T71S mutants. However, a Thr71 to serine mutant did not affect the catalytic 
activity drastically compared to TEM. The thermal stability was also shown to be affected; for 
the T71S mutant the thermal stability was reduced, while for the S70C mutant showed enhanced 
thermal stability. It was speculated that the additional methyl group of threonine may cause a 
too great sterically hindrance within the constraints of the active site, giving no activity for 
Ser70 mutants. The additional methyl group of Thr71 may act as a keystone to interlock with 
other segments of the b-lactamase polypeptide chain, being important for stabilizing the three-
dimensional structure [64]. To our knowledge no mutational studies on Ser70/Thr71 
substitutions have been conducted for class D b-lactamases. Three mutants were therefore 
designed; one single mutant Ser70 to threonine (S70T), and one double mutant Ser70 to 
threonine and Thr71 to serine (S70T/T71S), aiming for more insight into the importance of 
Ser70 and Thr71 in OXA-enzymes. The last mutant Ser70 to alanine (S70A) was design simply 
to have an inactive enzyme, for kinetic activity comparison. Figure 1-9 show the active site 
residues of OXA-48 with bound imipenem, including substituted active site residues in the 
mutants affecting the active site.   
The combination of ceftazidime-avibactam (b-lactam/ b-lactamase inhibitor) was 
designed to treat infections caused by Klebsiella pneumoniae carbapenemases (KPC) carrying 
pathogens [66]. Ceftazidime and ceftazidime/avibactam is used against a broad range of b-
lactamases, and it is possible that pathogens carrying the blaOXA-48 gene could be exposed to 
this treatment. Many pathogens carrying the blaOXA-48 gene, are multi-drug resistant, and a 
selective pressure of ceftazidime/avibactam on OXA-48 carrying bacteria might cause 
mutations to occur within OXA-48 conferring resistance towards this drug combination [51]. 
Organisms producing an enzyme with very low activity against a substrate, may evolve 
enzymes that are more efficient, when exposed to that substrate [28]. Emergence of resistance 
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to cephalosporin with inhibitor combinations has been reported for OXA-2 in P. aeruginosa. 
This is the first report of in vivo emergence of an extended-spectrum class D b-lactamase, 
during treatment of a human infection with broad spectrum cephalosporins [67]. 
Therefore, in vitro selection of an OXA-48 expressing E. coli strain against clinical 
relevant concentrations of ceftazidime, and ceftazidime/avibactam was conducted by PhD. 
student Christopher Fröhlich. Analysis of single point mutations within blaOXA-48 revealed 
single and double mutations; P68A and P68A/Y211S after selection on ceftazidime and 
ceftazidime/avibactam, respectively (unpublished data). The identified mutations were close to 
the active site serine (S70) of OXA-48, and therefore likely to affect the catalytic activity. 
Figure 1-9 shows the placement of residue P68A and Y211S in the active site. In this thesis, 
the mutants P68A and P68A/Y211S were expressed and purified, to study the effect of the 
mutations on the enzyme activity with selected antibiotics.      
 
Figure 1-9: Proposed assembly of the active site residues in OXA-48 with bound imipenem, from a crystal 
structure (PDB: 5QB4). OXA-48 is displayed by ribbon structure in cyan, imipenem is shown in orange. The 
active site residues suspected of being important for the reaction mechanism, as well as the residues substituted in 
the active site OXA-48 mutants, are shown as stick figures. The figure was made in PyMOL, in collaboration with 




1.4 Classical b-lactamase inhibitors  
During this thesis, the focus has been to study the stability, structure and enzyme 
mechanism, to gain more knowledge on this subject, also aiming for development of future 
OXA-inhibitors, and other solutions to the growing resistance problem. Only a brief mention 
of current inhibitors will therefore be given here.  
To extend the use of existing b-lactam antibiotics b-lactamase inhibitors like culvanic 
acid, sulbactam and tazobactam were developed to coincide with the antibiotics already 
discovered. Culvanic acid was the first b-lactamase inhibitor introduced clinically in the 1970s. 
All three inhibitors are compounds that share structural similarity with penicillin, and are 
especially efficient towards class A b-lactamases. Avibactam is the first non-b-lactam b-
lactamase inhibitor to be introduced clinically, in 2015. It has a broader spectrum activity than 
culvanic acid and sulbactam, inhibiting most class A and C b-lactamases, and even some class 
D carbapenemases. Unlike the previous inhibitors, avibactam is a tight binding reversible 
inhibitor for most enzymes (irreversible inhibitors bind irreversible to the enzyme causing a 
permanent inactivation) [68, 69]. However, resistance towards ceftazidime-avibactam 
combinations are already being reported for KPC (class A b-lactamase), showing the need for 




1.5 Studying protein stability and activity 
There are several different methods for studying protein stability and activity, focusing 
on different aspects. Only the methods used during this thesis will therefore be described here. 
  
1.5.1 Differential scanning calorimetry (DSC)  
Differential scanning calorimetry (DSC) is a powerful method for characterizing the 
stability of a system, and for directly determining the thermodynamic parameters; enthalpy 
(DH°) and heat capacity change (DCp), as well as the melting temperature (Tm). DSC have 
many applications, and are commonly used to study protein denaturation, thermal protein 
stability, and folding mechanisms [72].  
   The heat capacity is a measure of the heat required to increase the temperature by 1°C 
for a given substance. The change in heat capacity of a compound reflects its ability to absorb 
heat. DSC functions by measuring small temperature differences between a sample cell, filled 
with the protein of interest in a desirable buffer, and a reference cell filled with the identical 
buffer. As temperature is increased, heat will be absorbed differently by the sample cell, from 
the reference cell. Additional heat will be added to keep the cells at the same temperature, the 
additional heat is then proportional to the to the excess heat capacity. DSC measures the excess 
heat capacity of a protein as a function of temperature. The transition midpoint temperature 
(Tm) is defined as the state where 50% of the protein is unfolded or denatured, while the rest is 
still in its folded or native state, this melting temperature is characteristic for each protein. The 
transition state is visible as a sharp endothermic peak, centred at the melting temperature in the 
thermogram (Figure 1-10) [72, 73].  When a protein reaches Tm a change in heat capacity will 
occur, due to uptake of heat to break interactions in the protein, going from the native to the 
denatured state. But a difference in heat capacity can also be observed before and after the 
transition state, since more heat is required to raise the temperature of a solution with unfolded 
protein, compared to the folded protein. This is mainly due to exposure of hydrophobic protein 
parts to the solvent. This shift in baseline is DCp, as illustrated in Figure 1-10. By including 
sample volume and protein concentration the specific heat capacity can be determined [73, 74].  
Integration of the transition state curve yields the calorimetric enthalpy DHcal, and 
represent the value of endothermic contributions such as disruption of hydrogen bonds, and 
exothermic ones, such as exposure of hydrophobic areas. The shape of the curve is an indication 
of the nature of the denaturation process. A sharp symmetric curve indicates a two-state model, 
which is currently the most popular mechanism used to describe protein denaturation processes. 
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Using this model, it is assumed that the protein unfolds directly from the native state to the 
denatured state, other states are assumed to be insignificantly populated. The two-state model 
can be verified by fitting a two-state vant’s Hoff equation curve to the scan. From this, the 
vant’s Hoff enthalpy is determined, which may differ from the calorimetric enthalpy [75, 76]. 
If the two enthalpies are similar, or more accurately if  DHvH/ DHcal » 1 it can be assumed that 
the two-state model is correct. Values higher than 1 can indicate self-association of the protein, 
(e.g. assumed monomer is dimer), or the protein concentration may have been overestimated. 
Values lower than 1 indicates that the protein can unfold through several intermediate states, or 
the protein concentration may be underestimated. DHcal may not be completely accurate as it is 
dependent on protein concentration, and hence can be affected by protein impurities and 
denaturation [72, 73].   
DSC is a good method for studying thermal denaturation and protein stability, and is 
considered more accurate than Thermofluor and circular dichroism which are dependent on a 
spectroscopic signal [73].  
   
 
Figure 1-10: Illustration of a DSC thermogram – plotting heat capacity as a function of temperature. The melting 
temperature is shown in the centre of the transition state, and the integrated curve is the change in the calorimetric 
enthalpy (DHcal). The difference in baseline before and after the protein transition is the heat capacity change 








1.5.2 Microscale thermophoresis (MST)  
Microscale thermophoresis (MST) refers to the motion of molecules in a microscopic 
temperature gradient [77]. The use of thermophoresis to quantify biomolecular interactions 
makes MST a unique method, since the binding-affinity measured by thermophoresis is 
dependent on multiple properties, not relying on the measurement of a single parameter as other 
methods do [78].   
The temperature gradient in a solution with molecules induces a flow of molecules as 
well as a flow of heat. This coupling of heat- and mass-flow is known as thermophoresis or the 
Ludwig-Soret effect, its theoretical foundation is the subject of debate [77]. In general, the 
movement of molecules in a temperature gradient is described with a linear drift response; the 
molecular flow is linearly dependent on the temperature gradient, with a proportionally thermal 
diffusion constant [77-79].  
 The experimental setup of MST is illustrated in Figure 1-11 A, and is dependent on an 
infrared (IR) laser focused onto the sample through optics that is used for fluorescence 
detection. The IR-laser allows for very precise and reproducible heating of the sample, which 
is important since the general MST experiment involves interaction analysis of serial dilutions 
of 10-16 samples. The signal obtained by an MST instrument is shown in Figure 1-11 B, as a 
series of defined processes. The initial fluorescence is measured before heating the samples and 
should be constant. Turning on the IR-laser leads to a quick change in the fluorescence intensity, 
which is temperature dependent, referred to as the temperature jump. This is followed by the 
thermophoresis, where biomolecules will move with the thermal gradient dependent on their 
size, charge and hydration, weakening the fluorescent signal. When the IR-laser is switched off 
the inverse temperature jump can be observed, due to the fluorophore’s temperature 
dependence, before the sample molecules diffuses back to its homogenous initial state (Figure 
1-11 B). The difference in fluorescent on-signal (DFnorm) may be plotted against the protein 
concentration to give a dose-response curve from which the dissociation constant (Kd) can be 
derived [77, 78]. The use of fluorescence tags allows for higher sensitivity of the experiment, 
but unlabelled MST experiments can be conducted by measuring the fluorescence 
predominantly form tryptophan residues in the protein. For a typical MST experiment the 
concentration of a fluorescent labelled protein is kept constant (generally the concentration 
should be in the order of the expected Kd value or lower), with a dilution series of the unlabelled 





Figure 1-11: Overview of the experimental setup and a typical MST signal. A) An IR-laser is used to locally heat 
the sample volume in the capillaries, which is observed by fluorescence. B) A typical signal for a given capillary. 
When the initial fluorescence is measured the molecules in the sample are homogenous distributed. When the IR-
laser is turned on a fast temperature jump is observed, followed by thermic molecule motion, and the fluorescent 
decrease is measured. When the IR-laser is turned off, the inverse temperature jump is observed, followed by a 
diffusion of molecules back to the initial homogenous state. Figure from reference [77].      
 
1.5.3 Protein crystallization and X-ray crystallography 
Obtaining a well-ordered protein crystal that can diffract X-rays strongly, is the first 
step for solving the three-dimensional structure of a macromolecule by X-ray crystallography 
[80]. Even though there are several challenges for determining the three-dimensional protein 
structure by this method, the protein crystallization step is somewhat of a bottleneck [81].  
It is important to be able to obtain highly ordered protein crystals to retrieve high 
resolution diffraction patterns. The resulting three-dimensional protein crystal structure is not 
an image of the protein, but a map of the electron distribution in the protein. The X-ray 
scattering from a single molecule would be impossible to separate from the background noise, 
but by arranging the molecules in an ordered pattern the protein crystals functions as an 
amplifier (scattered waves adds up in phase), creating detectable diffraction spots [81]. The 
smallest repeating unit of a crystal is called the unit cell, each unit cell may contain one or more 
molecules. The arrangement of the unit cells makes up the symmetry of the protein crystal, and 
the crystal lattice [80].   
Well-ordered protein crystals are difficult to grow because proteins are large molecules, 
with irregular surfaces, which creates large solvent-filled channels or holes in the crystal 
packing structure. The amount of solvent in the crystal structure may vary from 25-90% 
depending on the specific protein structure. This is one reason why protein structures 
determined by X-ray crystallography are very similar to the protein structure in solution. But 
the solvent filled-channels also creates larges spaces between adjacent molecules, causing some 
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molecules to not occupy exactly the same orientations, being the main reason for the limited 
resolution of the diffraction patterns [82].      
There is no universal method for how to obtain macromolecular crystals. The methods 
applied for protein crystallization is therefore largely empirical in nature, remaining as what is 
basically a trial-and error approach. Protein crystallization is a matter of searching individual 
parameters affecting the crystallization, using patience, experience and intuition to identify 
successful factors. This may be done by systematically searching through the individual 
parameters, varying what is thought to be the most important factors, namely pH, temperature, 
protein concentration, precipitant type and use of additives. A more random search may prove 
to be more efficient. The use of crystallization robots and sparse-matrix crystallization kits, 
exploring a wide range of different conditions, has made the crystallization process more 
efficient. The sparse-matrix search may be good method for identifying promising conditions, 
but often becomes a matter of optimizing the protein crystallization [82].   
Proteins will stay in solution up to a certain concentration, when this concentration is 
reached a new phase will appear. Proteins may form several different solid states, such as 
amorphous precipitates, oils and crystals. To create crystals the protein much first nucleate, or 
initiate development at high levels of supersaturation, 2-3 times higher than the level of 
supersaturation required for crystal growth [82, 83]. During nucleation, molecules associate 
forming a thermodynamically stable aggregate (nucleus) from which the crystal can grow [81]. 
The supersaturated state is a non-equilibrium condition in which some quantity of the protein 
is in excess, equilibrium is re-established by the formation of a solid phase [82].  
The crystal growth and supersaturated state can be illustrated by a phase diagram, which 
can be an important tool for understanding when crystallization is likely to occur. The phase 
diagram is most often displayed as a two-dimensional graph as a function of the protein 
concentration and one other crystallization variable. When the protein solution is above its 
solubility limit it reaches the supersaturated state, which can be divided into three zones, 
depending on the level of supersaturation; metastable zone where crystal growth occurs, labile 
zone where nucleation occurs, and precipitation zone [81-83] (Figure 1-12).  
As briefly mentioned, many parameters are found to affect protein crystallization. pH is 
considered one of the most important factors as it may alter the sidechain interactions of the 
proteins. Salts are also commonly used since they dehydrate the protein by competing for the 
water molecules. Organic solvents may change the dielectric constant of the protein solution, 
and some polymers produce volume-exclusion effects which may also cause the protein to 
become less soluble. Chemical agents that reduce the protein solubility is referred to as a 
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precipitant. Additives such as chemical protectants, poisons and solubilizing agents may also 
help, any substance other than the crystallizing compound, the buffer and the precipitant agent 
is considered an additive. Last, but not lest the temperature, protein concentration and protein 
sample homogeneity is important for the protein crystallization [81, 82].      
 There are different techniques for protein crystallization. The most commonly used is 
vapor diffusion, but batch crystallization, dialysis and free-interface diffusion may also be used. 
Vapor diffusion utilizes the evaporation of water from a drop containing the protein and the 
reservoir solution, to the same reservoir solution in a well, but at higher concentrations than 
found in the drop. Water will move from the place with lowest concentration to the one with 
the highest in an equilibrium. Commonly used set-ups are the sitting-drop method (drop 
deposited on a pedestal in the well), or the hanging-drop method (drop deposited on a cover slit 
above the well).    
 
 
Figure 1-12: Phase diagram for the crystallization of macromolecules. The diagram is divided into regions of 
undersaturation (soluble protein) and supersaturation. The supersaturation zone can be divided into three separate 
zones; metastable zone where crystal growth occurs, labile zone where nucleation occurs, and precipitation zone. 







1.5.4 Enzyme kinetics 
The determination of the enzyme reaction rate, commonly referred to as enzyme 
kinetics, and how it is affected by different experimental parameters, is an important method 
for studying proteins [84].  
The Michaelis-Menten model is the foundation for enzyme kinetics, and is shown in 
equation 1-2. The model describes the rate of the reversible reaction where enzyme (E) binds 
to substrate (S), forming the enzyme-substrate(ES)-complex, and the irreversible reaction 
where substrate is converted to product. k2 is the reaction rate at which the enzyme converts 
substrate to product and is referred to as kcat or the turnover number. It is defined as the 
maximum number of substrate molecules converted to product per active site of the enzyme 
per unit of time [85].  
 
(1-2)             
 
There are several assumptions implicit in this model; the enzyme binds only a single substrate, 
there is only one kinetically significant step between the formation of the ES-complex and the 
product formation, and the product formation is irreversible. This is not strictly correct for some 
enzymes, but is still a useful model [86].   
 A one-substrate enzyme-catalysed reaction can be described by the rate equation, or the 
Michaelis-Menten equation, shown in equation 1-3. It is based on a constant enzyme 
concentration in the reaction, and the steady-state assumption; the initial rate of the reaction 
reflects a steady state, in which the concentration of the intermediate ES-complex is constant. 




The Km parameter is known as the Michaelis constant for the enzyme, and is the substrate 
concentration at which half-maximum reaction rate is observed. Km can be used as a rough 
indicator of how tightly the enzyme binds the substrate (large Km value indicates a weak 
interaction with the substrate). Km is however not the true dissociation constant for the substrate, 
as it is also dependent on kcat. The biomolecular rate constant kcat/Km is referred to as the overall 
conversion of substrate into product, and is considered to be the measure of catalytic efficiency 
of the enzyme [86]. Vmax is obtained when the enzyme is saturated with substrate, when there 
are no available free enzymes to turn over more substrate, and is defined in equation 1-4 [85].  
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 (1-4)   Vmax= kcat[E] 
The rate equation can be illustrated by the Michaelis-Menten kinetics curve, plotting the 
initial velocity as a function of the substrate concentration (Figure 1-13). As can be seen from 
Figure 1-13, the initial velocity v0 increases almost linearly at low substrate concentrations. v0 
will be less and less affected by the increase in substrate until a plateau-like region is reached, 
where v0 is close to the maximum velocity Vmax [84].    
 
 
Figure 1-13: Plot of the initial velocity or reaction rate (V0) as a function of the substrate concentration for an 
enzyme catalysed reaction, known as the Michaelis-Menten kinetics curve. Vmax is the maximal velocity, Km is the 
Michaelis constant, and is the substrate concentration at half of the maximal velocity. The initial velocity is related 











2 Materials and methods  
 




























































A major part of this thesis has been mutational studies of OXA-48 to investigate the 
active site, and the dimer interface. This was done to gain a greater understanding of how 
residue substitutions affect the enzyme activity and substrate specificity, as well as elucidating 
the oligomeric state of OXA-48, and study how specific mutations affect the thermal stability.  
The OXA-48 mutants S70A, S70T, S70T/T71S, R189A, R189A/R206A, P68A, and 
P68A/Y211S were designed, expressed and purified. Mutants were then analyzed by different 
methods to investigate different aspects of the residue substitution(s), namely MST, DSC, size-
exclusion chromatography, enzyme kinetics, and protein X-ray crystallography. Thermal 
stability and/or crystal structures were also used to investigate the effect of the residue 
substitutions and/or deletions between the OXA-48 like enzymes; OXA-181, OXA-245, OXA-
163 and OXA-436.  A schematic representation of the studies conducted in this thesis is shown 
in Figure 2-1.   
 
2.1 Mutagenesis, protein expression and purification  
 
2.1.1 Preparing OXA-48 mutants; R189A, R189A/R206A, P68A, P68A/Y211S, S70T, 
S70T/T71S, and S70A 
 
Table 2-1: Solutions used for mutagenesis of OXA-48 
Solution  Content  
LB-agar (1 L) 10 g peptone  
5 g yeast extract 
10 g NaCl 
15 g agar 
LB-media (1 L) 10 g peptone  
5 g yeast extract 
10 g NaCl 
Agarose gel 1% agarose in Tris-acetate-EDTA (TAE) buffer (heated, stored 
at 60°C) 
TAE buffer  400 mM Tris pH 
20 mM acetic acid 
1 mM ethylenediaminetetraacetic acid (EDTA) 
NZY+ broth (1 L)  5 g NaCl 
2 g MgSO4  
5 g yeast extract  




2.1.1.1 Primer design for site-directed mutagenesis of OXA-48 
It was decided to design 7 different OXA-48 mutants affecting both the active site and 
the dimer interface (see paragraph 1.3.2); R189A, R189A/R206A, P68A, P68A/Y211S, S70T, 
S70T/T71S, and S70A. To make these mutants, forward and reverse primer sets were designed 
based on the blaOXA-48 gene sequence (GeneBank: NC_019154), using the program 
QuickChange Primer Design (Agilent) [87]. For the double mutant P68A/Y211S two separate 
primer pairs were designed, due to the long distance between the target codons in the sequence. 
For R189A/R206A only the R189A primer were designed as the OXA-48 R206A was already 
available in the lab from previous experiments (unpublished data). The primer sequences are 
complementary to the blaOXA-48 gene, except for the target codon(s) to be substituted in the 
mutant. The primer pair sequences are shown in Table 2-2, with the R206A primers also 
included. 
 
Table 2-2: Sequence of fwd. and rev. primer pairs for the OXA-48 mutants; R189A, R189A/R206A, P68A, 
P68A/Y211S, S70T, S70T/T71S, and S70A. Target codons are marked in red script, and exchanged nucleotides 
responsible for amino acid mutations are underlined. The melting temperature for the primer pairs are also included 
Tm, in °C.        
 Primer sequence (5' - 3') 
R189A 
Tm: 83.5 
Fwd.  ATCGGAGCGCAGCCAGGCTATTGTCAAACAAGCC 
Rev.  GGCTTGTTTGACAATAGCCTGGCTGCGCTCCGAT 
R206A 
Tm: 79.7 
Fwd.  ACCGAAGCCAATGGTGACTATATTATTGCGGCTAAAACTGAT 
Rev.  ATCCAGTTTTAGCCGCAATAATATAGTCACCATTGGCTTCGGT 
P68A 
Tm: 81.9 
Fwd.  CGGGCGAACCAAGCATTTTTAGCCGCATCTACC 
Rev.  GGTAGATGCGGCTAAAAATGCTTGGTTCGCCCG 
Y211S 
Tm: 78.0 
Fwd.  TATTATTCGGGCTAAAACTGGATCCTCGACTAGAATCGAACCTAAG 
Rev.  CTTAGGTTCGATTCTAGTCGAGGATCCAGTTTTAGCCCGAATAATA 
S70T 
Tm: 78.1 
Fwd.  GAACCAAGCATTTTTACCCGCAACTACCTTTAAAATTCCCAATAG 
Rev.  CTATTGGGAATTTTAAAGGTAGTTGCGGGTAAAAATGCTTGGTTC 
S70T/T71S 
Tm: 80.3 
Fwd.  GAACCAAGCATTTTTACCCGCAACTAGCTTTAAAATTCCCAATAGCTTG 
Rev.  CAAGCTATTGGGAATTTTAAAGCTAGTTGCGGGTAAAAATGCTTGGTTC 
S70A 
Tm: 79.1 
Fwd.  GAACCAAGCATTTTTACCCGCAGCTACCTTTAAAATTCCCAATAG 






2.1.1.2 Preparation of XL1-Blue competent cells   
Bacterial transformation is a process where bacteria take up foreign DNA, this may 
happen naturally. E. coli cells were made competent – making the cells more likely to take up 
foreign DNA. Making chemically competent cells involves treating the cells with Ca2+ ions, 
followed by a brief heat shock in the presence of foreign DNA, to allow uptake. This is referred 
to as the CaCl2 method or heat-shock method [88, 89]. The presence of Ca2+ ions neutralize the 
negative repulsion between the foreign DNA and the phospholipid-heads of the cell membrane, 
making the uptake easier.  
An “in-house” glycerol stock of the E. coli strain XL1-Blue was streaked on Lysogenic 
Broth (LB) -agar plates (Table 2-1) with 12.5 µg/mL tetracycline (TET), and left for incubation 
at 37°C, overnight (o/n). Two parallel pre-cultures were prepared, with 5 mL LB media (Table 
2-1) with 12.5 µg/mL Tet, inoculated with one XL1-Blue cell colony each, and incubated at 
37°C o/n. 100 mL LB media were inoculated with 1 mL pre-culture (1:100) and incubated at 
250 rpm at 37°C until cell density/ optical density (OD600) reached log-phase (0.3-0.9) [90]. 
The bacterial cultures were then centrifuged at 4000 rpm for 10 min at 4°C, before the media 
was carefully removed from the cell pellet. The pellet was resuspended in 10 mL ice cold 0.1 
M CaCl2 (sterilized solution), incubated on ice for 1 hour, before cells were collected by 
centrifugation. Finally, the pellet was resuspended in 2 mL 0.1 M CaCl2 and 10% glycerol 
(sterilized solution), before being transferred to pre-frozen Eppendorf-tubes as 50 µL aliquots, 
and stored at -80°C. 
 
2.1.1.3 Site-directed mutagenesis of OXA-48      
For the site-dierected mutagenesis, a construct of blaOXA-48 in a pDEST17 vector with 
Ampicillin resistance (Figure 2-2) (prepared by PhD. Bjarte Lund) was used as a template, with 
the previously described primers, and the QuikChange II Site-Directed Mutagenesis Kit 
(Agilent). In the construct, a hexa-histidine tag had been inserted together with a TEV protease 
cleavage site, and a linker sequence (HHHHHH-LESTSLYG-ENLYFQG). While the predicted 
native leader sequence (residues 1-22, see Figure 1-7) at the 5¢-end had been removed, normally 






Figure 2-2: Illustration of the vector pDEST17. The gene of interest is inserted between the attR1 and attR2 
sites (removing the CmR and ccdB gene).  Figure from ThermoFisher Scientific-Gateway pDEST17 vector map.  
 
The mutant strand synthesis reaction was carried out according to the QuikChange II 
Site-directed Mutagenesis Kit supplied instruction manual (Agilent). Some modifications were 
applied to the manual, due to different optimizations of the site-directed mutagenesis process. 
The reaction was set up with approximately 50 ng template, 125 ng fwd. primer, 125 ng rev. 
primer, 2.5 µL 10x PfuUltra HF reaction buffer, 0.5 µL dNTP mix (10 mM each), 1% DMSO, 
and 0.5 µL PfuUltra HF DNA polymerase (2.5 U/µL). Nuclease-free water was added to a final 
volume of 25 µL, for each mutant. Samples were mixed by flicking the PCR tubes, before a 
brief centrifugation. Mutant strand synthesis reaction was performed using Thermo Scientific 
Arktik Thermal Cycler with the following Polymerase Chain Reaction (PCR) -conditions: 
initial 30 sec denaturation at 95°C, 16 cycles of [30 sec denaturation at 95°C, 1 min annealing 
at 60°C, 5.5 min elongation at 68°C], before cooling to 37°C. These conditions were used for 
all the mutants with the exception of OXA-48 P68A/Y211S, where the conditions were 
modified slightly; initial 30 sec denaturation at 95°C, 16 cycles of [30 sec denaturation at 95°C, 
1 min annealing at 55°C, 6 min elongation at 68°C], before cooling to 37°C.  
The amplified products were treated with 0.5 µL DpnI (10 U/µL), and incubated at 37°C 
for 1 hour. This was done to remove the non-mutated template. DpnI recognizes a commonly 
methylated sequence by E. coli. Mutated DNA created in the PCR process will not be 
methylated, and hence is not affected. 2 µL DpnI treated DNA was added to 50 µL XL1-Blue 
competent cells and mixed carefully. The cells were then heat-shock treated; incubated on ice 
for 30 min, transferred 42°C water-bath for 45 sec, before 2 min on ice. The cells were then 
incubated in 0.5 mL preheated NZY+ broth (Table 2-1) at 37°C and 225 rpm for 1 hour, and 
spread on LB-agar plates with 100 µg/mL ampicillin (Amp). For OXA-48 P68A/Y211S mutant 




2.1.1.4 Amplicon screening and DNA analysis with gel electrophoresis 
PCR amplification reaction was conducted for the constructs and analyzed by gel 
electrophoresis. The thermophilic Taq DNA polymerase was used for this purpose. It is 
commonly used to amplify PCR products of 5 kb or less, but has no proof reading activity. For 
routine PCR amplification the Taq polymerase is sufficient, but for mutation analysis of 
amplified product Pfu DNA polymerase (which has one of the lowest error rates of all known 
thermophilic DNA polymerases) should be used [92].    
For each mutant construct 3 colonies were picked for colony PCR, using a sterile pipette 
tip, lightly stroked onto a LB-agar 100 µg/mL (or 50 µg/mL) Amp plate (reference plate), and 
transferred to reaction mix; 22.5 µL Taq DNA polymerase 1.1x Master Mix RED (Ampliqon), 
1 µL T7 primer fwd. (0.4 mM), 1 µL T7 primer rev. (0.4 mM), and 0.5 µL ddH2O. In addition 
to the mutant construct samples, one negative control (only reaction mix), and one positive 
control (reaction mix and 10 ng pDEST17 blaOXA-48 construct) were prepared. The reference 
plate was incubated at 37°C for minimum 6 hours. PCR-conditions used for amplicon 
screening; initial 5 min denaturation at 98°C, before 30 cycles of [30 sec denaturation at 98°C, 
30 sec annealing at 55°C, 30 sec elongation at 72°C], before termination with 7 min elongation 
at 72°C, and finally cooling to 10°C.    
The PCR reaction products were analyzed using gel electrophoresis. 1% agarose gel 
(Table 2-1) was casted with 0.05% (w/v) RedSafe nucleic acid staining solution (ChemBio). 
The gel was run with 1xTEA buffer (Table 2-1) at 90V for about 45 min, to separate DNA 
fragments. For OXA-48 S70T, S70A, R189A and S70T/T71S mutants 10µL PCR product was 
loaded directly to the wells, using 5 µL 0.1-12 kbp DNA ladder (Invitrogen) as a standard. This 
gave overloaded samples and a very weak ladder, but still a visible result. For the OXA-48 
P68A, P68A/Y211S, R189A/R206A mutants 5 µL PCR product was loaded to the gel, using 
10 µL ladder, instead. The gel and DNA-bands were analyzed under UV-light using Geldoc 








2.1.1.5 Plasmid purification and Big-Dye 3.1 sequencing  
   A bacterial colony from the reference plate was picked, for the OXA-48 mutants 
showing DNA-bands at the correct size on the agarose gel (~1 kbp for all mutants), transferred 
to 5 mL LB-media with 100 µg/mL (50 mg/mL) Amp, and incubated at 37°C and 225 rpm o/n. 
The Wizard Plus SV Minipreps DNA Purification System Kit (Promega) was used for plasmid 
purification. The purification was conducted as described in the System supplied protocol. 5 
mL cell culture was harvested after incubation o/n, and centrifuged (4000 rpm, 15 min, 4°C), 
supernatant was removed. The cell pellet was completely resuspended in 250 µL Cell 
Resuspension Solution, and transferred to 1.5 mL sterile Eppendorf tubes. 250 µL Cell Lysis 
Solution was added to the samples, mixed by inverting the tube 4 times, and left for incubation 
in room temperature for 4-5 min until clearing of the cell suspension was observed. 10 µL 
Alkaline Protease Solution was added, incubated for 4-5 min, before 350 µL Neutralization 
Solution was added, and the bacterial lysate was centrifuged (13000 rpm, 15 min, 21°C). The 
cleared lysate (without precipitate) was then transferred to a Spin Column (inserted in 
Collection Tube) and centrifuged (13000 rpm, 1 min, 21 °C). 750 µL Column Wash Solution 
(diluted in 95% ethanol) was added to the Spin Column, samples were centrifuged, and flow-
through was discarded. Procedure was repeated with 250 µL Column Wash Solution, before 
the Spin Column was transferred to a new Collection Tube. The plasmid DNA was eluted by 
adding 100 µL nuclease free water to the Spin Column. The DNA concentration of the purified 
plasmids were measured at OD280 using NanoDrop 2000c (Thermo Scientific), before storing 
samples at -20°C.   
 The purified DNA samples were prepared for Sanger sequencing (using BigDye 3.1), 
according to the BigDye Terminator v3.1 Cycle Sequencing Kit Protocol (Applied 
Biosystems). Approximately 200 ng purified DNA was mixed with 1 µL BigDye 3.1, 4 µL 5x 
Sequencing Mix, 1 µL T7 primer fwd/rev (0.5 mM), and ddH2O up to 20 µL reaction volume. 
One fwd. and one rev. reaction was prepared for each OXA-48 mutant. The PCR cycle program 
was set to; initial 5 min denaturation at 96°C, 25 cycles of [10 sec denaturation at 96°C, 5 sec 
annealing at 50°C, and 4 min elongation at 60°C], before cooling to 10°C. The sample products 
were sent to the University Hospital of Northern Norway for BigDye 3.1 Sanger sequencing.  
The sequences were analyzed to confirm the correct mutation, using the program 
BioEdit Sequence Alignment Editor Version 7.2.5.0 [93]. ClustalW [94] alignment was used 
to align the provided OXA-48 mutant sequences with the blaOXA-48 gene (GeneBank: 




2.1.2 Protein expression of OXA-48 mutants, OXA-48 and OXA-163 
 
Table 2-3: Solutions used for protein expression of OXA-48, OXA-163, and OXA-48 mutants 
Solution  Content  
SOC  2% tryptone  
0.5% yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose  
LB-agar (1 L) 10 g peptone  
5 g yeast extract 
10 g NaCl 
15 g agar 
LB media (1 L) 10 g peptone  
5 g yeast extract 
10 g NaCl 
1xSB (10 mL) 1.25 mL 0.5 M Tris pH 6.8 
1.15 mL 20% sodium dodecyl sulphate (SDS)  
1 mL 87% glycerol 
0.5 mL 100% 2-mercaptoethanol  
0.1 mL 0.1% bromophenol blue  
Running buffer (BioRad) 25 mM Tris pH 8.0 
192 mM glycine  
0.1% SDS 
TB media (1 L) 10 g peptone 
5 g yeast extract 
4.6 mL 87% glycerol 
100 mL 10x TB salt  
10x TB salt  0.72 M KH2PO4 








2.1.2.1 Protein expression of OXA-48 and OXA-163 
The OXA-48 like enzymes OXA-181, OXA-245, OXA-436, and OXA-163 were 
needed for crystallization trials and DSC analysis. Purified OXA-181, OXA-245, OXA-436 in 
sufficient amounts were already available, only OXA-48 and OXA-163 were therefore 
expressed and purified. OXA-163 was a synthetic DNA gene optimized for E. coli expression, 
while the OXA-48 gene was cloned from Klebsiella pneumoniae samples.    
OXA-48 had previously been successfully expressed by Dr. Bjarte A. Lund [39], and 
the same expression conditions were used. Glycerol stocks with OXA-48 and OXA-163 in the 
in house E. coli strains BL21(DE3)pLysS and BL21(DE3)pRARE  were available, and were 
used to start pre-cultures. 
Preheated 50 mL LB media with 100 µg/mL Amp and 34 µg/mL CAM was inoculated 
with one “scoop” from each glycerol stock, pre-cultures were left for incubation at 37°C and 
225 rpm o/n. 5 mL pre-culture was added (1:100) to 4 x 500 mL Terrific Broth (TB) media 
(Table 2-3) with 100 µg/mL Amp and 34 µg/mL CAM, in cultivation flasks, and grown at 37°C 
and 180 rpm until log-phase was reached. The cell cultures were induced with 0.4 mM isopropyl 
b-D-1-thiogalactopyranoside (IPTG) (VWR) at log-phase, and expression was continued at 
20°C o/n. Cells were collected by centrifugation (6000 rpm, 40 min, 4°C) and the cell pellets 
stored at -20°C before protein purification.  
Before induction (BFI) and after induction (AFI) samples were collected and analyzed 
using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), to check the 
effect of the induction and protein expression. BFI and AFI samples were centrifuged at 13000 
rpm for 1 min, and the pellet resuspended in 1x sample buffer (SB) solution (Table 2-3), heated 
to 96°C for approximately 5 min, and loaded (10 µL) to a 4-20% mini-PROTEAN TGX Precast 
Gel (BioRad). 5 µL Precicion Plus protein dual color marker (BioRad) was used as a ladder. 
The gel was ran using Running buffer (Table 2-3), for 35 min at 200 V. The gel was stained 
using SimplyBlue SafeStain (Novex) for 10 min after brief heating, and left to destain in ddH2O 
on an orbital shaker.            
 
2.1.2.2 Protein expression of OXA-48 mutants 
Since the expression of OXA-48 worked well with the given conditions, it was decided 
to use the same conditions for expression of the OXA-48 mutants in large scale. Previously 
expressed OXA-48 mutants had generally shown a lower protein yield pr. liter of cell culture, 
compared to OXA-48 [95]. Since at least two of the designed OXA-48 mutants were expected 
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to affect the protein stability, it was decided to lower the induction temperature from 20°C to 
18°C, and IPTG concentration from 0.4 mM to 0.1 mM. This was done to allow for a slower 
protein expression, and theoretically, less misfolding and increased protein solubility.  
 Since 2x 1 L TB media was used in the expression for each mutant (1 L used for the 
protein purification, 1 L extra in case of unexpected errors), it was decided to test the in house 
E. coli strain Rosetta2(DE3)pLysS, in addition to the BL21Star(DE3)pRARE strain. The 
Rosetta2(DE3)pLysS strain had previously shown to work well, when expressing OXA-181 
(unpublished data). For the transformation of OXA-48 mutant constructs into the selected 
strains, 1 µL plasmid (50-60 ng) was added to 50 µL chemically competent cells, and heat 
shock protocol was followed (incubation for 30 min on ice, 45 sec at 42 °C, on ice for 5 min). 
1 mL preheated Super Optimal broth with Catabolite repression (SOC) (Table 2-3) was added 
to the cells, and left for incubation at 37°C and 225 rpm for 1 hour. The cultures were spread 
(testing different concentrations – 50 µL gave the best result) on preheated LB-agar plates with 
100 µg/mL Amp and 34 µg/mL CAM (50 µg/mL Amp and 34 µg/mL CAM for OXA-48 
P68A/Y211S mutant), and left for growth at 37°C o/n.  
One bacterial colony from both E. coli strains for each mutant was picked and used to 
inoculate 15 mL LB media with Amp/CAM. The pre-cultures were left at 37°C and 225 rpm 
o/n. 5 mL pre-culture was used to inoculate (1:100) 2x 0.5 L room temperature TB media with 
Amp/CAM. 7 mL pre-culture from the OXA-48 P68A, P68A/Y211S and R189A/R206A 
mutants were used to inoculate 2x 0.5 L TB media, as previously expressed OXA-48 mutants 
(S70A, S70T, S70T/T71S, R189A) grew quite slowly. The cell cultures were grown until log-
phase was reached, at 37°C and 180 rpm. At log-phase the cell cultures were induced by 0.1 
mM IPTG, expression was continued at 18°C and 180 rpm o/n. The cells were collected by 
centrifugation (6000 rpm, 40 min, 21°C) and stored at -20°C.  
From the pre-cultures 500 µL were collected to make glycerol stocks (carefully mixed 
with 500 µL 89% glycerol), and sored at -80°C.  
SDS-PAGE analysis of the BFI and AFI samples was conducted as previously 
described, for the OXA-48 P68A, P68A/Y211S and R189A/R206A mutants. For the OXA-48 
S70A, S70T, S70T/T71S and R189A mutants SDS-PAGE analysis of the BFI and AFI samples 




2.1.3 Immobilized metal ion affinity chromatography (IMAC) purification of OXA-48 
mutants, OXA-48, OXA-163 and TEV protease 
 
Table 2-4: Solutions used for protein purification using immobilized metal ion affinity chromatography, for OXA-
48, OXA-163, TEV protease, and OXA-48 mutants.  
Solution  Content  
Running buffer (BioRad) 25 mM Tris pH 8.0 
192 mM glycine  
0.1% SDS 
2xSB (1 mL) 500 µL NuPAGE LDS SampleBuffer (4x) (Invitrogen)  
400 µL ddH2O 
100 µL 2-mercaptoethanol  
Buffer A 50 mM Tris pH 7.5 
500 mM NaCl 
10% glycerol 
2 mM 2-mercaptoethanol  
Buffer B 50 mM Tris pH 7.5 
500 mM NaCl 
10% glycerol  
2 mM 2-mercaptoethanol 
500 mM imidazole  
Buffer C 50 mM HEPES pH 7.0 
200 mM NaCl 
80% glycerol 
2 mM 2-mercaptoethanol 
1 mM EDTA 
Buffer D 50 mM HEPES pH 7.2  
50 mM K2SO4 
Buffer E 50 mM HEPES pH 7.2  
50 mM K2SO4 
500 mM imidazole  
Buffer F 50 mM HEPES pH 7.2  
50 mM K2SO4 
300 mM NaCl 







2.1.3.1 Protein purification of TEV protease 
Transformation of two TEV protease variants; TEVsh (amino acid substitution T17S, 
N68D, I77V) [96] and TEVpM2 (amino acid substitution T17S, L56V, N68D, I77V, S135G, 
S219V) [97] (in pTH24 vector, with His-tag) into Rosetta2(DE3)pLysS cells was attempted 
without success, using an in house protocol based on paper by van den Berg et al. [96].  
Due to problems with the TEV expression, one frozen TEVsh pellet from a previous 
expression (2014) was provided, for purification (herby simply referred to as TEV). 90 mL 
Buffer A (Table 2-4) was added to the thawed pellet, together with one tablet of EDTA-free 
protease inhibitor cocktail (Roche Diagnostics). Cells were disrupted by sonication, using 5 
seconds pulses with 9 seconds intervals, 35% amplitude, for approximately 1.5 hours total. 10 
µL whole cell (WC) sample was collected from the disrupted cells, and mixed with 10 µL 2x 
sample buffer (SB), for SDS-PAGE analysis as previously described. The supernatant 
containing soluble proteins was collected by centrifugation (14000 rpm, 40 min, 4°C). 10 µL 
cell supernatant (CS) sample was collected and mixed with 10 µL 2xSB, before purification of 
the collected supernatant was started.  
Since the TEV protein was constructed with a His-tag for IMAC protein purification, a 
5 mL HisTrap FF crude column (GE healthcare) was used. The His-tagged protein have a strong 
affinity for the nickle-column [98]. ÄKTA prime plus system, and the computer program 
PrimeView Evaluation (GE Healthcare) were used for the purification, with flowrate set to 2.5 
mL/min, 0.5 mPa pressurelimit, and 0.5 mL collected fractions. 5% Buffer B (Table 2-4) was 
added to the bacterial lysate before purification was started, and the column was washed with 
ddH2O, before equilibration with Buffer A, and 5% Buffer B (approx. 5 column volumes). The 
protein sample was injected using a 150 mL super-loop connected to the ÄKTA prime plus 
system. The injected sample was loaded onto the column using Buffer A and 5% Buffer B. 
After the flow-through (non-binding proteins), the system was washed with 1 column volume 
of buffer before a Buffer B gradient from 5-100% over 70 mL was started (imidazole gradient 
from 25-500 mM). Imidazole functions as a metal ion ligand, reducing the His-tag binding 
affinity to the Ni2+ ions in the column, and eluting the His-tagged TEV protease [98]. This is 
visible as a protein elution peak in the chromatogram. Samples from the elution-peak fractions 
(as well as one from the flow-through) were collected for SDS-PAGE analysis as previously 
described. From the gel, it was determined that the protein was pure enough, and needed no 
further purification, as instability of the TEV protease could lead to reduced protein yield.  
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The collected protein fractions (selected from SDS-PAGE analysis) were pooled, and 
dialyzed o/n at 4°C in Buffer C (Table 2-4). NanoDrop 2000c Spectrophotometer (Thermo 
Sciences) was used to measure the protein absorbance at OD280. The protein concentration was 
calculated using equation 2-1, by the NanoDrop software. The online program; ExPASy 
ProtParam tool [99] was used to determine the molecular weight (Mw) and the extinction 
coefficient based on the protein sequence.  
 
 (2-1)  𝑃𝑟𝑜𝑡𝑒𝑖𝑛 = )*(,-./)×23
45678967:8	9:4<<797486	(∆ e)
	                                    
 
The protein sample was diluted to approximately 1 mg/mL, before storage at -80°C.     
 
2.1.3.2 Protein purification of OXA-48, OXA-163, and OXA-48 mutants 
The same purification conditions were applied for all the OXA-48 mutants, as well as 
for the purification of OXA-48 and OXA-163.  
 25 mL Buffer D (Table 2-4) was added to the thawed bacterial pellet, together with one 
tablet of EDTA-free protease inhibitor cocktail (Roche Diagnostics). Cells were disrupted by 
sonication, as previously described. The supernatant and soluble protein was collected by 
centrifugation (14000 rpm, 40 min, 4°C). WC and CS samples were collected for SDS-PAGE 
analysis. For the OXA-48 mutants the BL21Star(DE3)pRARE cell pellet was used for the 
purification, while the Rosetta2(DE3)pLysS was used if  purification had to be repeated, due to 
errors.  
 The same ÄKTA prime plus settings as described for TEV protease were applied, using 
a 5 mL HisTrap HP column (GE healthcare). The column was washed in ddH2O, and 
equilibrated using Buffer D (approx. 5 column volumes), before injecting the protein sample 
using a 50 mL super-loop connected to the ÄKTA prime plus system. The injected sample was 
loaded onto the column using Buffer D. After the flow-through, 5% Buffer E (Table 2-4) was 
loaded to the column (25 mM imidazole). A low imidazole concentration of 10-50 mM is used 
to elute weakly non-specific binding proteins from the nickle-column [98]. After the 
contaminants had been eluted, a Buffer E gradient from 5-100% was started, over 70 mL (25-
500 mM imidazole), eluting the protein binding strongly to the column. Samples from the 
eluted-protein peak, flow-through and contaminant-peak was collected for SDS-PAGE 
analysis. Based on the SDS-PAGE results, fractions containing the protein of interest were 
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pooled, and left for dialysis o/n at 4°C in Buffer F (Table 2-4), with approximately 1 ml TEV 
protease (1 mg/mL), per 5 mL of collected protein sample.  
 In the second HisTrap purification step the His-tag has been removed from the protein, 
by TEV protease cleavage, and is therefore found in the flow-through. The settings and 
procedure were the same as for the first purification step, except for the Buffer E gradient being 
set from 0-100%. TEV and other strongly binding contaminant proteins were eluted during this 
gradient. Protein samples from the flow-through and one sample from the contaminant peak 
were collected for SDS-page analysis. Based on the SDS-PAGE OXA-48, OXA-163, and the 
OXA-48 mutants were determined to be more than 95% pure after this second purification step. 
No further purification was needed, the fractions containing the desired protein were pooled, 
and left for dialysis at 4°C o/n in Buffer D.  
 Protein concentration was measured using NanoDrop as previously described, and 
concentrated to around 10 mg/mL. For OXA-48, OXA-163, and OXA-48 S70T, 15 mL Amicon 
Ultra Centrifugal Filter (Millipore) with 10 kilo Dalton (kDa) cut-off membrane was used for 
the concentration. For the rest of the OXA-48 mutants it was decided to use Centriprep 
centrifugal filters (Merck) with 10 kDa cut-off membrane instead, due to a higher degree of 



















2.2 Protein X-ray crystallography  
 
2.2.1 Crystallization of OXA-48 mutants, and OXA-181, OXA-163 and OXA-436  
 
2.2.1.1 Crystallization of OXA-163 
A new crystal structure of OXA-163 was desired (previously published structures PDB: 
5HAR, 4S2L, 4S2M). Favorable conditions from initial screening trials, conducted by Dr. 
Bjarte A. Lund, were used as a starting point for optimization trials. Two 24-well plates were 
set up manually at room temperature, using the hanging-drop method, around two conditions; 
1) 0.1 M Tris pH 8.5, 26.5% PEG MME 500, from in house screening. 2) 0.1 M HEPES pH 
7.7, 14% PEG 8000, from crystallization conditions for OXA-163 reported by Stojanoski et al. 
[100]. Micro crystals were obtained for several drops from the screen set up around the in- 
house conditions. Another optimization screen was therefore set up around the same conditions, 
varying the protein concentration systematically. Good crystals were obtained from this screen. 
The final crystallization conditions from the diffracting crystal are listed in Table 2-5.  
Cryo solution were prepared identically to the crystallization conditions yielding good 
crystals, with 17% ethylene glycol (> 30% cryo protectant). With the assistance from Dr. Bjarte 
A. Lund crystals were transferred from the drop into the cryo solution, before being collected 
in a crystal mounting loop, and flash frozen in liquid nitrogen.   
 
2.2.1.2 Crystallization of OXA-436 
A crystal structure of the novel OXA-48 like, class D b-lactamase OXA-436 was 
desired. Multiple screens were set up using the Phoenix DT crystallization robot (Rigaku), in 
96-wells MRC plates, with the sitting drop method (drop-size 500 + 500 nL, protein 
concentration 12.5 mg/mL). Structure screen 1 and 2, PGA screen, PACT premiere screen and 
SG1 screen were used for OXA-436 crystallization attempt. Multiple crystals were obtained 
from this, and other manually set up, optimization screens. It was however, discovered that 
most of the crystals were salt crystals. Most likely being CaSO4, from a reaction between the 
CaCl2 in many of the crystallization conditions and K2SO4 in the protein storage buffer. New 
SG1 screens with dialyzed OXA-436 in 50 mM HEPES pH 7.2, and concentrated dialyzed 
OXA-436 (25.1 mg/mL) were therefore set up using the crystallization robot. The latter gave a 
crystal for the conditions; 0.1 M HEPES pH 7.5, 0.2 M NaCH3COO, 25% PEG3350.  
An optimization screen for the given conditions was set up manually using the hanging-
drop method. This gave one condition with good crystals. Another optimization screen was 
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fine-tuned around these crystallization conditions, with varying protein concentration. This also 
gave one condition with good crystals. The final crystallization conditions are listed in Table 
2-5. 
The crystals obtained from the two different optimization screens were transferred to 
the same cryo solution, as the crystallization conditions were very similar. 25% ethylene glycol 
was added, giving >30% cryo-protectant in the solution. The cryo-protecting and flash freezing 
of protein-crystals was conducted with assistance from Dr. Bjarte A. Lund.   
 
Table 2-5: Crystallization conditions for OXA-163, OXA-436 and OXA-181. OXA-181 was not crystallized 
during this master thesis (expressed, purified and crystallized during bachelor thesis), but the structure was solved 
during this thesis, and the crystallization conditions is therefore included.   
 OXA-163 OXA-436 OXA-181 
Method Vapor diffusion  
Plate-type  Hampton Research VDX 24-well plate with sealant  




9.4 25.1  11.1 
Buffer composition of 
protein solution  
50 mM HEPES pH 
7.2, 50 mM K2SO4 
50 mM HEPES pH 
7.2 
50 mM Tris pH 7.2, 
50 mM K2SO4 
Composition of 
reservoir solution  
0.1 Tris pH 9.0, 
28% PEG MME 
500 
0.1 M HEPES pH 
8.0, 0.2 M 
NaCH3COO, 26% 
PEG 3350 
0.1 M Tris pH 7.0, 
0.2 M (NH4)2SO4, 
20.5% PEG MME 
5000 
Drop volume (µL) 2 2 1 
Reservoir volume 
(µL) 
1000 1000 1000 
Protein:reservoir 
ratio  
3:20 1:1 1:1 
 
 
2.2.1.3 Crystallization of OXA-48 mutants; S70A, S70T, S70T/T71S, and R189A 
Previous in-house crystallization trials conducted by master student Birgit Nesheim, 
with different OXA-48 mutants showed good results for the conditions; 0.1 M BIS-Tris propane 
pH 9.0 and 9.5, 14-18% PEG MME 5000 [95]. Manually designed 24-well plate screens were 
therefore set up for the OXA-48 mutants R189A, S70A, S70T, S70T/T71S for the reported 
conditions at room temperature. This gave promising results with a lot of micro-crystals, and 
even some good crystals. New optimization screens with varying protein concentration were 
set up at 4°C. This also yielded some good crystals. But sufficiently large crystals were not yet 
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obtained for all the mutants. One manually set up, 24 well screen was also done at room 
temperature for the reported crystallization conditions of OXA-48 [101]; 0.1 M HEPES pH 7.5, 
8-11% PEG 8000, 4-8% 1-butanol.  
Two 96-well plate sitting-drop crystallization screens; SG1 and Structure screen, were 
set up using the new crystallization robot; NT8 – Drop Setter (Formulatrix). This showed crystal 
formation at very different conditions. It was therefore decided to design a 24 well 
crystallization screen spanning a broad pH and precipitant concentration range, with varying 
protein concentration at 4°C; 0.1 M BIS-Tris propane pH 6.5-9.5, 5-30% PEG MME 5000. The 
screens were set up using Formulator Liquid dispenser (Formulatrix).  
Three crystals from each mutant was sent to the synchrotron. The final crystallization 
conditions for the diffracting crystals are listed in Table 2-6.   
Cryo-solutions identical to the crystallization conditions, with ethylene glycol added to 
>30% cryo-protectant in the solution was prepared. The crystals were transferred to the cryo-
solution, mounted, and flash frozen in liquid nitrogen, with the assistance of Dr. Bjarte A. Lund.       
 
Table 2-6: Crystallization conditions for the OXA-48 mutants; R189A, S70A, S70T, and S70T/T71S   
 R189A S70A S70T S70T/T71S 
Method Vapor diffusion  
Plate-type  Hampton Research VDX 24-well plate with sealant 
Temperature (K) 294 277 294 277 
Protein concentration 
(mg/mL) 
7.6 10.1 12.8 11.9 
Buffer composition of 
protein solution  
50 mM 
HEPES pH 












7.2, 50 mM 
K2SO4 
Composition of 
reservoir solution  
0.1 M BIS-Tris 
propane pH 
9.5, 16% PEG 
MME 5000 
0.1 M BIS-Tris 
propane pH 
9.5, 38% PEG 
400 
0.1 M BIS-Tris 
propane pH 
9.5, 19% PEG 
MME 5000 
0.1 M BIS-Tris 
propane pH 
8.5, 20% PEG 
MME 5000 
Drop volume (µL) 3 2 3 2 
Reservoir volume (µL) 1000 1000 1000 200 
Protein:reservoir 
ratio  





2.2.2 X-ray data collection and structure determination 
The protein crystals (OXA-181, OXA-163, OXA-436, and OXA-48 mutants; S70A, 
S70T, S70T/T71S and R189A) were sent to the beamline 14.1 at BESSY II, Berlin, Germany. 
The diffraction data were collected by the NorStruct team.  
The crystal structures for OXA-181 and OXA-436 were solved by Dr. Bjarte A. Lund. 
The crystal structures for OXA-163 and the OXA-48 mutants S70A, S70T, S70T/T71S and 
R189A were solved by researcher Hanna-Kirsti S. Leiros.      
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2.3 Protein stability  
 
2.3.1 Differential scanning calorimetry (DSC) 
 
Table 2-7: Solutions used for differential scanning calorimetry (DSC) for selected OXA-48 mutants, OXA-48, 
OXA-181, OXA-245, OXA-163, and OXA-436.  
Solution Content 
Buffer G 50 mM HEPES pH 7.0 
50 mM K2SO4 
Buffer H 50 mM NaH2PO4/ Na2HPO4 pH 7.2 
 
 DSC analysis were conducted for the OXA-48 like enzymes OXA-181, OXA-163, 
OXA-436 and OXA-245 to investigate the differences between the enzymes. OXA-245 differs 
from OXA-48 only by one amino acid substitution. The experimental method was conducted 
according to the method description in the User`s Manual; model CSC 6300 Nano-Differential 
Scanning Calorimeter III chapter 4 [102]. OXA-245, OXA-181, OXA-163, OXA-48, and 
OXA-48 mutants; R206A, R189A, and R189A/R206A were analyzed in duplicate 
measurements, dialyzed against Buffer G and Buffer H (Table 2-7). OXA-436 was dialyzed 
only against Buffer G, and analyzed in duplicate measurements. All samples were dialyzed o/n 
at 4°C, with a few exceptions. The experiments were performed using a CSC N-DSC III 
instrument, and all data were analyzed using the program NanoAnalyze 3.6 (TA Instruments). 
 All solutions used; water, buffer, and protein samples were filtrated and degassed before 
use. The temperature gradient was set from 10-80°C, with an increase/decrease in temperature 
of 1°C/min. Protein sample concentration was in the range of 0.7-1.0 mg/mL. 
   For every experiment, a run with water in both cells were conducted first. Then both 
the reference and the sample cell were flushed with buffer once, before buffer was loaded to 
both cells, making sure there were no air bubbles in the cells. The system was pressurized to 3 
atm, and the program could be started. This was done to allow for the determination of the 
experiment baseline. After one heating cycle, buffer was removed from the sample cell, and the 
protein sample added instead. After one more heating cycle, the program was ended. And data 
could be analyzed. For the clean-up of the DSC instrument, 50% formic acid was added to both 
cells, and an own formic acid program (25-80°C) was ran, without pressurizing the system. 
After completion of the program the cells were washed with 1 L ddH2O, before water was 




2.3.2 Microscale thermophoresis (MST) 
 
Table 2-8: Solutions used for Microscale Thermophoresis (MST) of OXA-48 R189A and R189A/R206A 
Solution Content  
Buffer I 50 mM HEPES pH 7.0 
50 mM K2SO4 
0.05% Tween-20 
 
To determine the dimer affinity of OXA-48 R189A and R189A/R206A a microscale 
thermophoresis experiment was conducted. The experimental method was conducted according 
to a previous MST experiment with the OXA-48 R206A mutant (unpublished data).   
OXA-48 R189A and R189A/R206A were labelled using the Monolith NT Protein 
Labelling Kit RED-NHS (NanoTemper Technologies). According to the manufacturer’s User 
Manual the proteins were diluted to 20 µM in the provided Labelling Buffer with a molar 
protein:dye ratio of 1:3, before being incubated at room temperature for 30 min in darkness. 
Unreacted dye was then removed using the supplied Gravity Flow dye removal Column. The 
column was equilibrated using 6 mL Buffer I (Table 2-8).  
Three individual series of 16 two-fold dilutions of unlabeled OXA-48 R189A/R206A 
from 500 nM to 15 pM were prepared (MST analysis of OXA-48 R189A was unsuccessful). 
Labelled OXA-48 R189A/R206A was added to each dilution with a final concentration of 150 
pM. Both labeled and unlabeled protein was diluted in Buffer I.  
Samples were incubated for 10-20 min in room temperature, before being loaded into 
Monolith NT.115 Standard Treated Capillaries (NanoTemper Technologies). The Monolith 
NT.115 instrument (NanoTemper Technologies) settings were adjusted to 60% LED power, 
40% (medium) MST power, and temperature of 25°C. Data from three measurements, using 
the signal from an MST-on time of 20 seconds, were analyzed using the MO.Affinity Analysis 








2.3.3 Size-exclusion chromatography  
To further investigate the dimer stability, and how the dimer formation is affected at 
different pH, size-exclusion chromatography (SEC) using a pH gradient from 4.0-7.0 for OXA-
48 and OXA-48 R206A, R189A, and R189A/R206A mutants were conducted. Through SEC it 
is possible to separate proteins based size. Larger molecules will move around the porous beads 
in the column material, and hence move through the column more quickly than smaller 
molecules which may enter through the pore of the beads [103]. In this manner, it should also 
be possible to separate monomer and dimer forms of the enzyme.   
The method conditions were the same as when testing OXA-48 and OXA-48 R206A in 
a previous experiment, by Trine J. O. Carlsen and Bjarte A. Lund (unpublished data). From the 
results, it was clear that both OXA-48 and OXA-48 R206A eluted as monomers with 
phosphate-citrate buffer pH 4.0 with 50 mM K2SO4, and dimers at pH 5.0. It was therefore 
interesting to test the elution with phosphate-citrate buffer pH 4.5 for these enzymes.    
The proteins were run through a Superdex 200 10/300 GL gel column with phosphate-
citrate buffers supplemented with 50 mM K2SO4 at pH 4.0, 4.5, 5.0, 6.0, and 7.0, with a protein 
concentration of 10 µM. The proteins were injected into the column through a 200 µL loop. 
The ÄKTA explorer Fast Protein Liquid Chromatography (FPLC) system with the computer 
program Unicorn 5.0 (GE Healthcare) was used for the size-exclusion chromatography. Flow 
rate was set to 1 mL/min, and the pressure limit to 0.5 mPa. Before use, the column was 
equilibrated with phosphate-citrate buffer supplied with potassium sulphate, at the appropriate 
pH, for one-column volume. To correlate the molecular weight to the elution volume (cannot 
be correlated directly, as protein charge and shape differ in addition to their molecular weight), 
the standards Conalbumin (Mw: 75 kDa) and Carbonic anhydrase (Mw: 29 kDa) were used, as 











2.4 Enzyme kinetics  
 
Table 2-9: Solutions used to investigate the enzyme kinetics activity of OXA-48 and a selection of OXA-48 
mutants with nitrocefin, ampicillin, imipenem and ceftazidime.   
Solution  Content  
Buffer J 100 mM Na2HPO4/NaH2PO4 pH 7.0 
50 mM NaHCO3  
Buffer K 100 mM Na2HPO4/NaH2PO4 pH 7.0 
50 mM NaHCO3 
0.2 mg/mL BSA 
 
 It was originally planned to test the enzyme activity of OXA-48 and all the OXA-48 
mutants designed during this thesis with nitrocefin (reporter substrate), ampicillin (penicillin), 
imipenem (carbapenem), and ceftazidime (cephalosporin). Due to time-limitations it was 
decided to test OXA-48 and all the OXA-48 mutants with nitrocefin, OXA-48 and OXA-48 
S70T, S70T/T71S, P68A, P68A/Y211S with ampicillin and imipenem, and only OXA-48 and 
OXA-48 P68A, P68A/Y211S with ceftazidime.  
 The enzyme assays were conducted according to the method description of the enzyme 
kinetic experiments for OXA-48 by Lund et al. [39]. The enzyme- and substrate concentrations 
used as a starting point for the assays were also based on the reported concentrations used in 
the previously mentioned article [39]. For the substrate concentration starting point for       
OXA-48 P68A and P68A/Y211S mutants MIC values from the studies by PhD. student 
Christopher Fröhlich, were compared to MIC values of OXA-48 and OXA-163 in a study by 
Poirel et al. [53] which also reported enzyme activity.  
 A small amount of ampicillin, imipenem and ceftazidime was dissolved in 1 mL Buffer 
J (Table 2-9) (nitrocefin was dissolved in DMSO). To determine the substrate concentration 10 
µL of the dissolved substrate was added to 990 µL Buffer J in an UV-cuvette, and the initial 
OD was measured at the appropriate wavelength (individual for each substrate – see Table 2-
10). 1 µL OXA-48 (~7 mg/mL) was then added (mixed well), and the absorbance was measured 
at regular intervals until substrate was hydrolysed. Using equation 2-2 the substrate 
concentration was calculated. For substrate concentration determination of ceftazidime 10 µL 
VIM-2 (~10 mg/mL) was used for the hydrolysis (due to OXA-48 being considered inactive 
against ceftazidime), the enzyme concentration was increased due to slow hydrolysis rate. The 








Table 2-10: Wavelengths, extinction coefficients, and plate specific extinction coefficients for the substrates 
nitrocefin, ampicillin, imipenem and ceftazidime.  
Substrate Wavelength (nm) Extinction coefficient 
(De) 
Plate specific extinction 
coefficient (De, OD/µM) 
Nitrocefin  
(reporter substrate)  
482 17400 0.004200 
Ampicillin 
(penicillin) 
235 -820 0.0004566 
Imipenem 
(carbapenem) 
300 -9000 0.002005 
Ceftazidime 
(cephalosporin) 
260 -9000 0.004843 
 
 The measurements were performed on a UV spectrophotometer SpectraMax M2e 
(Molecular Devices) with the program SoftMax Pro 5.2 software (Molecular Devices), using 
Corning 96-well UV-plates. Dilution series of 8 dilutions were prepared for each substrate, with 
three parallel runs. The assay was set up with 100 µL reaction volume; 40 µL Buffer J, 50 µL 
substrate - at appropriate concentration diluted in Buffer J, and 10 µL enzyme – at appropriate 
concentration diluted in Buffer K (Table 2-9). Bovine Serum Albumin (BSA) was added to 
kinetics Buffer K used to dilute the enzymes, to stabilizes the enzyme at such low 
concentrations, keeping it from denaturation [104]. The assay was run for 40 min, with reading 
intervals from 15-25 sec, at 25°C.  
 The software GraphPad Prism 7 was used to analyse the data. To create the Michaelis-
Menten curves the substrate concentration (µM) is plotted against the initial velocity (µM/s). 
The initial velocity is measured in mOD/min by the spectrophotometer, and is converted to the 
appropriate unity by the plate specific extinction coefficient. The plate specific extinction 
coefficient for the given batch of plates was calculated for ampicillin, imipenem and 
ceftazidime by Dr. Susann Skagseth. Nitrocefin is not measured using UV-plates, and the plate 







3 Results and discussion  
 
3.1 Mutagenesis, protein expression and protein purification  
 
3.1.1 Site-directed mutagenesis of residues 68, 70, 71, 189, 206 and 211 in OXA-48 
It was set out to investigate the effect of residues 68, 70, 71, 189, 206 and 211 in the 
active site and dimer interface, to study its effect on the enzyme activity and thermostability. 
To do this site-directed mutagenesis of OXA-48 was conducted. 
Mutagenesis of the first OX-48 mutants; S70A, S70T, S70T/T71S, R189A was 
challenging, and several optimization methods were tested. After the first attempt, no colonies 
could be observed growing on the LB-agar plate after transformation. The prepared XL1-Blue 
cells were first suspected. A different in-house E. coli cloning strain DH5a was tested, as well 
as commercial competent XL1-Blue cells (Agilent), without results. A positive control using 
the supplied pWhitescript 4.5-kb control plasmid, and oligonucleotide control primers (fwd. 
and rev.) was also set up using the in-house competent XL1-Blue cells for transformation, and 
seemed to work fine. 
Due to high melting-temperature of the primers (78-83°C, see Table 2-1) the annealing 
temperature was increased from 55°C to 60°C. The elongation time was increased as well, from 
5 min (1 min/1kbp) to 5 min and 30 sec. This did not yield any results, therefore a DMSO 
gradient from 1-5% was tested. Again, no colonies were obtained.  
The annealing temperature is known to affect the purity and yield of a PCR reaction. 
Increasing the annealing temperature may increase the specificity of the annealing reaction, 
reducing the amplification of non-specific DNA fragments, and increasing the formation of the 
correct/desired product [105]. Having a sufficiently long elongation step is also important for 
the yield of the PCR reaction, as the polymerase requires sufficient time to replicate the 
sequence of interest. The elongation time is dependent on the polymerase used, and should not 
be increased by too much compared to the manufacturers recommendations as a too long 
elongation time may result in higher error rates [106]. As it was suspected that the primers 
might be the problem, a DMSO gradient was also tested. DMSO has been found to increase the 
yield of the PCR reaction in GC-rich DNA templates and primers by preventing secondary 
structure formation [107]. Even though the primers had a recommended GC content of <60% 
this might have an effect.   
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The QuikChange II Site-Directed Mutagenesis Kit used for the mutagenesis of OXA-
48 was from 2015, and it was decided to test a more recently purchased, available, polymerase; 
Phusion (BioLabs). The QuikChange II Site-Directed protocol was used with the Phusion 
polymerase. Even though none of the optimization test had yielded any positive results, it was 
decided to continue using the increased annealing temperature (60°C), and elongation time (5 
min and 30 sec), as well as 1% DMSO. This gave a few colonies for the OXA-48 S70T and 
S70T/T71S mutants. The constructs were analysed using PCR amplification and gel 
electrophoresis, showing DNA bands at the appropriate size for OXA-48 S70T/T71S, but none 
for OXA-48 S70T. Plasmid purification and sequencing of the OXA-48 S70T/T71S construct 
was carried out, which confirmed the first correct mutation.  
It was speculated if the DNA polymerase was the problem, therefore a new QuikChange 
II Site-Directed Mutagenesis Kit was purchased. An annealing temperature gradient from 55-
75°C, and a concentration gradient using 5, 20 and 40 ng template, were set up for the mutant 
strand synthesis reaction, to identify optimum PCR conditions. Once again, no colonies after 
the transformation of the OXA-48 mutant construct was observed. The template gradient was 
investigated since the total amount of DNA in a PCR reaction has an effect on the outcome. 
Too much DNA may cause packed DNA in the confined reaction space and lead to poor DNA 
synthesis by the obstruction of the polymerase enzymes. The template:primer ratio should be 
optimized, as a too high primer ratio compared to template may cause primer self-annealing 
[106].  
The positive control reaction was set up according to protocol, to eliminate any errors 
with the new kit, which also this time worked fine. It was decided to test the Phusion polymerase 
instead of PfuUltra polymerase again, but without results.  
It was concluded that the problem most likely was the primers. But why only the OXA-
48 S70T/T71S primer should work was not clear, as the primer length, GC contents, secondary 
structure and melting temperature were quite similar among the different primers. It was then 
finally discovered, when planning to test a primer concentration gradient, that the primer 
concentration had been miscalculated, and the primer concentration used had been too high. 
Then with the correct primer concentration the mutant strand synthesis reaction was finally 
conducted with success, as specified in the method description, for OXA-48 S70A, S70T, 





 To create the double mutant OXA-48 R189A/R206A, the OXA-48 R206A gene 
construct was used as a template. For OXA-48 P68A/Y211S the OXA-48 P68A construct was 
the template to create the double mutant, but without success. A OXA-48 Y211S mutant was 
therefore prepared, by applying this template instead, and the P68A primers the second double 
mutant was made. For the mutant strand synthesis reaction, the temperature was lowered to 
55°C (as originally suggested by the protocol), and the elongation time increased to 6 min. In 
addition, the transformed construct was spread on LB-agar plates with reduced ampicillin 
concentration. This gave a positive result.  
 The successful transformation of the OXA-48 mutant constructs were confirmed by 
PCR amplification and gel electrophoresis analysis. The size of the gene constructs after 
amplification PCR, using the T7 fwd. and rev primers to transcribe the region between the T7 
promotor and terminator region of the pDEST17 vector (see Figure 2-2) is 958 bp. The OXA-
48 mutants showed DNA bands around 1000 bp from the gel electrophoresis, as shown in 
Figure 3-1. The OXA-48 mutant constructs were purified using the Wizard Plus SV Minipreps 
DNA Purification System Kit. The final DNA concentrations for the purified plasmids are given 
in Table 3-1. Finally, the correct mutations (nucleotide substitutions) were confirmed by Sanger 
sequencing (at the Sequencing Lab at the University Hospital of Northern Norway), and 
identified by sequence alignment in BioEdit. Generally, 3 bacterial colonies for each mutant 
were selected for cultivation, plasmid purification and sent to sequence analysis, as about half 
of the sequence analyzed constructs contained the desired mutation(s).  
 
Table 3-1: DNA concentration of the purified OXA-48 mutant constructs after mutagenesis. The DNA 
concentration was measured from the OD280 absorption on the NanoDrop instrument.   













Figure 3-1: Agarose-gel image of a selection of positive OXA-48 mutants after PCR screening (STTS is short for 
the mutant OXA-48 S70T/T71S). Perfect DNA 0.1-12 kbp marker was used, and relevant ladder-bands are 
indicated with size in kilo base pairs (kbp). As can be seen from the image the positive OXA-48 mutants showed 
bands around 1000 bp after amplification using T7 primers. Positive control with pDEST17 OXA-48 construct 
(also amplified using T7 primers) showed the same size, as expected. Negative control showed no bands, as it 
consisted only of reaction mix (no construct).   
 
3.1.2 Protein expression of OXA-163, OXA-48, and OXA-48 mutants; R189A, 
R189A/R206A, P68A, P68A/Y211S, S70T, S70T/T71S, and S70A 
Glycerol stocks of OXA-163 (BL21(DE3)pRARE) and OXA-48 (BL21(DE3)pLysS) 
was provided for cultivation and expression of the enzymes. OXA-163 grew faster than OXA-
48, and was therefore allowed to reach a higher cell density (measured OD600) before induction. 
The cells were induced at 20°C with 0.4 mM IPTG o/n. Both OXA-48 and OXA-163 seemed 
to be expressed well after induction. For the OXA-48 samples less of other cell components 
seemed to be expressed with the protein, compared to OXA-163. Probably explained by the 
lower cell density upon induction, visible by the difference between the BFI samples of OXA-
48 and OXA-163. The SDS-PAGE gel image from the large scale expression of OXA-48 and 
OXA-163 is shown in Figure 3-2.    
The selection of different E. coli expression strains and expression conditions for the 
OXA-48 mutants in this thesis was based on previous positive results from expression and 
purification of OXA-48 [39], OXA-181 and other OXA-48 mutants [95]. Small scale 
optimization would probably have identified more ideal conditions, and given a higher protein 
yield. Finding the optimal expression conditions was not the goal here however, and identifying 
the conditions that yielded enough protein for the following experiments was sufficient.  
Two strains were used for large scale expression; (1 L) E. coli BL121Star(DE3)pRARE 
and Rosetta2(DE3)pLysS. The first OXA-48 mutants obtained were S70A, S70T, S70T/T71S 
and R189A, and these were also expressed first. For these mutants, no AFI and BFI samples 
could be analysed by SDS-PAGE due to sticky samples. It was therefore not possible to 
determine which strain that gave the best protein expression, or how the expression was affected 
by the reduced induction temperature and IPTG concentration compared to OXA-48. It was 
decided to use the cell culture from the previously successful strain BL121Star(DE3)pRARE 
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[39] for protein purification. From the large scale expression of OXA-48 P68A, P68A/Y211S, 
and R189AA/R206A it was possible to load the AFI and BFI sample to the SDS-PAGE gel, 
and the expression could be evaluated. From the gel analysis it was concluded that the protein 
expression was slightly better in Rosetta2(DE3)pLysS cells, than in BL21Star(DE3)pRARE 
cells. Still, the cell culture from the BL21Star(DE3)pRARE strain were used for protein 
purified. The SDS-PAGE gel image from the large scale expression of OXA-48 P68A, 
P68A/Y211S and R189A/R206A is shown in Figure 3-3.  
 
 
Figure 3-2: SDS-PAGE gel image showing before induction (BFI) and after induction (AFI) samples, from 
expression of OXA-48 and OXA-163. Precision Plus 10-250 kDa ladder was used, the marks of interest are 
labelled in kDa. The expressed protein is approximately 30 kDa, and can be seen as a clear band in the AFI samples 












Figure 3-3: SDS-PAGE gel image showing before induction (BFI) samples (A), and after induction (AFI) samples 
(B), from expression of OXA-48 P68A (PA), P68A/Y211S (PAYS), and R189A/R206A (RARA) in both 
Rosetta2(DE3)pLysS and BL21Star(DE3)pRARE cell strains. Precision Plus 10-250 kDa ladder was used, the 
markers of interest are labelled in kDa. The expressed protein is approximately 30 kDa, and can be seen as a clear 





3.1.3 Using immobilized metal ion affinity chromatography for protein purification  
To be able to test the enzyme activity, enzyme stability and conduct successful 
crystallization experiments the purity of the enzyme is crucial, aiming for samples without other 
cell contaminants and proteins affecting the measurements. OXA-48, OXA-163 and the OXA-
48 mutants were all designed with a hexa histidine-tag and a TEV protease cleavage site 
upstream to the genes. The hexa His-tag is for purification with a HisTrap nickel column 
followed by a TEV protease to cleave the His-tag and most of the TEV binding site.  
TEV protease had to be produced, to cleave the His-tag from the proteins of interest. 
The TEV protease also carries a His-tag, making it feasible to separate non-cleaved protein and 
His-TEV protease that will both bind to the nickel column, from the successfully cleaved 
protein eluting in the flow through, in the second His-tag purification step. Expression and 
purification of TEV yielded quite a lot of protein.     
For the OXA enzymes the highest yield of pure protein was obtained for OXA-163. For 
OXA-48 and the OXA-48 mutants the total protein yields were significantly lower. This is 
likely related to OXA-163 being a synthetic DNA gene optimized for E. coli expression, while 
OXA-48 were cloned from a K. pneumoniae sample. Still sufficient amounts of OXA-48 and 
OXA-48 mutants were obtained.  The final obtained protein yields are listed in Table 3-2.  
 
Table 3-2: Final obtained protein yield after protein purification, from expression in 1 liter (L) culture.  
Enzyme  Protein yield (mg)             
per litre culture 
TEV protease 77.1 
OXA-163 98.7 
OXA-48 23.9 
OXA-48 S70A 15.1 
OXA-48 S70T 42.2 
OXA-48 S70T/T71S 23.8 
OXA-48 R189A 24.5 
OXA-48 R189A/R206A 23.7 
OXA-48 P68A 9.9 





3.1.3.1 Protein purification of TEV protease  
It was clear from the first purification step that there was quite a lot of TEV present in 
the protein sample, evidenced by a large protein peak measured absorption at OD280, eluting 
during the imidazole gradient in the chromatogram (Figure 3-4). Samples from the protein peak 
fractions (35-41) were collected for SDS-PAGE analysis, as well as one sample from the flow-
through. The His-tagged TEV protease is around 29 kDa. From the SDS-PAGE gel analysis it 
was clear that a lot of TEV protease was present, visible as “smeared” bands above the 25 kDa 
ladder mark. Some contaminants (binding to the HisTrap column) were still in the sample, and 
the TEV protease sample was estimated to be >90% pure (Figure 3-5).  
Since TEV protease and other contaminants binding to the HisTrap column will be 
removed from the protein of interest in the second purification step, it was decided that TEV 
was pure enough for its purposes. It was also desirable to conduct the purification of TEV 
quickly, to obtain as much protein as possible. The total amount of obtained protein is listed in 








Figure 3-4: Chromatogram from ion metal affinity chromatography purification of TEVsh using a 5 mL HisTrap 
FF crude column. The blue line is the measured absorbance at 280 nm, show the large flow-through, and the eluted 
protein peak, thus proteins with affinity for the nickel column. The green line shows the concentration of Buffer 
B with 500 mM imidazole and the gradient. The other lines show the pressure (brown) and conductivity (red). The 
fraction number is shown in red along the x-axis, while the absorbance (OD280) is shown in blue along the y-axis.      
 
Figure 3-5: SDS-PAGE gel image from the purification of TEV protease. The ladder Precision Plus 10-250 kDa 
was used (left), and marks of relevance are labelled in kDa. The whole cell (WC) sample (after sonication of the 
cells) is shown in lane 1, cell supernatant (CS) sample (before purification) is shown in lane 2. One sample from 
the flow-through is shown in the last lane. Samples from the protein peak, are labelled according to the fractions 




3.1.3.2 Protein purification of OXA-163         
The chromatogram of OXA-163 showed a quite large protein peak measured 
absorbance at OD280. The chromatogram is shown in Figure 3-6. Samples from the fractions of 
the contaminant peak (eluting at 5% Buffer E – Table 2-4, 25 mM imidazole), and from the 
protein peak (eluting during the imidazole gradient), as well as one sample from the flow-
through, were collected for SDS-PAGE gel analysis. The uncleaved, His-tagged, expressed 
OXA-163 construct (and OXA-48) is 29.8 kDa, while the protein without the His-tag is 28.2 
kDa. The SDS-PAGE gel image (Figure 3-9) shows protein bands at the appropriate size for 
BTEV and ATEV samples. The band of the BTEV sample appears slightly higher up on the 
gel, while the ATEV sample is visible as two separate bands, most likely being the TEV 
protease and the cleaved protein slightly further down on the gel. A weak band at the bottom 
of the gel is also visible for the ATEV sample, this is most likely the cleaved His-tag.   
The SDS-PAGE gel analysis showed a high yield of protein in the sample, visible as 
smeared bands slightly above the 25 kDa ladder mark. Some protein seemed to be present in 
the contaminant peak (Figure 3-7 A), indicating that the HisTrap column might be overloaded, 
causing some of the protein to elute at low imidazole concentrations. When analysing the SDS-
PAGE gel image from the protein peak fractions (Figure 3-7 B) fraction 20-28 were selected 
for TEV-cleavage during dialysis.  
From the second HisTrap purification step the chromatogram showed a large flow-
through, containing the cleaved OXA-163, and two contaminant peaks eluting during the 
imidazole gradient (Figure 3-8). The first and sharpest of the contaminant peaks is most likely 
TEV protease due to its high concentration. From the SDS-PAGE gel analysis there seemed to 
be some uncleaved protein eluting with the contaminants. However, it is difficult to differentiate 
between the TEV protease and the OXA-48 like enzymes on a SDS-PAGE gel, as they are 
approximately the same size. The SDS-PAGE gel from the second HisTrap purification step 
indicate that the OXA-163 sample is >95% pure (Figure 3-9), fraction 4-12 were collected.  
OXA-163 was concentrated by centrifugation using Amicon Ultra centrifugal filter (10 
kDa MWCO), to 9.4 mg/mL. The total amount of OXA-163 that was obtained after protein 







Figure 3-6: Chromatogram from the first HisTrap purification step of OXA-163 using a 5 mL HisTrap HP column 
The blue line is the measured absorbance at 280 nm, show the large flow-through, and the eluted protein peak, 
thus proteins with affinity for the nickel column. The green line shows the concentration of Buffer E with 500 mM 
imidazole and the gradient. The other lines show the pressure (brown) and conductivity (red). The fraction number 




Figure 3-7: SDS-PAGE gel image from the first purification step of OXA-163. The ladder Precision Plus 10-250 
kDa was used, and marks of relevance are labelled in kDa. A) The whole cell (WC) sample (after sonication of 
the cells) are shown in lane 1, cell supernatant (CS) sample (before purification) is shown in lane 2, and the flow-
through (FT) in lane 3. Samples are labelled according to the fractions from which they were collected (see Figure 




Figure 3-8: Chromatogram from the second HisTrap purification step of OXA-163 using a 5 mL HisTrap HP 
column. The blue line is the measured absorbance at OD280, showing the protein flow-through first, and two 
contaminant peaks at increasing imidazole concentrations, the first one of those most likely being TEV protease. 
The green line shows the concentration of Buffer E with 500 mM imidazole and the gradient gradient. The other 
lines show the pressure (brown) and conductivity (red). The fraction number is shown in red along the x-axis, 
while the absorbance (OD280) is shown in blue along the y-axis.   
 
Figure 3-9: SDS-PAGE gel image from the second purification step of OXA-163. The ladder Precision Plus 10-
250 kDa was used, and marks of relevance are labelled in kDa. Selected samples from the protein flow-through 
(4-13), are labelled according to the fractions from which they were collected (see Figure 3-8). Samples from 
fraction 17 and 20 are collected from the contaminant peaks (at increased imidazole concentration). Before TEV 




3.1.3.3 Protein purification of OXA-48 
Cells from 1 L cell culture was used to purify OXA-48, the observed protein peak in the 
chromatogram from the first HisTrap column the protein concentration seems to be quite high 
(Figure 3-10). This was confirmed on the SDS-PAGE gel (Figure 3-11), where the protein was 
quite pure already after the first purification step. Fraction 21-26 were collected for TEV-
cleavage by dialysis. The chromatogram of the second HisTrap purification step (Figure 3-12) 
had a smaller flow-through than OXA-163, but the protein yield was still sufficient. A sharp 
TEV protease peak was visible at the beginning of the imidazole gradient, and one small 
contaminant peak containing other proteins with a high affinity to the HisTrap column. From 
the SDS-PAGE gel analysis (Figure 3-13) it seemed that the contaminant peaks this time as 
well contained mostly uncleaved OXA-48, thus confirming the separation of cleaved and non-
cleaved OXA-48. BTEV sample was not collected, but the ATEV sample was analysed by 
SDS-PAGE (Figure 3-13).  
 Fraction 5-10 were collected after the purification. It was clear that the protein sample 
was >95% pure. OXA-48 was concentrated by centrifugation using the Amicon Ultra 
centrifugal filter (10 kDa MWCO) to 7.8 mg/mL. The total amount of OXA-48 that was 




Figure 3-10: Chromatogram from the first HisTrap purification step of OXA-48 using a 5 mL HisTrap HP column. 
The blue line is the measured absorbance at 280 nm, showing the large flow-through, and the eluted protein peak, 
thus proteins with affinity for the nickel column. The green line shows the concentration of Buffer E with 500 mM 
imidazole and the gradient. The other lines show the pressure (brown) and conductivity (red). The fraction number 
is shown in red along the x-axis, while the absorbance (OD280) is shown in blue along the y-axis.      
 
 
Figure 3-11: SDS-PAGE gel image from the first purification step of OXA-48. The ladder Precision Plus 10-250 
kDa was used, and marks of relevance are labelled in kDa. The cell supernatant (CS) sample (before purification) 
is shown in lane 1, and the flow-through (FT) in lane 2. Samples from the contaminant peak (12-14) and protein 





Figure 3-12: Chromatogram from the second HisTrap purification step of OXA-48 using a 5 mL HisTrap HP 
column. The blue line is the measured absorbance at OD280, showing the protein flow-through first, and two 
contaminant peaks at increasing imidazole concentrations, the first one of those most likely being TEV protease. 
The green line shows the concentration of Buffer E with 500 mM imidazole and the gradient gradient. The other 
lines show the pressure (brown) and conductivity (red). The fraction number is shown in red along the x-axis, 
while the absorbance (OD280) is shown in blue along the y-axis.   
 
 
Figure 3-13: SDS-PAGE gel image from the second purification step of OXA-48. The ladder Precision Plus 10-
250 kDa was used, and marks of relevance are labelled in kDa. Samples from the protein flow-through (4-10), are 
labelled according to the fractions from which they were collected (see figure 3-12). Samples from fraction 14, 15 




3.1.3.4 Protein purification of OXA-48 mutants; S70T/T71S, S70T, S70A, R189A, 
R189/R206A, P68A and P68A/Y211S 
All the mutants were expressed in both BL21Star(DE3)pRARE and 
Rosetta2(DE3)pLysS, the BL21Star(DE3)pRARE cells were used for protein purification for 
most of the mutants. OXA-48 S70A showed a lower concentration of protein after the 
purification from Rosetta2(DE3)pLysS cells (15.1 mg) compared to BL21Star(DE3)pRARE 
cells (~30 mg), while OXA-48 R189A displayed the opposite effect (Rosetta2(DE3)pLysS cells 
24.5 mg, BL21Star(DE3)pRARE cells ~10 mg).  
The chromatogram from purification of OXA-48 P68A/Y211S are showed in Figure 3-
14 and Figure 3-15, as an example of the chromatograms from the first and second purification 
steps of the different OXA-48 mutants, as the chromatograms displayed the same trends, with 
varying peak intensity (OD280), also reflected in the final protein concentrations. The protein 
peak absorbance (OD280) from the first HisTrap purification step (Figure 3-14) varied from 500-
1500 mAu. The late protein flow-through elution in the second HisTrap purification step, 
displayed in Figure 3-15 for OXA-48 P68A/Y211S, was similar for most mutants, and OXA-
48 (Figure 3-12). This may indicate a weak affinity for the nickel column even after cleavage 
of the His-tag, and the protein should perhaps have been loaded onto the column with a low 
concentration (eg. 20 mM) of imidazole. The sharp peak with absorbance (OD280) around 1000 
mAu, eluting first of the two contaminant peaks, was observed in all the chromatograms from 







Figure 3-14: Chromatogram from the first HisTrap purification step of OXA-48 P68A/Y211S, shown as an 
example from the purification of the OXA-48 mutants. A 5 mL HisTrap HP column was used for the purification. 
The blue line is the measured absorbance at 280 nm, showing the large flow-through, and the eluted protein peak, 
thus proteins with affinity for the nickel column. The green line shows the concentration of Buffer E with 500 mM 
imidazole and the gradient. The other lines show the pressure (brown) and conductivity (red). The fraction number 















Figure 3-15: Chromatogram from the second HisTrap purification step of OXA-48 P68A/Y211S, shown as an 
example from the purification of the OXA-48 mutants. A 5 mL HisTrap HP column was used for the purification. 
The blue line OD280, show the protein flow-through first, and two contaminant peaks at increasing imidazole 
concentrations. The green line shows the concentration of Buffer E with 500 mM imidazole and the gradient. The 
other lines show the pressure (brown) and conductivity (red). The fraction number is shown in red along the x-















Concerning the purification of the OXA-48 S70T/T71S mutant, samples from fractions 
selected from chromatogram protein peak absorbance at OD280 were collected for SDS-PAGE 
gel analysis for the first and second HisTrap purification for estimation of the sample purity, as 
previously described for OXA-48 and OXA-163. The SDS-PAGE gel images from both the 
HisTrap purification steps of OXA-48 S70T/T71S are shown in Figure 3-16.  The wrong light 
source was used when imaging the gels, thus explaining the black background.  
The protein was quite pure already after the first purification step, and fraction 12-17 
were collected for dialysis and TEV cleavage. After the second HisTrap purification the protein 
was clearly >95% pure, and fraction 3-7 were collected for concentration. OXA-48 S70T/T71S 
was concentrated to 11.7 mg/mL. The total amount of obtained OXA-48 S70T/T71S after 




Figure 3-16: SDS-PAGE gel images from the purification of OXA-48 S70T/T71S, where incorrect light setting 
was used thus explaining the black background. The ladder Precision Plus 10-250 kDa (left) show relevant 
molecular weight standards in kDa. A) SDS-PAGE gel image from the first HisTrap purification step. The whole 
cell (WC) sample and cell supernatant (CS) sample are shown to indicate the protein solubility. The flow-through 
(FT) sample is shown as a control to check that no protein is eluted there, as would indicate an error. Samples from 
the contaminant peak (7-9) and protein peak (12-17), are labelled according to the fractions from which they were 
collected. B) SDS-PAGE gel image from the second HisTrap purification step. Samples from the protein flow-
through (3-9), are labelled according to the fractions from which they were collected. Samples from fraction 16, 
17 and 22 were collected from the contaminant peaks (at increased imidazole concentration). Before TEV (BTEV) 




 OXA-48 S70T were purified in the same manner as previously described. SDS-PAGE 
gel image from the first HisTrap purification is shown in Figure 3-17 A, where fractions 22-26 
were collected for TEV cleavage by dialysis. From the second HisTrap purification step the 
flow-through peak (OD280) was quite broad, and fraction 6-19 were collected for SDS-PAGE 
gel analysis (Figure 3-17 B). Fraction 6-11 were pooled and concentrated by centrifugation 
using the Centriprep centrifugal filters (10 kDa MWCO) to 12.8 mg/mL. It was clear from the 
gel image that OXA-48 S70T was >95% pure. The total amount of OXA-48 S70T that was 




Figure 3-17: SDS-PAGE gel images from the purification of OXA-48 S70T. The ladder Precision Plus 10-250 
kDa (left) show relevant molecular weight standards in kDa. A) SDS-PAGE gel image from the first HisTrap 
purification step. The whole cell (WC) sample and cell supernatant (CS) sample are shown to indicate the protein 
solubility. The flow-through (FT) sample is shown as a control to check that no protein is eluted there, as would 
indicate an error. Sample(s) from the contaminant peak (14) and protein peak (22-26), are labelled according to 
the fractions from which they were collected. B) SDS-PAGE gel image from the second purification step. Samples 
from the protein flow-through (6-15), are labelled according to the fractions from which they were collected. 
Samples from fraction 19 and 23 were collected from the contaminant peaks (at increased imidazole 





The purification of OXA-48 S70A was performed with cells from the expression in 
Rosetta2(DE3)pLysS, samples were collected for SDS-PAGE gel analysis after the first 
HisTrap purification step (Figure 3-18 A). Fraction 18-23 were collected for dialysis and TEV 
cleavage. Fraction 4-8 was collected for protein concentration by centrifugation using 
Centriprep centrifugal filters (10 kDa MWCO), and OXA-48 S70A was concentrated to 10.1 
mg/mL. Form the SDS-PAGE gel analysis from the second HisTrap purification it was clear 
that the protein was >95% pure. The total amount of OXA-48 S70A that was obtained after 




Figure 3-18: SDS-PAGE gel images from the purification of OXA-48 S70A. The ladder Precision Plus 10-250 
kDa (left) show relevant molecular weight standards in kDa. A) SDS-PAGE gel image from the fist HisTrap 
purification step. The whole cell (WC) sample and cell supernatant (CS) sample are shown to indicate the protein 
solubility. The flow-through (FT) sample is shown as a control to check that no protein is eluted there, as would 
indicate an error. Sample(s) from the contaminant peak (11) and protein peak (17-23), are labelled according to 
the fractions from which they were collected. B) SDS-PAGE gel image from the second HisTrap purification step. 
Samples from the protein flow-through (3-8), are labelled according to the fractions from which they were 
collected. Samples from fraction 12 and 16 were collected from the contaminant peaks (at increased imidazole 






 OXA-48 R189A was purified from Rosetta2(DE3)pLysS cells as well, and the SDS-
PAGE gel image form the first HisTrap purification step is shown in Figure 3-19 A. At this 
stage, the protein already seemed pure, based on the SDS-PAGE gel analysis, and fractions 11-
15 were collected for dialysis and TEV cleavage. From the second HisTrap purification step 
fractions 2-7 were collected from the flow-through and pooled. OXA-48 R189A was 
concentrated to 9.8 mg/mL by centrifugation using the Centriprep centrifugal filters (10 kDa 
MWCO). It was clear from the gel analysis that the protein sample was >95% pure (Figure 3-
19 B). The total amount of obtained OXA-48 R189A after protein purification from 1 L cell 




Figure 3-19: SDS-PAGE gel images from the purification of OXA-48 R189A. The ladder Precision Plus 10-250 
kDa (left) show relevant molecular weight standards in kDa. A) SDS-PAGE gel image from the fist HisTrap 
purification step. The whole cell (WC) sample and cell supernatant (CS) sample are shown to indicate the protein 
solubility. The flow-through (FT) sample is shown as a control to check that no protein is eluted there, as would 
indicate an error. Sample(s) from the contaminant peak (8) and protein peak (11-15), are labelled according to the 
fractions from which they were collected. B) SDS-PAGE gel image from the second HisTrap purification step. 
Samples from the protein flow-through (2-7), are labelled according to the fractions from which they were 
collected. Samples from fraction 9 and 12 were collected from the contaminant peaks (at increased imidazole 





From the SDS-PAGE gel analysis of OXA-48 R189A/R206A after the first HisTrap 
purification step (Figure 3-20 A), fractions 18-23 were collected for dialysis and TEV cleavage. 
Fraction 17 was also a part of the protein peak eluting during the imidazole gradient, but was 
excluded based on the SDS-PAGE gel analysis, where the sample contained almost as much 
contaminants as the protein of interest. From the second purification step HisTrap fraction 3-
10 were pooled, based on the SDS-PAGE gel analysis (Figure 3-20 B). It was clear that OXA-
48 R189A/R206A was >95% pure, and the protein sample was concentrated to 7.0 mg/mL by 
centrifugation using the Centriprep centrifugation filters (10 kDa MWCO). The total amount 
of obtained OXA-48 R189A/R206A after protein purification from 1 L cell culture is listed in 




Figure 3-20: SDS-PAGE gel images from the purification of OXA-48 R189A/R206A. The ladder Precision Plus 
10-250 kDa (left) show relevant molecular weight standards in kDa. A) SDS-PAGE gel image from the fist 
HisTrap purification step. The whole cell (WC) sample and cell supernatant (CS) sample are shown to indicate the 
protein solubility. The flow-through (FT) sample is shown as a control to check that no protein is eluted there, as 
would indicate an error. Sample(s) from the contaminant peak (12) and protein peak (17-23), are labelled according 
to the fractions from which they were collected. B) SDS-PAGE gel image from the second HisTrap purification 
step. Samples from the protein flow-through (2-10), are labelled according to the fractions from which they were 
collected. Samples from fraction 14 and 18 were collected from the contaminant peaks (at increased imidazole 




 The SDS-PAGE gel of OXA-48 P68A from the first HisTrap purification (Figure 3-21 
A) does not include the whole cell (WC), cell supernatant (CS) and flow-through (FT) samples 
as these were lost. Fractions 17-21 were collected for dialysis and TEV cleavage. After the 
second HisTrap purification step the SDS-PAGE gel analysis (Figure 3-21 B) showed that the 
protein was >95% pure, thus fraction 3-14 were collected. Fractions 12-14 were also pooled 
with the other HisTrap fractions despite a very low protein concentration, since they appeared 
pure on the SDS-PAGE gel. OXA-48 P68A was concentrated to 5.5 mg/mL by centrifugation 
using the Centriprep centrifugal filters (10 kDa MWCO). The total yield of OXA-48 P68A after 




Figure 3-21: SDS-PAGE gel images from the purification of OXA-48 P68A. The ladder Precision Plus 10-250 
kDa (left) show relevant molecular weight standards in kDa. A) SDS-PAGE gel image from the fist HisTrap 
purification step. WC, CS and FT samples were lost. The gel had to be re-ran, and before TEV (BTEV) and after 
TEV (ATEV) samples were included. Sample(s) from the contaminant peak (11) and protein peak (17-21), were 
labelled according to the fractions from which they were collected. B) SDS-PAGE gel image from the second 
HisTrap purification step. Samples from the protein flow-through (2-14), are labelled according to the fractions 
from which they were collected. Samples from fraction 19 and 24 were collected from the contaminant peaks (at 






 Purification of the double mutant P68A/Y211S showed a good amount of protein after 
the first HisTrap purification (Figure 3-22 A), fractions 16-21 were collected for dialysis and 
TEV cleavage. After the second HisTrap purification the protein sample was determined to be 
>95% pure based on the SDS-PAGE gel analysis (Figure 3-22 B), and fraction 3-10 was 
collected. OXA-48 P68A/Y211S was concentrated to 6.9 mg/mL by centrifugation using the 
Centriprerp centrifugal filter (10 kDa MWCO). The total yield of OXA-48 P68A/Y211S after 




Figure 3-22: SDS-PAGE gel images from the purification of OXA-48 P68A/Y211S. The ladder Precision Plus 
10-250 kDa (left) show relevant molecular weight standards in kDa. A) SDS-PAGE gel image from the fist 
HisTrap purification step. The whole cell (WC) sample and cell supernatant (CS) sample are shown to indicate the 
protein solubility. The flow-through (FT) sample is shown as a control to check that no protein is eluted there, as 
would indicate an error. Sample(s) from the contaminant peak (11) and protein peak (16-21), are labelled according 
to the fractions from which they were collected. B) SDS-PAGE gel image from the second HisTrap purification 
step. Samples from the protein flow-through (2-10), are labelled according to the fractions from which they were 
collected. Samples from fraction 14 and 17 were collected from the contaminant peaks (at increased imidazole 







3.2 Crystallization and crystal structure analysis   
 
3.2.1 Crystallization of OXA-48 like b-lactamases 
A part of this thesis was to gain better insight into the structure activity relationship 
between OXA-48 like b-lactamases. Therefore OXA-181 and the novel b-lactamase OXA-436 
were crystallized and crystal structures solved; and a new crystal structure of OXA-163 was 
determined to 2.05, 2.20 and 2.07 Å resolution, respectively.  
The crystal structure of OXA-181 (PDB: 5OE0) and OXA-436 was solved by Dr. Bjarte 
A. Lund, and the crystal structure of OXA-163 (PDB: 5ODZ) was solved by researcher Hanna-
Kirsti S. Leiros. X-ray data collection and processing statistics for OXA-181 and OXA-163 are 
given in the article “Structure, activity and thermostability investigations of OXA-163, OXA-
181 and OXA-245 using biochemical analysis, crystal structures and differential scanning 
calorimetry analysis”, supplied in Appendix Paper 1.     
In order to obtain protein crystals for structure determination, crystallization trials were 
set up both with the hanging-drop method (by hand) and by the sitting-drop method 
(crystallization robot). The crystallization conditions yielding diffracting crystals for OXA-181, 
OXA-163 and OXA-436, used for the structure determination, are listed in Table 2-5.  
2-4 protein crystals were collected for each enzyme, from different crystallization 
conditions, and/or multiple protein crystals within the same crystallization drop. The crystals 
were cryo-protected, flash frozen, and stored in liquid nitrogen, before being sent to a 
synchrotron for X-ray data collection. OXA-181 was cryo-protected in 0.1 M Tris pH 7.0,       
0.2 M (NH4)2SO4, 20.5% PEG MME 5000, and 20% ethylene glycol. A crystal image of a 
OXA-181 crystal is shown in Figure 3-23 A. OXA-181 protein crystallization yielded long, but 
solid, needle-like crystals. OXA-163 was cryo-protected in 0.1 Tris pH 9.0, 28% PEG MME 
500, and 17% ethylene glycol. OXA-163 crystallization yielded few, small, and square-looking 
crystals, as shown in Figure 3-23 B. The cryo-solution for OXA-436 was 0.1 M HEPES pH 
8.0, 25% PEG 3350, 0.2 M NaCH3COO, and 25% ethylene glycol. Small square-shaped 












Figure 3-23: A) Protein crystal of OXA-181, grown from well conditions with 0.1 M Tris pH 7.0, 0.2 M 
(NH4)2SO4, 20.5% PEG MME 5000. B) Protein crystal of OXA-163, grown from well conditions with 0.1 Tris 
pH 9.0, 28% PEG MME 500.      
 
3.2.2 Crystallization and structure analysis of OXA-48 R189A, S70A, S70T and S70T/T71S 
Crystallization trials were set up using both the hanging-drop method (manually) and 
the sitting-drop method (crystallization robot), for the OXA-48 mutants S70A, S70T, 
S70T/T71S, and R189A. This was done to confirm the mutation, and study the effect from the 
mutation to the surrounding protein structure. Crystallization trials were only set up for the 
mentioned mutants since these were the first to be expressed and purified.  
The resolution of the crystal structures of OXA-48 S70A, S70T, S70T/T71S and R189A 
were determined to 1.85, 2.50, 1.89, and 2.55 Å resolution, respectively. The crystal structures 
were solved by researcher Hanna-Kirsti S. Leiros. X-ray data collection and processing 
statistics for the mutants are supplied in Appendix Table A1.    
3 protein crystals were collected for each mutant, from the same crystallization drop, or 
from different crystallization conditions. The crystallization conditions from the diffracting 
protein crystals of OXA-48 S70A, S70T, S70T/T71S and R189A are given in Table 2-6. The 
crystals were sent to the synchrotron BESSY, Berlin for X-ray data collection. Images of the 
protein crystals, used to determine the crystal structure are shown in Figure 3-24.   
The protein crystals were cryo-protected before being flash frozen and stored in liquid 
nitrogen. S70A was cryo-protected in 0.1 M BIS-Tris propane pH 9.5, and 38% PEG 400. S70T 
in 0.1 M BIS-Tris propane pH 9.5, 19% PEG MME 5000, and 15% ethylene glycol. S70T/T71S 
in 0.1 M BIS-Tris propane pH 8.5, 20% PEG MME 5000, and 15% ethylene glycol. And R189A 


















Figure 3-24: A) Protein crystal of OXA-48 R189A, grown from 0.1 M BIS-Tris propane pH 9.5, 16% PEG MME 
5000. B) Protein crystal of OXA-48 S70A, from reservoir solution with 0.1 M BIS-Tris propane pH 9.5, 38% PEG 
400. C) Protein crystal of OXA-48 S70T, grown from conditions with 0.1 M BIS-Tris propane pH 9.5, 19% PEG 
MME 5000. D) Protein crystal of OXA-48 S70T/T71S, grown from 0.1 M BIS-Tris propane pH 8.5, 20% PEG 
MME 5000.   
 
  The mutations had already been verified by DNA sequencing and were also 
confirmed by studying the 2Fo-Fc electron density map for the substituted residues. OXA-48 
S70A crystal structure was solved at quite high resolution (1.85 Å), the 2Fo-Fc map traced the 
amino acids clearly. It seemed evident that the polar hydroxyl group of serine was not present 
in the structure (Figure 3-25 A). For the OXA-48 S70T mutant it was not as clear, since the 
resolution was significantly lower (2.50 Å), and the serine and threonine residues differ only 
by a methyl group on threonine (Figure 3-25 B). OXA-48 S70T/T71S had two substituted 
residues and 1.89 Å resolution, which made it quite clear from the 2Fo-Fc map that an extra 
methyl group should be found at residue 70, and be removed from residue 71, giving the 
correct mutation (Figure 3-25 C). The resolution was quite low for OXA-48 R189A (2.55 Å), 
but the significant size difference between the amino acids alanine and arginine, made it clear 






Figure 3-25: Crystal structures of OXA-48 S70A, S70T, S70T/T71S, and R189A. Electron density maps 2Fo-Fc 
(1.0s, blue) and Fo-Fc maps (+4.0s green/-4.0s red) are shown for the substituted residues, to give evidence of 
the mutation. Electron density maps and amino acids from the crystal structures by researcher Hanna-Kirsti S. 
Leiros. A) S70A, with mutation clearly confirmed by the 2Fo-Fc map. The relatively high resolution makes it 
possible to easily trace the shape of the amino acid, the polar hydroxyl group of serine seems to be absent. B) 
S70T, due to lower resolution the mutation from serine to threonine (addition of one methyl group) is not that 
evident in the electron density map. C) S70T/T71S, due to a quite high resolution it is easier to trace the 2Fo-Fc 
map to the amino acid structure, and it seems clear that the correct mutation has occurred. D) R189A, the resolution 













3.3 Thermal stability and dimer affinity   
 
3.3.1 Thermal stability investigations by differential scanning calorimetry (DSC)  
OXA-48 and OXA-48 like enzymes differ only by a few amino acid substitutions and/or 
deletions, the effect from these mutations is not fully elucidated. Both OXA-181, and OXA-
245 for example, have a very similar catalytic activity compared to OXA-48 [54]. OXA-181 
differs from OXA-48 by four amino acid substitutions; T104A, N110D, E168Q, and S171A. 
OXA-245 is the enzyme with the highest sequence identity to OXA-48, differing only by one 
amino acid substitution; E125Y. OXA-163, which has a more different catalytic activity 
compared to OXA-48 [53] has a four-amino acid deletion (residue 214-217), shortening the 
loop between b-sheet 7 and 8, in addition to one amino acid substitution S212D. OXA-436 also 
displays a kinetic activity similar to that of OXA-48 has the lowest sequence identity to OXA-
48 of all the identified OXA-48 like b-lactamases, by 91.3% sequence identity [55]. The 
sequence alignment of OXA-48, OXA-181, OXA-245, OXA-163 and OXA-436 are shown in 
Figure 1-7.       
To investigate the differences between OXA-48 and the OXA-48 like enzymes the 
thermal stability of OXA-181, OXA-245, OXA-163 and OXA-436 were studied using DSC to 
determine the transition midpoint, or melting temperature (Tm) of the proteins. OXA-48 mutants 
affecting the dimer interface (R206A, R189A, R189A/R206A) were also investigated.     
All the enzymes (including the mutants) unfolded in a single transition step, without any 
stable intermediate, as seen from the shape of the melting curves. This allowed for using the 
two-state transition model, when calculating the thermodynamic data (see section 1.5.1). The 
DSC data transition curve, with the fitted theoretical two-state model, for OXA-48 is shown in 
Figure 3-26, as an example. DSC transition curves for the enzymes dialyzed in 50 mM 
phosphate buffer pH 7.2, are supplied in Appendix Figure A1. The transition peaks spanned 
from 5-7°C. The reason that some peaks were slightly broader than others were not completely 
clear, but protein concentration, sample inhomogeneity and/or minor impurities may affect this.  
According to interaction analysis of the crystal structure of OXA-48, OXA-181, OXA-
245, and OXA-163 10-20% of the surface is buried in dimerization [54, 108]. Gel filtration 
experiments as well as microscale thermophoresis also indicated a strong dimer formation for 
OXA-48 and OXA-48 R206A mutant (unpublished data). The DSC curves were therefore fitted 
with the molecular weights and concentrations of dimers. This assumption was also confirmed 
by comparing the van´t Hoff enthalpy (DHvH) calculated from the fitted two-state model, and 
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the calorimetric enthalpy (DHcal) from the transition curves. When assuming dimer formation, 
the two enthalpy values were approximately the same, but when using molecular weights and 
protein concentrations of the monomeric form the two values deviated more. In the case of the 
monomer DHvH/ DHcal generally gave values much higher than 1, indicating that dimer is the 
most likely state. However, the proportions between the enthalpies varied from run to run, and 
the method should therefore not be used to determine monomer or dimer form of the protein, 
merely to determine if the two-state unfolding model fits well with the given conditions.  
 
 
Figure 3-26: DSC transition curve (red) for OXA-48 dimer, with the fitted two-state model (blue) to be able to 
calculate the enthalpy of protein unfolding. The temperature is given along the x-axis, and the heat capacity along 
the y-axis. Figure from reference [54]. 
 
 The enzymes were dialyzed overnight in 50 mM HEPES pH 7.0 and 50 mM K2SO4 and 
the determined Tm and enthalpy from the DSC experiments are given in Table 3-3. A lower 
thermal stability was found for OXA-181 (52.6°C) and OXA-436 (53.8°C) compared to OXA-
48 (55.2°C), while OXA-245 (55.8°C) actually displayed a slightly increased thermal stability 
compared to OXA-48. OXA-163 showed the lowest stability (49.4°C) of the OXA-48 like 
enzymes tested. Greater active site flexibility was proposed to explain the observed easier 
access for cephalosporin hydrolysis, and this might also reduce the thermal stability [53, 109]. 
These findings together with kinetic and structural data for OXA-48, OXA-181, OXA-245 and 
OXA-163 were used to discuss which residues were responsible for the difference in thermal 
stability in the article “Structure, activity and thermostability investigations of OXA-163, 
OXA-181 and OXA-245 using biochemical analysis, crystal structures and differential 
scanning calorimetry analysis” by Lund et al [54]. The full article is supplied in Appendix Paper 
1. In the article, it was determined that the loss of residues 214-217 in OXA-163 disrupts two 
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ionic bonds (Arg214-Asp159 and Glu216-Lys218) found in OXA-48, causing a reduced 
thermal stability by structure destabilization, but which allows for greater flexibility. For OXA-
181 the N110D substitution introduces an ionic bond from Asp110 to His90, causing the His90 
residue to shift, disrupting the ionic network Asn88-His90-Glu89. The polarity of the protein 
surface is also decreased by the mutations T104A and S117A for OXA-181. Taken together 
this may lower the thermal stability of OXA-181 compared to OXA-48. The slightly increased 
stability of OXA-245 compared to OXA-48 is likely to originate from the one residue 
substitution Glu125 to Tyr. Glu125 forms an ionic bond with Arg129 in OXA-48. However, 
Tyr125 forms p-p stacking interactions with Phe126 and Phe93, which may compensate for the 
loss of the ionic bond [54] and explain the +0.5°C higher temperature stability of OXA-245.  
The OXA-48 mutants; R189A, R189A/R206A and R206A showed a quite significant 
reduction in thermal stability. OXA-48 R206A (50.8°C) and R189A (51.1°C) displayed a 
similar stability, while the double mutant R189A/R206A (42.8°C) showed a severely reduced 
thermal stability (Table 3-3). From size-exclusion chromatography experiments OXA-48 is 
shown to be a monomer at pH 4.0 (phosphate-citrate buffer) (unpublished data by Lund et al.). 
OXA-48 and OXA-48 R189A were therefore dialyzed in phosphate-citrate buffer pH 4.0 prior 
to thermal stability investigation by DSC. This resulted in Tm of 41.0°C (OXA-48) and 40.9°C 
(OXA-48 R189A), thus being quite similar to the Tm obtained for the double mutant (42.8°C 
for OXA-48 R189A/R206A). This indicate that the dimer:monomer equilibrium has been 
moved towards monomer formation, and that the thermal stability of monomers have been 
measured.  
The reduced thermal stability for the suspected monomer may be a reason for the dimer 
formation, to further stabilize the protein. However, the low pH and buffer composition may 
also affect the thermal stability of the protein in other ways than through monomer formation, 
and contribute to the observed low Tm. Also, comparison of the enthalpies from fitting of the 
two-state model still indicated that the dimeric molecular weight and concentration gave the 
best fit for both the double mutant and OXA-48 at pH 4.0. This indicates that the monomer-
formation for the OXA-48 double mutant is not as certain as first assumed.      
A study by Stojanoski et al. [110] determined the midpoint melting temperature of 
OXA-48 to be 58.9°C by circular dichroism using 50 mM phosphate buffer pH 7.2. We then 
became interested in testing whether the method or the buffer was responsible for the higher 
Tm, OXA-48 was dialyzed in the 50 mM phosphate buffer pH 7.2, before investigating the 
thermal stability by DSC. This gave a melting temperature of 59.1°C for OXA-48 (Table 3-4), 
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consistent with the circular dichroism results. The buffer composition is well known to affect 
the protein stability, but these buffers composition, HEPES/K2SO4 pH 7.0 versus PO4 2- pH 7.2, 
differed mainly by the addition of potassium sulphate, and the relatively large change in thermal 
stability was therefore interesting. It was decided to test OXA-181, OXA-245, OXA-163 and 
the mutants OXA-48 R206A, R189A and R189A/R206A in 50 mM phosphate buffer pH 7.2 
as well, to study the effect. A comparison of the DSC curves of OXA-48 and OXA-48 R206A, 
in the two different buffers is shown in Figure 3-27, as an example.  
The DSC results from duplicate measurements using 50 mM phosphate buffer pH 7.2, 
listing the transition midpoint temperatures (Tm) and enthalpies (DH) are given in Table 3-4.  
 
 
Figure 3-27: DSC curves for OXA-48 and the mutant R206A, tested in 50 mM HEPES pH 7.0 and 50 mM K2SO4 
(OXA-48; red, OXA-48 R206A; green) and 50 mM sodium phosphate buffer pH 7.2 (OXA-48; blue, OXA-48 
R206A; magenta). The transition midpoint temperatures are indicated. OXA-48 shows a distinct difference in Tm 













Table 3-3: Transition midpoint temperature (Tm) and unfolding enthalpy (DH) with standard deviations, calculated 
from two-state model with the enzyme molecular weight and concentration as dimer. Using 50 mM HEPES pH 
7.0, 50 mM potassium sulpahte buffer for OXA-48, OXA-181, OXA-245, OXA-436 and OXA-48 mutants R189A, 
R206A, and R189A/R206A, determined by differential scanning calorimetry (DSC).  
Enzyme Run 1 Run 2 
Tm (°C) DH(kJ/mol) Tm (°C) DH(kJ/mol) 
OXA-48 55.12 ± 0.01 1336 ± 6 55.37 ± 0.01 1638 ± 8 
OXA-163 49.40 ± 0.01 1247 ± 6 49.39 ± 0.01 1311 ± 4 
R206A 50.94 ± 0.01 1386 ± 7 51.02 ± 0.01 1432 ± 6 
OXA-181 52.53 ± 0.04 1248 ± 17 52.96 ± 0.02 1606 ± 13 
OXA-245 55.67 ± 0.01 1800 ± 12 55.87 ± 0.01 1639 ± 9 
R189A 49.77 ± 0.01 1256 ± 6 50.23 ± 0.02 1313 ± 11 
R206A/R189A 43.55 ± 0.02 957 ± 5 43.61 ± 0.02 965 ± 6 
OXA-436 53.92 ± 0.01 1547 ± 9  53.71 ± 0.01 1384 ± 5 
 
Table 3-4: Transition midpoint temperature (Tm) and unfolding enthalpy (DH) with standard deviations, calculated 
from two-state model with the enzyme molecular weight and concentration as dimer. Using 50 mM phosphate 
buffer pH 7.2, for OXA-48, OXA-181, OXA-245 and OXA-48 mutants R189A, R206A, and R189A/R206A, 
determined by differential scanning calorimetry (DSC). Standard deviation and enthalpy was not obtained for one 
of the OXA-48 R189A measurements, due to baseline error. However, the melting temperature was very similar 
between the duplicates, and the second measurement was considered reliable.  
Enzyme Run 1 Run 2 
Tm (°C) DH(kJ/mol) Tm (°C) DH(kJ/mol) 
OXA-48 59.08 ± 0.01 1558 ± 11 59.07 ± 0.01 1518 ± 9 
OXA-163 54.15 ± 0.01 1521 ± 9 53.73 ± 0.01 1461 ± 5 
R206A 50.54 ± 0.01 1371 ± 6 51.15 ± 0.01 1306 ± 4 
OXA-181 55.14 ± 0.01 1371 ± 6 55.34 ± 0.01 1419 ± 6 
OXA-245 59.41 ± 0.02 1402 ± 13 59.35 ± 0.02 1425 ± 13 
R189A 51.17 --- 51.01 ± 0.01 1142 ± 4 







Comparison of Tm between the two buffers for OXA-48, OXA-245 and OXA-163 
showed a 3.5-4.5°C increased melting temperature in 50 mM phosphate buffer pH 7.2, 
compared to 50 mM HEPES pH 7.0 and 50 mM potassium sulphate. The Tm for OXA-181 
increased by only 2.5°C. OXA-48 R189A and R189A/R206A differed by an increased 
temperature of approximately 1°C, while R206A did not differ at all. One possible explanation 
for this is that the sulphate ion from the first buffer replaces the chloride ion observed in the 
anion binding between Arg206 and Arg206´ in the dimer interface (see Figure 1-8). A sulphate 
molecule has a large molecular radius than the chloride ion observed in the crystal structure of 
OXA-48, and could therefore potentially destabilize the dimer. This would explain why OXA-
48 R206A is unaffected, as this interaction is already disrupted. R189A could be only slightly 
affected by this as the dimer is already destabilized, while the native enzymes will be affected 
the most since the dimer is stable. However, this does not explain why OXA-48 R189A/R206A 
is not also unaffected. It must also be taken into consideration that there is a significant size 
difference between the chloride and sulphate ion, and thus it is uncertain how likely the 
suggested SO4 2- Arg206 binding is.   
 
3.3.2 Investigating the dimer affinity by microscale thermophoresis (MST)  
From previous MST experiments the dimer affinity for the OXA-48 R206A mutant was 
determined to be 700 ± 300 pM. It was not possible to obtain any reliable dose-response curves 
for OXA-48, and it was reasoned that this might be due to an even stronger dimer affinity in 
OXA-48, compared to OXA-48 R206A (unpublished data). It was attempted to measure the 
dimer affinity (Kd) for OXA-48 R189A and R189A/R206A to more accurately study the amino 
acid substitution upon dimer formation. However, determining the dimer affinity by MST for 
OXA-48 R189A was unsuccessful. Kd value was obtained for OXA-48 R189A/R206A and 
determined to 21.8 ± 4.4 nM, with good signal to noise ratio, as shown in the dose-response 
curve from the MST experiments (Figure 3-28), from which the dissociation constant is 
calculated. As previously mentioned OXA-10 and OXA-14 was reported with a dimer affinity 
in the nano molar to micro molar range [58]. A Kd value of 22 nM, therefore means the dimer 
affinity for OXA-48 R189A/R206A is still quite strong compared to other OXA-dimers, even 
though the double mutant has a lower dimer affinity than the one reported for OXA-48 R206A. 
This indicates that OXA-48 has an unusually strong dimer formation, where salt-bridges are 





Figure 3-28: Microscale thermophoresis curve from three individual measurements with error bars representing 
the standard deviation. OXA-48 R189A/R206A was labelled using RED-dye, and measured at a concentration of 
150 pM, with unlabeled OXA-48 R189A/R206A from 0.015 nM-500 nM. A dissociation constant (Kd) of 21.8 ± 
4.4 nM was derived for the dimer interaction from the normalized fluorescence (DFNorm; y-axis), plotted against 
the concentration of the unlabelled OXA-48 R189A/R206A (x-axis).       
 
3.3.3 Size-exclusion chromatography analysis of the dimer and monomer formation  
To study the dimer interaction and stability OXA-48 and OXA-48 R206A were tested 
at different protein concentrations, as well as different pH values (phosphate-citrate buffer with 
50 mM K2SO4 pH 4.0, 5.0, 6.0, 7.0) by staff engineer Trine Carlsen and Dr. Bjarte A. Lund in 
a previous size-exclusion chromatography experiment. Both proteins were determined to be 
dimers from pH 5.0-7.0, and monomers at pH 4.0. Indicating that salt-bridges are important for 
the dimer association. Both proteins also eluted as dimers at protein concentrations down to 35 
nM, indicating a dimer affinity in the nM range and lower (unpublished data).  
To further investigate the dimer affinity size-exclusion chromatography was conducted 
for OXA-48 mutants R189A and R189A/R206A using the same buffer conditions as previously 
mentioned. In addition, OXA-48 and OXA-48 R206A were tested by SEC using a phosphate-
citrate buffer at pH 4.4 to hopefully, better study the transition between dimer and monomer. 
The resulting elution volumes are shown in Figure 3-29.   
The molecular weight standards Conalbumin (76 kDa) and Carbonic anhydrase (29 
kDa) were eluted at 14.4 and 16.8 mL respectively, using phosphate-citrate buffer pH 7.0 with 
50 mM potassium sulphate. From the previous SEC experiments the OXA-48 dimer eluted at 
15.4 mL, and the monomer at 16.5 mL, which correlates well with the elution volumes of the 
standards used. At pH 4.4 OXA-48 R206A eluted at 16.5 mL, indicating monomer formation. 
OXA-48 eluted at 15.8 mL, which was a bit surprising. We anticipated to obtain two separate 
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peaks showing both monomer and dimer formation from the same elution, however one slightly 
displaced elution peak was obtained instead. This was also observed for OXA-48 R189A which 
eluted at 16.6 mL using pH 4.4, indicating monomer formation, and at 15.8 mL at both pH 7.0 
and 6.0 suggesting more of an equilibrium. OXA-48 R189A/R206A was clearly the most 
destabilized of the mutants tested, and eluted at 16.6 mL, indicating monomer formation, at 
both pH 6.0 and 7.0. At pH 7.0 a small shoulder-like peak was observed at 14.4 mL next to the 
main elution peak. The reason for this was not clear.  
 Elution peak displacement was also reported by Woodbury et al. [111] for an oligomeric 
protein, observing that the elution volume increased with decreasing protein concentrations. It 
was suggested that the monomer:dimer equilibrium favored the monomer formation at lower 
concentrations. The protein dimer might therefore dissociate into a monomer during the column 
migration as the sample is diluted during the experiment. Woodbury et al. observed a slightly 
asymmetric shape to their elution peaks, suggested as a result of the monomer trailing [111]. It 
is possible that this is also the case for our results presented here. A slight asymmetric elution 
peak shape is observable, especially for OXA-48 at pH 4.4 (Figure 3-29). Even though OXA-
48 was previously reported to not be significantly affected by concentration changes, it is 
possible that the dimer interface mutations destabilized the protein enough to be affected by 
this. Whether or not this is the case, R189A/R206A has shown to be the least stable dimer, 
eluting in fact, as a monomer even in neutral pH. R189A is more stable eluting as a mix of 
monomer and dimer at neutral pH, while R206A is the most stable dimer requiring a pH as low 





Figure 3-29: Chromatogram from size-exclusion chromatography with Superdex 200 10/300 GL, showing elution 
volumes for OXA-48, and OXA-48 R206A, R189A and R189A/R206A using phosphate citrate buffer with 50 
mM potassium sulphate at different pH. The elution peaks for the proteins are indicated by color; pH 4.0 – light 
blue, pH 4.4 – orange, pH 5.0 – yellow, pH 6.0 – blue, pH 7.0 – red. Figure by Dr. Bjarte A. Lund (unpublished 
data).   
 
From the dimer affinity and thermal stability experiments it is clear that the mutants 
affecting the dimer interface destabilizes the dimer, compared to the wild type OXA-48. And it 
seems OXA-48 R206A and R189A effect the dimer to a lesser extent compared to the double 
mutant OXA-48 R189A/R206A. However, it is not quite clear from the methods used if 
R189A/R206A is predominantly in the monomeric form. Based on the DSC experiments, 
comparing the enthalpy values from the measurement and the fitted two-state model it seems 
that assuming a dimer yields the best results. The MST experiments indicate a reduced dimer 
association for OXA-48 R189A/R206A (Kd 22 nM), through an increased dissociation constant 
compared to OXA-48 R206A. But the determined Kd value is still quite low compared to the 
reported values for other OXA-dimers, indicating that R189A/R206A still has a quite strong 
 
 94 
dimer association. While DSC and MST experiments suggest dimer formation for OXA-48 
R189A/R206A, the gel filtration (SEC) elutes the protein at a volume consistent with monomer 
formation at neutral pH.  
As it is puzzling that the different methods applied to study the dimer interface mutants 
does not seem to yield the same results, it is perhaps not surprisingly. The different techniques 
use different methods to analyze the protein, not to mention that different buffers were used for 
all the techniques; 50 mM HEPES pH 7.0, 50 mM K2SO4/ 50 mM phosphate buffer pH 7.2 for 
DSC, 50 mM HEPES pH 7.0, 50 mM K2SO4, 0.05% Tween-20 for MST, and citrate-phosphate 
buffer with 50 mM K2SO4 for SEC. DSC measures the thermal stability, or the heat capacity 
difference between the denatured and native protein sample. SEC measures the absorbance 
(OD280) of the proteins eluting from the size-exclusion column, after interacting with the gel 
column material. The differently charged mutants could then interact slightly different with the 
column material. MST measures the movement of molecules in a thermal gradient, using 
fluorescence to detect the florescent tagged protein.     
Taken together it is only possible to conclude that the OXA-48 dimer interface 
mutations has shifted the monomer:dimer equilibrium towards monomer formation, thus 
destabilizing the dimer observed through lower melting temperatures, lower dissociation 





3.4 Enzyme activity 
To study the enzyme activity, effects from different mutations, steady state enzyme 
kinetic assays were performed. The substrates nitrocefin, ampicillin, imipenem, and 
ceftazidime were investigated at different concentrations with a selection of the OXA-48 
mutants. The substrate concentrations used for the different kinetic measurements are listed in 
Table 3-5. The final steady-state enzyme kinetic parameters are listed in Table 3-6. Enzyme 
kinetic curves for the OXA-48 mutants compared to OXA-48 with different substrates are 
shown in Figure 3-31. The individual Michaelis-Menten curves are suppled in Appendix Figure 
A2-A5.      
 
Table 3-5: Concentration-range used for the different substrates; nitrocefin, ampicillin, imipenem, and 
ceftazidime, when measuring the enzyme activity for OXA-48 and the prepared OXA-48 mutants.  
 Nitrocefin Ampicillin Imipenem Ceftazidime  
OXA-48 3.4-300 µM  60-1000 µM 1.2-150 µM 11-400 µM 
S70A 94-750 µM NHa NDb NDb 
S70T 16-2000 µM NHa 210-1000 µM NDb 
S70T/T71S 12-1500 µM NHa 210-1000 µM NDb 
P68A 3.4-300 µM 45-750 µM 1.2-150 µM 9-320 µM 
P68A/Y211S 3.4-300 µM 45-750 µM 1.2-150 µM 9-320 µM 
R189A 6.8-750 µM NDb NDb NDb 
R189A/R206A 6.8-750 µM NDb NDb NDb 
aNH, no detectable hydrolysis  












Table 3-6: Steady-state enzyme kinetic parameters for OXA-48 and prepared mutants with nitrocefin, ampicillin, 
imipenem and cephalosporin. Standard errors are given. 
aNH, no detectible hydrolysis  




Enzyme Km (µM) kcat (s
-1) kcat/Km      
(µM-1s-1) 





OXA-48 31 ± 4 1260 ± 50 40  
S70A 90 ± 40 3.4 ± 0.4 0.04  
S70T 2260 ± 420 285 ± 33 0.1 0.003 
S70T/T71S 640 ± 80 47 ± 3 0.07 0.002 
P68A 32 ± 4 286 ± 11 9 0.2 
P68A/Y211S 39 ± 6 62 ± 3 2 0.04 
R189A 122 ± 21 1950 ± 130 16 0.4 
R189A/R206A 120 ± 20 1550 ± 80 13 0.3 
Ampicillin 
(penicillin)  
OXA-48 370 ± 70 1600 ± 140 4  
S70T NHa  NDb NDb - 
S70T/T71S NHa  NDb NDb - 
P68A 77 ± 12 67 ± 3 0.9 0.2 
P68A/Y211S 211 ± 26 48 ± 2 0.2 0.05 
Imipenem 
(carbapenem) 
OXA-48 13 ± 2 12.5 ± 0.5 1  
S70T 2770 ± 850 58 ± 14 0.02 0.02 
S70T/T71S 1180 ± 450 27 ± 8 0.02 0.02 
P68A 4.2 ± 0.9 2.1 ± 0.1 0.5 0.5 
P68A/Y211S 14 ± 3 1.50 ± 0.09 0.1 0.1 
Ceftazidime 
(cephalosporin)  
OXA-48 300 ± 150 8 ± 2 0.03  
P68A 220 ± 50 68 ± 8 0.3 11 
P68A/Y211S 190 ± 40 110 ± 13 0.6 21 
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3.4.1 Enzyme activity of OXA-48 mutants affecting the dimer interface  
The hydrolytic activity of the OXA-48 mutants R189A and R189A/R206A were studied 
against nitrocefin to investigate how the potential monomer formation could affect the enzyme 
activity. Even if it was hard to determine with certainty if OXA-48 R189A/R206A is a 
monomer, the monomer:dimer equilibrium is most likely shifted towards monomer formation 
at ~1 nM the enzyme concentrations used during the enzyme assays. This is since the dimer 
dissociation constant (Kd) was measured to 22 nM by MST. If a monomer had significantly 
lower activity than a dimer, this should be detectable by enzyme activity measurements. The 
steady-state enzyme kinetic parameters for OXA-48 and OXA-48 mutants are listed in Table 
3-6, and the enzyme kinetic curves are shown in Figure 3-32 G. Here, the enzyme kinetic results 
showed that OXA-48 displayed only 2 times higher activity than R189A, and approximately 3 
times higher activity than R189A/R206A (Table 3-6). Previous enzyme kinetic experiments of 
OXA-48 and OXA-48 R206A (conducted by Dr. Bjarte A. Lund) showed that the two enzymes 
possessed almost the same degree of enzyme activity. 
In summary, this suggests that the OXA-48 mutants R206A, R189A, and 
R189A/R206A affect the dimer affinity and thermal stability, but have little effect on the 
enzyme activity. Based on these observations, OXA-48 R189A and R189A/R206A were not 
prioritized for further enzyme activity testing.   
 
3.4.2 Enzyme activity of the OXA-48 active site mutants S70A, S70T and S70T/T71S 
OXA-48 S70A was designed as an inactive mutant for comparison of the other mutants 
and OXA-48. However, at a specific concentration range of nitrocefin it was possible to detect 
a very low activity (kcat/Km 0.04 µM-1s-1). S70A was also tested with ampicillin, but no enzyme 
activity was detected.  
OXA-48 S70T and S70T/T71S displayed almost no hydrolytic activity against 
nitrocefin and imipenem, as can be seen from the enzyme kinetic curves (Figure 3-32 A and E) 
and determined Km values (Table 3-6), the substrate specificity was very low. During the 
kinetics experiment the substrate concentrations were increased to the detection limit (high 
OD). However, it was still not possible to detect substrate saturation of the enzymes. Enzyme 
activity experiments with similar active site mutants were reported for TEM (class A b-
lactamase) S70T and T71S in the 1980s [63, 64]. They reported no detectable hydrolysis for 
the S70T mutant, but only a slightly decreased activity for the T71S mutant, and with a much 
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lower thermal stability compared to the wild type [64]. A different study reported low but 
detectable activity for a TEM S70C mutant [65].  
A low activity was detectable for both OXA-48 S70T and S70T/T71S with nitrocefin 
and imipenem, but no hydrolysis could be detected with ampicillin. This is shown in the steady-
state enzyme kinetics in Table 3-6, and the enzyme kinetic curves in Figure 3-32 A and E. It 
can be speculated that the additional methyl group in S70T introduced to the active site by the 
mutation add a steric strain, and prevent the hydroxyl nucleophilic attach from occurring. This 
could then explain the drastically lowering of the enzyme activity, mainly by reducing the 
ability to covalently bind to the substrates. It was hypothesized that the double mutation 
S70T/T71S could compensate for the steric strain of the extra methyl-group introduced for the 
active site nucleophilic residue S70, by removing one methyl-group from T71. However, a 
slightly lower activity was actually detected for the double mutant with the substrate nitrocefin, 
compared to the S70T mutant (Table 3-6).  In a study by Stojanoski et al. [110] the S70 residue 
was substituted by a glycine in a number of serine b-lactamases, including OXA-48. The overall 
results showed an increased thermal stability for the S70G mutants (no hydrolytic activity). 
This supports the stability-function hypothesis; stating that active-site residues are optimized 
for substrate binding and catalysis, which often is not consistent with the requirements for 
optimal stability [110]. These findings might support our hypothesis that the highly decreased 
enzyme activity observed for the OXA-48 S70T and S70T/T71S mutants is mainly due to an 
even further increased steric strain in the active site, and reduced optimal orientation of the 
active site residues.       
In the crystal structure of OXA-48 in complex with imipenem (PDB: 5QB4), by Dr. 
Bjarte A. Lund, a covalent bond between Ser70 and the carbonyl carbon of the b-lactam ring 
of imipenem was observed. It is possible that the correct orientation of the substrate and the 
hydroxyl-group of residue 70 is affected by addition of the methyl group of threonine. Thr71 
does not seem to be directly involved in the reaction mechanism of class D b-lactamases, but 
is a conserved active site residue. The hydroxyl-group of Thr71 forms hydrogen bonds with 
nearby residues (main chain of Pro68, and sidechain of Gln169), and herein the methyl-group 
seem important for the sidechain orientation (Figure 3-30). So, by introducing the double 
mutant we not only disturb the orientation of the active site nucleophile, but also the interaction 





Figure 3-30: Crystal structure of OXA-48 (PDB: 5QB4) showing the interactions of the hydroxyl group of Thr71 
to the residues Pro68 and Gln169. The methyl group of Thr71 seem important for the side-chain orientation. Ser70 
is also shown residing on the same a-helix as Thr71. Figure made in PyMOL in collaboration with researcher 
Hanna-Kirsti S. Leiros.   
 
3.4.3 Enzyme activity of OXA-48 mutants introducing ceftazidime activity 
OXA-48 P68A and P68A/Y211S showed reduced enzyme activity compared to the wild 
type OXA-48 for the substrates nitrocefin, imipenem and ampicillin. P68A displayed the 
highest enzyme activity of the two mutants, with 2-5 times lower activity than OXA-48. 
P68A/Y211S had a 10-20 times lower activity than OXA-48 respectively. Differently with the 
substrate ceftazidime, P68A showed an approximately 10 fold increase in activity, and 
P68A/Y211S 20 fold increase, compared to the wild type OXA-48. The steady-state enzyme 
kinetic parameters are listed in Table 3-6, and enzyme kinetics curves are shown in Figure 3-
32 B, C, D and F.   
Residue Pro68 is found at the beginning of the a3-helix in OXA-48, where Ser70 is 
located (Figure 3-30). Proline makes the structure more rigid, and the introduction of alanine 
will most likely increase the flexibility and affect the helix orientation. This may reduce the 
activity of the mutant, as Ser70 may not occupy an ideal conformation for hydrolysis of 
nitrocefin, ampicillin and imipenem. However, both the R1 and R2 sidechains of ceftazidime 
are bulkier than the sidechains of other substrates. Hence the more flexible helix and location 
of Ser70 in the P68A and P68A/Y211S mutants may better accommodate the binding of such 
a large substrate. The molecular structure of ceftazidime is shown in Figure 3-31. Figure 1-9 





Figure 3-31: Molecular structure of ceftazidime, showing the bulky side-groups R1 and R2. Figure from 
Wikipedia.   
 
OXA-48 P68A/Y211S probably increases the accessibility of the active site even further 
by substituting tyrosine with the smaller serine. This may make binding and hydrolysis of 
ceftazidime easier, but reduces its ability to bind smaller substrates accurately in the active site.   
 The measured activity of OXA-48 wild type with ceftazidime was at first surprisingly 
high, with a kcat/Km value of 0.03 µM-1s-1 (Table 3-6). Kinetic parameters for OXA-48 with 
ceftazidime was by Docquier et al. [46] reported to be inactive (2009), Poirel et al. [50] reported 
a very low activity of 0.001 µM-1s-1 (2004). However, both studies measured the kinetic data in 
the absence of a carbonate (CO32-) source. Docquier et al. conducted their kinetic measurements 
in 100 mM Tris-H2SO4 pH 7.0, 300 mM K2SO4 buffer, and Poirel et al. used 100 mM sodium-
phosphate pH 7.0 buffer. It has been shown that the presence of a carbonate source is highly 
important for reliable and reproducible enzyme kinetic results for the class D b-lactamases, to 
allow for carboxylation of Lys73. Kinetic data obtained with a CO2 source, can therefore not 
be meaningfully compared to data obtained without a CO2 source [24]. The higher enzyme 
activity of OXA-48 with ceftazidime reported here, compared to previously reported kinetic 
parameters, can therefore most likely be explained by the lack of a carbonate source in the 
previous enzyme assays.  
 Chloride inhibition has long been a distinct feature in the field of the class D b-
lactamases [37]. Later it turned out that the presence of chloride does only display an inhibitory 
effect in the absence of a carbonate source, thus when Lys73 is not carboxylated. Our DSC 
experiments of OXA-48 like enzymes with two different buffers (with and without PO43-/ 
K2SO4) suggest that the presence of sulphate ions destabilizes the dimer, and reduces the 
thermal stability of the enzyme. This is an interesting observation as many previous kinetic 
experiments concerning OXA-enzymes used K2SO4, since Cl- was thought to be an inhibitor. 
The presence of K2SO4 in addition to the absence of a carbonate source might contribute to 










Figure 3-32: Enzyme kinetics curves comparing OXA-48 to the OXA-48 mutants S70A, S70T, S70T/T71S, 
P68A, P68A/Y211S, R189A and R189A/R206A with different substrates. The substrate concentrations are given 
along the x-axis, while the reaction velocity is given along the y-axis. The enzyme concentrations used in the 
assays are listed. OXA-48 is labelled OXA-48 WT. A) Imipenem with 1 nM S70T (blue), 1 nM S70T/T71S 
(green), and 2 nM OXA-48 (red). B) Imipenem with 2 nM P68A (blue), 2 nM P68A/Y211S (green), and 2 nM 
OXA-48 (red). C) Ampicillin with 3 nM P68A (blue), 5 nM P68A/Y211S (green), and 1 nM OXA-48 (red). D) 
Ceftazidime with 0.1 nM P68A (blue), 0.05 nM P68A/Y211S (green), and 1 nM OXA-48 (red). E) Nitrocefin with 
0.1 nM S70T (blue), 0.5 nM S70T/T71S (green), and 0.1 nM OXA-48 (red). F) Nitrocefin with 1 nM P68A (blue), 
1 nM P68A/Y211S (green), and 0.1 nM OXA-48 (red). G) Nitrocefin with 0.1 nM R189A (blue), 0.1 nM 












The blaOXA-48 gene, with the signal peptide removed and an inserted N-terminal hexa-
histidine tag and TEV cleavage site were used as a template to create OXA-48 mutants affecting 
the active site and dimer interface. The mutants OXA-48 S70A, S70T, S70T/T71S, R189A, 
R189A/R206A, P68A, and P68A/Y211S were designed, produced and sequence analysed. In 
addition to the mutants, OXA-163 and OXA-48 were also expressed and purified. The highest 
yield of pure protein was obtained when purifying OXA-163, likely related to OXA-163 being 
a synthetic DNA gene that was codon optimized for E. coli. Still sufficient amounts of protein 
were obtained for OXA-48 and its mutants. 
The crystal structures for OXA-48 S70A, S70T, S70T/T71S and R189A were 
determined, displaying that residue substitutions did not alter the overall conformation. The 
first crystal structures of OXA-181 and the novel b-lactamase OXA-436 were also obtained, as 
well as the structure of a new crystal form of OXA-163.  
Differential scanning calorimetry was used to investigate the thermal stability of OXA-
48, OXA-181, OXA-163, OXA-245, OXA-436 and the OXA-48 mutants R206A, R189A, and 
R189A/R206A, using two different buffer systems. Taken together, these studies suggest that 
the addition of sulphate in OXA-buffers reduces the thermal stability, possibly caused by the 
binding of a sulphate ion by residue R206 instead of a chloride ion, destabilizing the dimer. The 
DSC analysis were also used to investigate the differences between selected OXA-48 like 
enzymes, as well as determine the destabilizing effect of the dimer interface mutations, 
suggesting that the dimer formation is important for the thermal stability. These results together 
with the structural data were used to investigate the structure and thermostability relationship 
between OXA-181, OXA-163 and OXA-245 in the article “Structure activity and 
thermostability investigations of OXA-163, OXA-181 and OXA-245, using biochemical, 
crystal structures and differential scanning calorimetry analysis”.     
Based on previous dimer affinity investigations, size-exclusion chromatography and 
microscale thermophoresis were used to inspect the dimer affinity further for OXA-48, and 
OXA-48 mutants affecting the dimer interface. From the MST analysis, the dissociation 
constant for OXA-48 R189A/R206A were determined to 22 nM, which taken together with 
previous MST results suggests that the OXA-48 dimer affinity is very strong. The strong dimer 
affinity was considered to be further confirmed by size-exclusion chromatography, which 
indicated monomer formation of OXA-48 only at pH 4.0. However, monomer formation was 
indicated for OXA-48 R189A/R206A at neutral pH. This suggest that salt-bridges are highly 
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important for stability of the OXA-48 dimer. The deviating results may be explained by the 
different methods employed.   
Enzyme activity investigations for OXA-48 and a selection of the OXA-48 mutants 
were conducted with the substrates nitrocefin, ampicillin, imipenem and ceftazidime. This 
showed almost no activity for the active site mutants S70T and S70T/T71S, with S70T/T71S 
having the lowest activity of the two. The mutants affecting the dimer interface, namely R189A 
and R189A/R206A, showed only a slightly reduced enzyme activity, with OXA-48 having 2 
times higher catalytic activity. The active site mutants P68A and P68A/Y211S, discovered by 
evolutionary studies selecting for ceftazidime resistance, did hydrolyse ceftazidime at a higher 
rate than OXA-48. P68A showed a 10 fold increase in catalytic activity, and P68A/Y211S a 20 
fold increase, compared to OXA-48. However, this seemed to come at a cost of reduced 
hydrolytic activity for other substrates, compared to OXA-48.  
To conclude, the reported results suggest that the strong dimer affinity for OXA-48 is 
dependent on salt-bridges for its formation. It appears that destabilizing the dimer does not 
affect the enzyme activity significantly, but is important for the thermal stability. Substituting 
residues in the active site greatly affect the enzyme activity, possible by increasing the steric 
strain in the active site, and affect the optimal residue orientation. The suspected increased 
flexibility in the active site for P68A and P68A/Y211S mutants may allow for the hydrolysis 
of larger substrates, but reduces the ability to hydrolyse substrates to which OXA-48 displays 
activity.    
 





5 Future Work  
Crystal structures were not obtained for the OXA-48 mutants P68A/Y211S and 
R189A/R206A, and this would be a natural next step in studying the structural details of the 
mutants. It would be especially interesting to study the binding of different substrates by the 
active site mutants P68A and P68A/Y211S. At a very late phase of this thesis, the crystal 
structure of OXA-48 P68A binding ceftazidime was obtained by PhD. student Christopher 
Fröhlich.  
Even though the OXA-48 R189A, R206A and R189A/R206A mutants affecting the 
dimer interface did not display a significantly reduced enzyme activity with the substrate 
nitrocefin compared to OXA-48, the enzymes could be measured towards additional b-lactam 
classes. The aim could be to determine if the relatively similar activity to OXA-48 for mutants 
with different thermal stability, is a general effect, or if the amino acid substitutions could affect 
the hydrolysis of certain, but not all substrates.  
Further, the thermal stability of the active site mutants S70T and S70T/T71S could be 
analysed. It was suspected that the amino acid substitutions S70T/T71S increased the steric 
strain of the active site, and potentially could destabilize the structure. This could be an 
important step in elucidating the function of the highly conserved residue Thr71.  
 There is a need for further studies to determine the complete reaction mechanism for 
class D b-lactamases. Mutational studies involving multiple active sites residues, such as 
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Figure A1: DSC transition curves (blue) for (A) OXA-48, (B) OXA-163, (C) OXA-48 
R206A, (D) OXA-181, (E) OXA-245, (F) OXA-48 R189A, and (G) OXA-48 R189A/R206A, 
dialyzed in 50 mM phosphate buffer pH 7.2, with the theoretical fitted two-state model (red) 
for the respective dimers, to calculate the enthalpy of protein unfolding. The temperature is 





















Figure A2: Enzyme kinetics curves for OXA-48 (A) and OXA-48 mutants S70A (B), S70T (C), S70T/T71S (D), 
P68A (E), P68A/Y211S (F), R189A (G) and R189A/R206A (H) with nitrocefin. The substrate concentrations are 
given along the x-axis, while the reaction velocity is given along the y-axis. The curves are labelled according to 
































Figure A3: Enzyme kinetics curves for OXA-48 (E) and OXA-48 mutants S70T (A), S70T/T71S (B), P68A (C), 
and P68A/Y211S (D) with imipenem. The substrate concentrations are given along the x-axis, while the reaction 
















Figure A4: Enzyme kinetics curves for OXA-48 (C) and OXA-48 mutants P68A (A), and P68A/Y211S (B) with 
ceftazidime. The substrate concentrations are given along the x-axis, while the reaction velocity is given along the 

















Figure A5: Enzyme kinetics curves for OXA-48 (C) and OXA-48 mutants P68A (A), and P68A/Y211S (B) with 
ampicillin. The substrate concentrations are given along the x-axis, while the reaction velocity is given along the 








Table A1: X-ray data collection and crystallographic refinement statistics for OXA-48 mutants S70A, S70T, 












PDB entry     












Data collection statistics     
Space group P6522 (no. 179) P21 P21 P21 
No. Mol in AU 2 8 8 8 




 b (°) 
 
122.34   




107.82    




107.22    




107.73    
85.55   
125.81 
90.08 








Wavelength (Å) 0.9184 0.9184 0.9184 0.9184 
No. unique reflections 61 335 (3 726) 77 870 (4 452) 175 904 (8 670) 72 168 (4 435) 
Multiplicity 12.0 (11.6) 3.5 (3.6) 3.90 (3.9) 3.1 (3.2) 
Completeness (%) 100.0 (100.0) 99.1 (99.6) 96.7 (96.5) 96.7 (96.9) 
Mean (<I> /<sI>) 12.6 (1.8) 6.0 (1.1) 7.7 (1.1) 4.9 (1.0) 
R-merge a 0.177 (1.449) 0.165 (1.036) 0.107 (1.109) 0.188 (0.971) 
CC 1/2 0.998 (0.701) 0.990 (0.568) 0.997 (0.513) 0.980 (0.538) 
Wilson B-factor (Å2) 17.5 31.7 24.5 28.3 
Refinement statistics     
Resolution (Å) 25.0-1.85 25.0-2.50 25.0-1.89 25.0-2.55  
R-factor (all reflections) 0.1480 0.2074 0.216 0.20 
R-free 0.1761 0.2756 0.256 0.29 
RMSD bond lengths (Å) 0.009 0.004 0.012 0.002 
RMSD bond angles (°) 0.98 0.63 1.07 0.46 
Ramachandran favored 
(%)  
98.11 95.52 96.84 96.10 
Ramachandran outliers 
(%) 
0.00 0.21 0.11 0.37 
Clashscore 3.28 2.87 4.16 1.69 
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The first crystal structures of the class D -lactamases OXA-181 and OXA-245
were determined to 2.05 and 2.20 Å resolution, respectively; in addition, the
structure of a new crystal form of OXA-163 was resolved to 2.07 Å resolution.
All of these enzymes are OXA-48-like and have been isolated from different
clinical Klebsiella pneumoniae strains and also from other human pathogens
such as Pseudomonas aeruginosa and Escherichia coli. Here, enzyme kinetics
and thermostability studies are presented, and the new crystal structures are
used to explain the observed variations. OXA-245 had the highest melting point
(Tm = 55.8
C), as determined by differential scanning calorimetry, compared
with OXA-163 (Tm = 49.4
C) and OXA-181 (Tm = 52.6C). The differences
could be explained by the loss of two salt bridges in OXA-163, and an overall
decrease in the polarity of the surface of OXA-181 compared with OXA-245.
1. Introduction
After 70 years, penicillin and other -lactam antibiotics are
still the best weapons for fighting bacterial infections;
however, the rise of bacterial strains resistant to -lactam
antibiotics threatens to make them obsolete (O’Neill, 2016;
Bush & Macielag, 2010). The most common mechanisms for
bacteria to become resistant to -lactam antibiotics is the
uptake of foreign genetic material encoding -lactamases:
enzymes that break down the central -lactam ring of these
antibiotics, rendering them inactive (Bush & Bradford, 2016).
To date (June 2017), over 2600 -lactamases have been
described (Bush, 2013a; http://bldb.eu). Based on their genetic
sequence and structural motifs, -lactamases can be grouped
into four classes: A–D (Hall & Barlow, 2005; Bush, 2013b).
The largest class, with more than 500 members, is class D. This
class is often referred to as the oxacillinases (OXAs) owing to
their preferential hydrolysis of oxacillin. Typically, this class
has not been considered to be as threatening as the other
classes. Still, it contains members which may inactivate the
entire spectrum of -lactam antibiotics (Leonard et al., 2013;
Evans & Amyes, 2014; Docquier & Mangani, 2016).
One of the most geographically widespread members of the
class D -lactamases is OXA-48 (Vallejo et al., 2016). OXA-48
and the increasing number of OXA-48-like variants have been
called the ‘phantom menace’ owing to their broad substrate
specificity and the difficulties in identifying bacteria expressing
OXA-48-like enzymes (Poirel et al., 2012). The OXA-48-like
ISSN 2053-230X
# 2017 International Union of Crystallography
electronic reprint
-lactamases OXA-163, OXA-181 and OXA-245 have all
been identified in Klebsiella pneumoniae (Potron, Nordmann
et al., 2011; Oteo et al., 2013). Although K. pneumoniae is most
commonly found in soil and water, it frequently causes
infections in immunocompromised individuals and has been
connected to outbreaks of nosocomial infections (Podschun &
Ullmann, 1998; Paczosa & Mecsas, 2016; Navon-Venezia et al.,
2017). OXA-163 and OXA-181 have also been identified in
other human pathogens such as Escherichia coli (McGann et
al., 2015; Stoesser et al., 2016), and OXA-181 has been iden-
tified in Pseudomonas aeruginosa strains (Meunier et al.,
2016). OXA-181 is reported to originate from a Shewanella
xiamenensis chromosomal -lactamase (Potron, Poirel et al.,
2011) and OXA-163 also appears to originate from Shewa-
nella. spp, while OXA-245 appears from random mutations of
the OXA-48 gene in K. pneumoniae strains (Pérez-Vázquez et
al., 2016). OXA-163 was first identified in Argentina (Poirel et
al., 2011), but has also been observed in Egypt (Abdelaziz et
al., 2012). OXA-181 has been identified all over the world
(Potron, Nordmann et al., 2011; Samuelsen et al., 2013; Rojas et
al., 2017). The strain responsible for OXA-245, however,
appears to be limited to Spain (Pérez-Vázquez et al., 2016).
The sequence identities compared with OXA-48 are 98.0% for
OXA-163, 98.4% for OXA-181 and 99.6% for OXA-245,
using Gly22 (left after TEV cleavage) and the periplasmic part
(Lys23–Pro256) for all four enzymes.
While class D -lactamases are a diverse class with respect
to protein sequence, their tertiary structures are highly
conserved. All known structures of OXAs share an -fold
and many form dimers in solution (Docquier et al., 2009;
Paetzel et al., 2000; Dale & Smith, 1976). The active site of
OXAs is made up of three conserved motifs, 70STFK73,
118SVV120 and 208KTG210, and each monomer has an inde-
pendent active site. The serine in the STFK motif has been
identified as the nucleophile that is responsible for the
formation of the acyl-complex with -lactam antibiotics
(Paetzel et al., 2000), while the lysine in the same motif has a
conserved post-translational carboxylation that is important
for deacetylation (Schneider et al., 2009). The structures of the
homologues OXA-48, OXA-163, OXA-232 and OXA-405
have been published (Docquier et al., 2009; Stojanoski et al.,
2015). In this study, we wanted to thoroughly characterize the
antibiotic-resistance enzymes OXA-163, OXA-181 and OXA-
245 by comparing their thermostabilities, hydrolytic properties
and crystal structures with those of the OXA-48 enzyme with
worldwide spread.
2. Materials and methods
2.1. Cloning of OXA-181 and OXA-245 and recombinant
macromolecule production
Genes encoding OXA-181 and OXA-245 were amplified
from clinical isolates and cloned into a pDEST-17 vector
using exponential megaprimer cloning (EMP) as described
previously (Lund et al., 2014, 2016). Two gene constructs were
made for both OXA-181 and OXA-245, in which one gene
construct encoded the full-length gene with the signal peptide,
thus including residues 1–265 (nOXA-181 and nOXA-245),
and a second gene construct encoded a truncated gene with a
hexahistidine (His) tag and a TEV protease site followed by
residues 23–265 (tOXA-181 and tOXA-245).
Synthetic DNA encoding an OXA-163 construct with a
TEV protease site (ENLYFQG) followed by residues Lys23–
Pro265 (tOXA-163), codon-optimized for expression in
E. coli, was purchased from Life Technologies (Thermo Fisher
Scientific). The DNA was inserted in pDEST17, which carries
an N-terminal His tag. The primers and strains used in this
study are described in Supplementary Table S1.
All enzymes were produced recombinantly. tOXA-181 and
tOXA-163 were produced in E. coli BL21 (DE3) pLysS cells in
Terrific Broth medium (TB) with 100 mg ml1 ampicillin and
34 mg ml1 chloramphenicol, the cells were induced by 0.4 mM
isopropyl -d-1-thiogalactopyranoside (VWR) at log phase
and expression was continued at 20C for 16 h. nOXA-181,
nOXA-245 and tOXA-245 were produced in E. coli BL21 Star
(DE3) pRARE cells in ZYP5052 autoinduction medium at
310 K (37C) for 3–4 h and then left at 293 K (20C) for 16 h.
Recombinant nOXA-181 and nOXA-245 were isolated
from the periplasm after lysozyme treatment and were puri-
fied by two steps using an anion exchanger (Giuliani et al.,
2005). Contaminants were bound on an anion-exchange Q
Sepharose column at 277 K (4C) equilibrated with 25 mM
bis-tris propane pH 7.2. The pH of the running buffer was
adjusted to pH 9.5 before applying a pH gradient from pH 9.5
to 6.5 with 25 mM bis-tris propane. A cation-exchange column
(HiTrap SP) was used for polishing with a gradient from pH
6.5 (25 mM HEPES) to pH 8.5 (25 mM HEPES) with 150 mM
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Table 1
Crystallization conditions for tOXA-163, tOXA-181 and tOXA-245.
tOXA-163 tOXA-181 tOXA-245
Method Vapour diffusion
Plate type Hampton Research VDX 24-well plate with sealant
Temperature (K) 298
Protein concentration (mg ml1) 9 11 3
Buffer composition of protein solution 50 mM HEPES pH 7.2, 50 mM K2SO4 50 mM Tris pH 7.2, 50 mM K2SO4 25 mM HEPES pH 7.5
Composition of reservoir solution 0.1 M Tris pH 9.0, 28% PEG 500 0.1 M Tris pH 7.0, 0.2 M ammonium sulfate,
20.5% PEG MME 5000
0.1 M HEPES pH 7.0,
10% PEG 6000
Drop volume (ml) 2 1 2
Protein:reservoir ratio 3:20 1:1 1:1
Reservoir volume (ml) 1000 800 500
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potassium sulfate. Recombinant tOXA-163, tOXA-181 and
tOXA-245 were isolated from sonicated and clarified samples,
and were first purified by nickel immobilized metal-affinity
chromatography (Ni-IMAC) at 277 K (4C) with a 0–500 mM
imidazole gradient also including 25 mM HEPES pH 6.5 and
50 mM potassium sulfate (Lund et al., 2016). The semi-pure
enzyme extract was then cleaved using in-house-purified TEV
protease (with L56V, S135G, S219N, T17S, N68D and I77V
mutations; Leiros et al., 2014) to remove the His tag, and the
cleaved protein was again purified using Ni-IMAC, with the
cleaved protein eluting in the flowthrough (Lund et al., 2016;
Leiros et al., 2014). The last polishing step was a cation-
exchange column as described for the enzyme isolated from
the periplasm. Finally, the TEV constructs were dialysed in
different storage buffers (Table 1), and nOXA-181 and
nOXA245 were dialysed in 50 mM HEPES pH 7.2, 50 mM
potassium sulfate. The proteins were concentrated using
Centriprep centrifugal filters (Merck) and the protein
concentrations were measured using the OD280, molecular
weights (MW) and extinction coefficients for each gene
construct.
2.2. Enzyme kinetics of nOXA-181 and nOXA-245
Enzyme characterization and determination of the kinetic
parameters were carried out as previously described for
nOXA-48 (Antunes et al., 2014; Lund et al., 2016). Substrate
hydrolysis was measured by monitoring the UV absorbance
for ampicillin ("235 nm = 820 M1 cm1, 1–100 mM,
100 pM nOXA-181/nOXA-245); ceftazidime ("260 nm =
9000 M1 cm1, 18–300 mM, 5 nM nOXA-181/10 nM
nOXA-245); ertapenem ("300 nm = 6920 M1 cm1, 10–
1000 mM, 5 nM nOXA-181/nOXA-245); imipenem ("300 nm =
9000 M1 cm1, 1–100 mM, 5 nM nOXA-181/nOXA-245)
and meropenem ("300 nm = 6500 M1 cm1, 0.02–50 mM,
5 nM nOXA-181/2 nM OXA-245). A SpectraMax M2e
(Molecular Devices, Sunnyvale, California, USA) plate reader
at 25C and nonlinear regression using GraphPad Prism 6
(GraphPad Software) were used to determine kcat and Km with
substrate-hydrolysis velocities from the linear phase of the
reaction course.
2.3. Thermostability analysis by differential scanning
calorimetry (DSC)
Purified tOXA-48 (Lund et al., 2016), tOXA-163, tOXA-
181 and tOXA-245 were dialyzed against 50 mM HEPES pH
7.0 supplemented with 50 mM potassium sulfate. Enzyme
concentrations were in the range 0.5–1 mg ml1. All samples
were filtrated and degassed. Temperatures were scanned in the
range 10–80C with a gradient of 1C min1. To calculate the
heat capacities the concentrations and molecular weights were
given for the dimers. All measurements were collected using a
CSC Nano-Differential Scanning Calorimeter III (N-DSC III)
with the pressure kept constant at 304 kPa. All data were
analyzed in NanoAnalyze 3.6 (TA Instruments, New Castle,
Delaware, USA).
2.4. Crystallization conditions
tOXA-163, tOXA-181 and tOXA-245 were used for crys-
tallization experiments. Conditions for tOXA-163 (9 mg ml1)
and tOXA-181 (11 mg ml1) were identified from screening
284 in-house stochastic crystallization conditions, whereas the
conditions for tOXA-245 (3 mg ml1) were based on the
conditions for the tOXA-48 homologue. Ethanediol was
added to the crystallization condition at 17, 20 and 25% to
cryoprotect tOXA-163, tOXA-181 and tOXA-245, respec-
tively, prior to flash-cooling the crystals in liquid nitrogen.
Crystallization information is summarized in Table 1.
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Table 2
X-ray data-collection and processing statistics for tOXA-163, tOXA-181 and tOXA-245.
Values in parentheses are for the outer resolution shell.
tOXA-163 tOXA-181 tOXA-245
Diffraction source BL14.1, BESSY BL14.1, BESSY BL14.1, BESSY
Wavelength (Å) 0.918409 0.918409 0.918409
Temperature (K) 100 100 100
Detector PILATUS 6M PILATUS 6M PILATUS 6M
Crystal-to-detector distance (mm) 293.51 426.55 371.19
Rotation range per image () 0.1 0.1 0.1
Total rotation range () 200 120 200
Exposure time per image (s) 0.4 0.3 0.3
Space group P6522 P62 P21
a, b, c (Å) 121.92, 121.92, 160.43 143.93, 143.93, 53.543 64.16, 108.72, 83.68
, ,  () 90, 90, 120 90, 90, 120 90, 102.39, 90
Mosaicity () 0.12 0.08 0.13
Resolution range (Å) 24.49–2.07 (2.14–2.07) 35.98–2.05 (2.12–2.05) 41.06–2.20 (2.28–2.20)
Total No. of reflections 476104 (48568) 258749 (26225) 211084 (21915)
No. of unique reflections 43401 (4244) 40027 (3911) 56510 (5674)
Completeness (%) 99.90 (100.00) 99.55 (99.21) 99.25 (99.95)
Multiplicity 11.0 (11.4) 6.5 (6.6) 3.7 (3.9)
hI/(I)i 12.66 (2.98) 13.19 (2.27) 11.15 (3.63)
Rmeas 0.1614 (0.8966) 0.08461 (0.8693) 0.0954 (0.387)
Overall B factor from Wilson plot (Å2) 24.49 29.65 29.30
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2.5. X-ray data collection and processing
X-ray diffraction data were collected on BL14.1 operated
by the Helmholtz-Zentrum Berlin (HZB) at the BESSY II
electron-storage ring (Berlin-Adlershof, Germany; Mueller et
al., 2015). Images were indexed and integrated using XDS
(Kabsch, 2010) and were merged and scaled using AIMLESS
(Evans & Murshudov, 2013). 5% of reflections were used for
cross-validation for tOXA-163 and tOXA-181, whereas 2%
were used for tOXA-245. X-ray data-collection and processing
statistics are summarized in Table 2.
2.6. Structure solution and refinement
The structures were solved using Phaser (McCoy et al.,
2007) with one monomer of OXA-48 (PDB entry 3hbr;
Docquier et al., 2009) as the search model. Refinement was
carried out using phenix.refine (Afonine et al., 2012), with
individual isotropic B factors and torsion-angle NCS
restraints. Models were inspected and manually modified
using Coot (Emsley et al., 2010). For the final refinement, TLS
parameters were refined and refinement weights were opti-
mized. Refinement statistics are summarized in Table 3.
Interactions within each protein were evaluated using the
Protein Interactions Calculator (PIC; Tina et al., 2007) and the
Protein Interfaces, Surfaces and Assemblies service PISA at
the European Bioinformatics Institute (http://www.ebi.ac.uk/
pdbe/prot_int/pistart.html; Krissinel & Henrick, 2007). Figures
were prepared using PyMOL (v1.8; Schrödinger).
3. Results and discussion
3.1. Enzyme production and enzyme kinetics
In this paper two gene constructs were used: either with
native leader sequences followed by periplasmic purification
(nOXA-181 and nOXA-245) or His-TEV gene constructs
(tOXA-163, tOXA-181 and tOXA.245), where the His tag was
cleaved with TEV protease. All gene constructs were
expressed in E. coli. The highest yield was obtained for tOXA-
181, with up to 55 mg of enzyme per litre in BL21 (DE3)
pLysS cells in TB medium. tOXA-163 was expressed in BL21
(DE3) pLysS cells in TB medium, whereas nOXA-181,
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Figure 1
Sequence alignment of OXA-48, OXA-163, OXA-181 and OXA-245. The conserved active-site motifs are marked in blue. Secondary-structure elements
are from the crystal structures of tOXA-48 (top; PDB entry 5dtk) and tOXA-245 (bottom; PDB entry 5oe2). The red triangle denotes the end of the
signal peptide. The red star denotes the active-site serine. Grey stars indicate residues with alternate conformations in the crystal structure of OXA-48.
This figure was prepared using ESPript 3.0 (Robert & Gouet, 2014).
Table 3
Refinement statistics for tOXA-163, tOXA-181 and tOXA-245.
Values in parentheses are for the outer shell.
tOXA-163 tOXA-181 tOXA-245






Completeness (%) 99.90 (100.00) 99.55 (99.21) 99.25 (99.95)
No. of reflections
Working set 43401 (4244) 39856 (3913) 56501 (5674)
Test set 2186 (222) 1971 (165) 1290 (129)
Final Rcryst 0.1456 (0.1821) 0.2034 (0.3398) 0.1951 (0.2304)
Final Rfree 0.1870 (0.2014) 0.2418 (0.4248) 0.2307 (0.2924)
No. of non-H atoms
Protein 3975 3956 7944
Ligands 17 6 3
Water 367 476 536
Total 4359 4438 8483
R.m.s. deviations
Bonds (Å) 0.014 0.003 0.004
Angles () 1.38 0.54 0.86
Average B factors (Å2)
Overall 32.84 37.78 39.04
Protein 31.88 36.68 38.87
Ligands 54.98 76.17 25.01
Water 42.28 46.40 41.65
Ramachandran plot
Most favoured (%) 97.22 97.89 97.5
Allowed (%) 2.78 2.11 2.5
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nOXA-245 and tOXA-245 were expressed in BL21 STAR
(DE3) pRARE cells in ZYP5052 autoinduction medium.
The substitutions in the protein sequence for OXA-181 and
OXA-245 (Fig. 1) are located away from the active-site resi-
dues (Fig. 3), and none of the conserved motifs 70STFK73,
118SVV120 or 208KTG210 appear to be influenced. However, it is
well known that modifications of distal sites may influence
enzyme activity (Guarnera & Berezovsky, 2016), so we enzy-
matically characterized nOXA-181 and nOXA-245 and
compared our results with the reported values for OXA-48
(Lund et al., 2016; Docquier et al., 2009; Poirel et al., 2004) and
OXA-163 (Poirel et al., 2011). We tested the substrates
ampicillin, ceftazidime, ertapenem, imipenem and mero-
penem. Both enzymes showed activity against all of the
substrates (Table 4); however, ceftazidime was a poor
substrate. In summary, the substitutions in nOXA-181 and
nOXA-245 did not significantly change the enzymatic char-
acteristics compared with OXA-48. OXA-163, however, has
an overall lower catalytic efficiency, but much higher turnover
rates for ceftazidime.
3.2. Thermostability analysis by differential scanning
calorimetry
Even though the enzyme kinetics did not reveal any
significant functional changes between nOXA-181 and
nOXA-245, an investigation of thermostability properties
could still reveal differences. We determined the midpoint
melting temperatures (Tm) for tOXA-48, tOXA-163, tOXA-
181 and tOXA-245 by differential scanning calorimetry
(DSC). Since all four enzymes are dimers according to inter-
action analysis of the crystal structures, with 10–20% of the
surface buried up on dimerization (Krissinel & Henrick, 2007),
and gel-filtration experiments of OXA-48 indicate dimer
formation (data not shown), the curves were fitted with the
molecular weights and concentrations of the dimers. The
recorded melting curves (Fig. 2) and their fit to the two-state
model (Supplementary Fig. S1) indicate that all four enzymes
unfold via a two-state transition without a stable intermediate,
like many other dimeric proteins (Neet & Timm, 1994).
tOXA-163 and tOXA-181 have a broader melting curves than
tOXA-48 and tOXA-245 (Fig. 2) possibly owing to lower
protein concentrations, nonhomogeneous samples or minor
impurities. Still, we found tOXA-163 to be the least stable of
the OXA-48-like enzymes, with a Tm of 49.40
C compared
with the other OXA-48-like enzymes with midpoint melting
temperatures of 55.3C (tOXA-48), 52.6C (tOXA-181) and
55.8C (tOXA-245) (Table 5, Fig. 2).
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Figure 2
Differential scanning calorimetry curves for tOXA-48 (red), tOXA-163
(blue), tOXA-181 (purple) and tOXA-245 (green) showing that tOXA-
245 and tOXA-48 have the highest melting temperatures, whereas tOXA-
181 and tOXA-163 have lower melting points.
Table 4
Kinetic parameters of purified nOXA-181 and nOXA-245 with standard errors from three replicates, showing similar hydrolytic properties compared
with nOXA-48.
Results for nOXA-48 and OXA-163 are included for reference (Lund et al., 2016; Poirel et al., 2011).
Penicillin Cephalosporin Carbapenems
Ampicillin Ceftazidime Ertapenem Imipenem Meropenem
nOXA-181
Km (mM) 23  5 170  90 900  300 17  4 0.3  0.1
kcat (s
1) 2100  200 0.7  0.2 1.6  0.3 5.1  0.4 0.013  0.01
kcat/Km (mM
1 s1) 91 0.004 0.002 0.3 0.04
nOXA-245
Km (mM) 35  13 110  80 80  20 11  1 2  0.8
kcat (s
1) 1200  200 0.3  0.1 0.29  0.03 4.4  0.2 0.11  0.01
kcat/Km (mM
1 s1) 34 0.003 0.004 0.40 0.05
nOXA-48†
Km (mM) 150 5100 100 7.9 1
kcat (s
1) 560 4 0.13 4.5 0.1
kcat/Km (mM
1 s1) 4 0.0008 0.001 0.6 0.1
OXA-163‡
Km (mM) 320 >2000 150 530 2200
kcat (s
1) 25 200 0.01 0.03 0.07
kcat/Km (mM
1 s1) 0.1 <0.1 0.00007 0.00006 0.00003
† The enzyme kinetic parameters for nOXA-48 with ampicillin, imipenem and meropenem are from Lund et al. (2016), those with ceftazidime are from Poirel et al. (2004) and those with
ertapenem are from Docquier et al. (2009). ‡ The enzyme kinetic parameters for OXA-163 are from Poirel et al. (2011).
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3.3. New crystal structures of tOXA-181 and tOXA-245,
and a new tOXA-163 crystal form resolved by X-ray
crystallography
We present the first crystal structures of the OXA-48-like
-lactamases tOXA-181 and tOXA-245 and a new crystal
form of tOXA-163. The new crystal form of tOXA-163
belonged to space group P6522 and diffracted to 2.07 Å
resolution, with Rcryst and Rfree values of 0.15 and 0.19,
respectively. The tOXA-181 enzyme crystallized in space
group P62 and diffracted to 2.05 Å resolution, with Rcryst and
Rfree values of 0.20 and 0.24, respectively. Finally, tOXA-245
crystallized in space group P21 and diffracted to 2.20 Å reso-
lution, with refined Rcryst and Rfree values of 0.20 and 0.23,
respectively. Gly22 from the TEV site is absent in all struc-
tures and Lys23 is missing in all tOXA-181 and tOXA-245
chains, but otherwise all residues are included in the final PDB
models. The asymmetric unit of the new crystal structures are
different (Fig. 3): tOXA-163 and tOXA-181 have a dimer in
the asymmetric unit, corresponding to the expected biological
assembly, while tOXA-245 has two dimers in the asymmetric
unit. An interesting feature is the chloride ions that are
observed to bridge two arginines at the dimer interface: one
arginine from each monomer in all three new OXA structures.
Other class D -lactamases such as OXA-10 are known to
have a cation-mediated dimerization with a histidine acid in
the same position binding to a divalent cation such as cobalt,
copper or zinc (Paetzel et al., 2000; Danel et al., 2001).
As expected from the sequence alignment (Fig. 1), the new
structures show a close resemblance in their tertiary structure.
The mutations are all on the surface of the proteins and the
dimer interface is undisturbed. When all monomers of the new
structures are compared against each other (tOXA-163,
tOXA-181 and tOXA-245), the different chains in the asym-
metric units have r.m.s.d. values for C atoms in the range 0.3–
0.6 Å as calculated by the protein structure-similarity service
PDBeFold at the European Bioinformatics Institute (Krissinel
& Henrick, 2004).
3.4. The increased flexibility necessary for cephalosporin
hydrolysis makes OXA-163 less stable
OXA-163 differs from OXA-48 by an S212D substitution
and a four-amino-acid deletion corresponding to Arg214,
Ile215, Glu216 and Pro217 in OXA-48. Crystal structures of
OXA-163 have previously been reported (PDB entries 4s2l,
4s2m and 5har; Stojanoski et al., 2015, 2016); however, we
report a new space group and unit cell for our tOXA-163
structure, similar to a crystal form reported for a laboratory
mutant of OXA-48 (PDB entry 5hap; Stojanoski et al., 2016)
crystallized from similar conditions. Comparing our tOXA-
163 structure with another OXA-163 structure (PDB entry
4s2l) reveals perturbations that are localized primarily to polar
surface residues, and there are two molecules in the asym-
metric unit (Fig. 3). The r.m.s.d. for C atoms in one tOXA-163
chain compared with existing OXA-163 structures are: 0.32–
0.43 Å for PDB entry 4s2l, 0.52–0.67 Å for PDB entry 4s2m
and 0.32–0.46 Å for PDB entry 5har.
For tOXA-163, shortening the loop (Fig. 4) connecting 7
to 8 opens up access to the active site, allowing the binding
of bulkier groups, as found in, for example, cephalosporins
(Stojanoski et al., 2015). From the enzymatic characterization
(Table 4) it was clear that this structural change increases the
catalytic turnover for the cephalosporin ceftazidime dramati-
cally, but the carbapenemase enzyme activity is nearly abol-
ished. The DSC results shows that tOXA-163 had a 5.9C
lower melting temperature compared with tOXA-48 (Table 5)
and the structure shows that the deletion of residues 214–217
in tOXA-163 disrupts two ionic bonds, Arg214–Asp159
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Figure 3
The quaternary structures of tOXA-163 (a), tOXA-181 (b) and tOXA-245 (c) reveal biological dimers with buried chloride ions in the dimer interface
(grey). For OXA-245 there are two dimers in the asymmetric unit (one is shown). Active-site motifs are coloured in red and residues involved in
substitutions are shown in blue and marked with asterisks.
Table 5
Midpoint melting temperatures (Tm) determined by differential scanning
calorimetry for tOXA-48, tOXA-163, tOXA-181 and tOXA-245.
Tm values are given as the mean with standard deviations from duplicate
experiments performed in 50 mM HEPES pH 7.0 with 50 mM potassium
sulfate. The apparent unfolding enthalpies (H) with standard deviations
were calculated for a two-state model with the enzymes modelled as dimers.
Tm (
C) H (kJ mol1)
tOXA-48 55.3  0.2 1500  200
tOXA-163 49.4  0.1 1280  50
tOXA-181 52.6  0.1 1400  300
tOXA-245 55.8  0.1 1700  100
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(2.9 Å) and Glu216–Lys218 (2.4 Å), that are found in both
tOXA-181 and tOXA-245 (Figs. 4a, 4b and 4c). The effect of
the S212D mutation in OXA-163 seems to partially compen-
sate for the loss of two ionic bonds by forming two hydrogen
bonds from the Asp212 side chain to the main-chain N atoms
of residue 218 and 219 rather than one as found in tOXA-181
and tOXA-245 (Figs. 4a, 4b and 4c). For OXA-163 it appears
that the destabilization of the structure allows greater flex-
ibility and easier access to the active site, facilitating the
hydrolysis of bulky substrates (Simakov et al., 2017).
3.5. OXA-181 reveals decreased thermostability
The OXA-181 enzyme differs from OXA-48 by four
substitutions: T104A, N110D, E168Q and S171A. Our new
structure was resolved to 2.05 Å resolution in space group P62,
with two molecules in the asymmetric unit (Fig. 3). The
tOXA-181 structure has very similar unit-cell parameters to
some of the crystals of the homologues OXA-48 (PDB entry
4s2k; King et al., 2015) and OXA-232 (PDB entry 5hfo;
P. Retailleau, S. Oueslati, C. Cisse, P. Nordmann, T. Naas &
B. Iorga, unpublished work), but the tOXA-181 crystals grew
from different crystallization conditions.
The nOXA-181 enzyme has the highest activity against
ampicillin of the tested OXAs and has some activity against
ceftazidime (Table 4). The activity of nOXA-181 against the
carbapenems is lower than that of nOXA-48; however, these
in vitro results are not reflected in bacterial cells, where
OXA-48 and OXA-181 have very similar hydrolytic profiles
(Potron, Nordmann et al., 2011).
For tOXA-181 the thermal stability was reduced by 2.7C
compared with tOXA-48 (Table 5) and this could be attributed
to changes in the tertiary structure. The N110D mutation in
tOXA-181 introduces an ionic bond from Asp110 to His90,
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Figure 4
The substitutions in tOXA-163 (green), tOXA-181 (cyan) and tOXA-245 (magenta). (a), (b) and (c) show the S212D substitution and the deletion of
residues 214–217 in tOXA-163 which disrupt two ionic bonds. (e), ( f ) and (g) show the N110D substitution in OXA-181; the aspartic acid forms an ionic
bond to His90, which disrupts the Asp88-His90-Glu89 network. (i), (j) and (k) show the E125Y substitution in tOXA-245, where the loss of an ionic bond
to Arg128 is compensated by – stacking from Tyr125 to both Phe93 and Phe126. (d), (h) and (l) show superpositions of tOXA-163 (green), tOXA-181
(cyan) and tOXA-245 (magenta) for comparison of the three structures.
electronic reprint
causing the His90 residue to shift significantly. This disrupts
the ionic network Asp88-His90-Glu89 as found in OXA-48
(not shown), tOXA-163 and tOXA-245 (Figs. 4d, 4e and 4f).
The other OXA-181 mutations T104A and S171A decrease
the overall polarity of the surface, which is likely to make the
protein less stable (Vogt et al., 1997; Michetti et al., 2017), thus
explaining the lower thermal stability of tOXA-181 compared
with tOXA-48.
3.6. A new crystal structure of tOXA-245 uncovers a
stabilizing aromatic network
OXA-245 differs from OXA-48 by the single substitution
E125Y. The tOXA-245 crystal structure belonged to space
group P21 with four molecules in the asymmetric unit and was
refined to 2.20 Å resolution. tOXA-245 crystallized with
similar unit-cell parameters to another crystal form of
OXA-48 (PDB entry 3hbr).
In our substrate-hydrolysis experiments, nOXA-245 shows
the same behaviour as nOXA-181, with higher activity against
ampicillin compared with nOXA-48, some activity against
ceftazidime and weaker carbapenemase activity than nOXA-
48, except for the carbapenem ertapenem, towards which
nOXA-245 had the highest activity of the tested OXAs
(Table 4). This behaviour is consistent with the antibiotic-
susceptibility profile reported previously (Oteo et al., 2013).
tOXA-245 had an increased overall stability of 0.5C
compared with tOXA-48 (Table 5) and only has the E125Y
substitution. This stabilization is surprising, since Glu125 in
the other structures forms an ionic bond to Arg129 and a
hydrogen bond to Gln129. However, in the tOXA-245 crystal
structure Tyr125 makes a hydrogen bond to Gln129 with the
phenolic hydroxyl group and – stacking interactions with
Phe126 (6.0 Å between the ring centroids) and Phe93 (6.5 Å
between the ring centroids). The – stacking from Phe93 to
Phe126 and the hydrogen bond from the Gln129 amide N
atom to the Tyr125 hydroxyl group may compensate for the
loss of the ionic bond (Figs. 4g, 4h and 4i), and thus stabilize
the protein and explain the observed 0.5C increase in overall
stability. – stacking has been reported in the literature to
enhance the overall thermostability (Karlström et al., 2006).
4. Conclusion
Overall, it appears that the changes in the nOXA-181 and
nOXA-245 protein sequences are well tolerated, giving a
similar hydrolytic spectrum compared with nOXA-48. In
overall thermal stability, tOXA-163 was the least stable OXA-
48-like enzyme, with a melting temperature reduced by 5.9C
compared with tOXA-48. Based on the crystal structures, we
hypothesize that this decrease is caused by two broken salt
bridges (Glu126–Arg128 and Glu159–Arg214) and a more
accessible active site compared with the three other OXA
enzymes. The tOXA-181 enzyme has a 2.7C lower melting
point compared with tOXA-48, possibly owing to one broken
ionic interaction in the Asp88-His90-Glu89 network caused by
the shift of His90 towards Asp110, combined with an overall
decrease in surface polarity. Finally, tOXA-245 was most
similar to tOXA-48, with an increased Tm of 0.5
C, and this
increase could arise from one additional hydrogen bond
(Tyr125–Asn129) and the – aromatic stacking network with
Phe93-Tyr125-Phe126 compensating for the loss of the
Glu125–Arg128 salt bridge.
From these observations, we speculate that a bacterium
carrying a serine -lactamase already has an advantage in
-lactam resistance, that the differences in the sequences of
OXA-181 and OXA-245 depend on the original host
organism, and that these differences are tolerated as long as
there is no interference with substrate hydrolysis.
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Supporting information  
Table S1 Macromolecule production information for the cloning and production of OXA-
163,OXA-181 and OXA-245. Italic nucleotides   
Source organism Klebsiella pneumoniae 
DNA source  Genomic DNA  
 
Native construct with signal 
peptide: 




























Cloning vector pDEST17 
Expression vector pDEST17 
Expression host E. coli BL21 (DE3) STAR pRARE 












































































a The nucleotides in the TEV protease cleavage site sequence is in italics. Underlined residues in the amino acid 
sequence are cleaved off by signal peptide peptidases in transport to the periplasm for the native construct or by 
an in-house TEV-protease during purification for the His-tagged construct.  
b The gene for OXA-163 was synthesized with optimized codon usage and subcloned into the expression vector. 
 





Figure S1 Differential scanning calorimetry curves (red) for (A) OXA-48, (B) OXA-163, (C) OXA-
181 and (D) OXA-245 with the theoretical two-state model fitted (blue) for the respective dimers to 
calculate the ΔH of unfolding.  
 
